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My PhD three years course in Pharmaceutical Sciences at the Department 
of Pharmaceutical and Biomedical Sciences of Salerno U iversity was started 
in November 2008 under the supervision of Prof. Giuseppe Bifulco. 
My research activity was mainly focused onto study of ligand-receptor 
interactions and structural characterization by computational techniques and 
NMR spectroscopy in order to identify new antitumor and/or antiinflammatory 
molecules potentially utilizable in therapy.  
These approaches were successfully applied to the chara terization of novel 
inhibitors of Histone deacetilase (HDAC) Nicotinamide 
Phosphoribosyltransferase (NMPRTase or Nampt), microsomal prostaglandin 
E2 synthase (mPGES-1), human synovial Phospholipases A2, (hsPLA2), 
human Farnesoid-X-Receptor (FXR), and agonist of human Pregnane-X-
Receptor (PXR) and Bile Acid Receptor GPBAR-1 (TGR5). 
The entire work was carried out under the direct supervision of Prof. 
Giuseppe Bifulco. 
Furthermore, to improve my knowledge on methodologies for the 
stereostructural assignment, I moved to the Department of Chemistry of the 
Bristol University in 2011 (mid-July until mid-November 2011) under the 
supervision of the Dr. Craig Butts. 
During this period in his research laboratory, my research work has 
included learning and conducting advanced NMR spectros opic investigations 
of a number of natural products and synthetic compounds.  
In addition to PhD course activities, I was involved in different side 
projects, mainly regarding the characterization of ligand-targets interactions of 
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Computational methodologies in combination with experimental techniques 
as Nuclear Magnetic Resonance (NMR) have become a crucial component in 
drug discovery process, from hit identification to lead optimization.  
The study of ligand-macromolecule interactions, in fact, has a crucial role 
for the design and the development of new and more p werful drugs. In this 
project, different aspects of interaction and recognition processes between 
ligand and macromolecule, and streostructure assignment has been studied 
through this kind of combined approach with the aim to identify novel 
potential antitumor and/or antiinflammatory molecules. 
In particular, because the strong interconnection between the tumoral and 
inflammatory pathology has led to the identification f new target utilizable 
for the therapy, in this project will be described proteins (Histone deacetilase, 
HDAC; Nicotinamide Phosphoribosyltransferase, NMPRTase or Nampt; 
microsomal prostaglandin E2 synthase, mPGES-1; human synovial 
Phospholipases A2, hsPLA2; human Farnesoid-X-Receptor, FXR; human 
Pregnane-X-Receptor, PXR; Bile Acid Receptor GPBAR-1, TGR5) involved 
in essential cellular processes and acting at diverse levels and phases of the 
tumor and inflammation diseases.  
The results obtained can be summarized in three main areas of activity, 
whose relative weight was varied according to the development of the overall 
project: 
 
a) Support in the design of original scaffolds for the generation of 
libraries potentially utilizable in therapy.  This work was exclusively 
conducted in silico by a molecular docking technique in order to direct the 





interactions and the synthetic possibilities. This kind of approach was 
successfully applied leading to the identification of new potential inhibitors for 
HDAC enzymes with ciclic (mono and bis amides, paragraph 2.2; 
conformationally locked calixarenes, paragraph 2.4), and linear (hydroxamic 
tertiary amines, paragraph 2.3) structures, and isoform selective (paragraph 
2.6), and of ligands for microsomal prostaglandin E2 synthase (mPGES)-1 
(two series of triazole-based compounds; paragraphs 4.2 and 4.3).  
For each of this described studied, the good qualitative accordance between 
the calculated and experimental data has made possible the identifications of 
new lead compounds, rationalizing in this way the key features to the target 
inhibition.  
 
b) Rationalization of the biological activity of compounds by the study 
of the drug-receptor interactions. Molecular docking was used for the 
detailed study of antiinflammatory and antitumoral compounds whose 
activities are known a priori. In fact, thanks to this procedure, in this thesis 
several rationalizations of binding modes were repoted related to Ugi 
products derivatives of CHAP 1 (HDAC inhibitors, paragraph 2.5), new and 
potent inhibitor of NMPRTAse analogs of FK866 and CHS 828 (chapter 3), 
marine natural products as inhibitors of hsPLA2 (BLQ and CLDA, chapter 5), 
4-methylen sterols extracted from Theonella swinhoei as ligands of FXR and 
PXR (chapter 6), and known compounds as taurolitholic acid and 
ciprofloxacin (chapter 7), agonists of TGR5. 
Through the in silico methodology the putative binding modes for the 
reported molecules was described offering a complete rationalization of 
docking results, evaluating the influence of the ligand target interactions (e.g. 





c) Determination of relative configuration of natural products.  
The complete comprehension of the three dimensional structure of synthetic 
or isolated molecules is fundamental to design and characterize new platform 
potentially utilizable in therapy. On this basis, the combined approach between 
the quantum mechanical (QM) calculation of NMR parameters and NMR 
spectroscopy was revealed a very useful mean to lead the total synthesis of 
natural product toward the right isomer avoiding waste of time and resources 
(paragraph 8.1).  
Moreover, the stereostructure assignment of marine natural products 
conicasterol F and its analog thonellasterol I was reported in the paragraph 8.2. 
by a novel combined approach between the quantitative interproton distance 























































1.1 Inflammation and cancer 
The link between inflammation and cancers, rather tan a recent concern, 
was noticed ~150 years ago. As early as 1863, Virchow indicated that cancers 
tended to occur at sites of chronic inflammation.1  
Although it is now clear that proliferation of cells alone does not cause 
cancer, sustained cell proliferation in an environme t rich in inflammatory 
cells, growth factors, activated stroma, and DNA-damage-promoting agents, 
certainly potentiates and/or promotes neoplastic risk.  
During tissue injury associated with wounding, cell proliferation is 
enhanced while the tissue regenerates; proliferation and inflammation subside 
after the assaulting agent is removed or the repair completed. In contrast, 
proliferating cells that sustain DNA damage and/or mutagenic assault (for 
example, initiated cells) continue to proliferate in microenvironments rich in 
inflammatory cells and growth/survival factors that support their growth. In a 
sense, tumors act as wounds that fail to heal.2  
Today, the causal relationship between inflammation, in ate immunity and 
cancer is more widely accepted; however, many of the molecular and cellular 
mechanisms mediating this relationship remain unresolv d. Furthermore, 
tumor cells may usurp key mechanisms by which inflammation interfaces with 
cancers, to further their colonization of the host. Moreover, it was clear that 
the acquired immune response to cancer is intimately r ated to the 
inflammatory response.3,4 
Here, the critical points and the pathways connections between these two 








1.1.1 Inflammation: From Acute to Chronic 
Inflammation is a physiologic process in response to tissue damage 
resulting from microbial pathogen infection, chemical irritation, and/or 
wounding.5 At the very early stage of inflammation, neutrophils are the first 
cells to migrate to the inflammatory sites under the regulation of molecules 
produced by rapidly responding macrophages and mastcell  prestationed in 
tissues.6 As the inflammation progresses, various types of leukocytes, 
lymphocytes, and other inflammatory cells are activated and attracted to the 
inflamed site by a signaling network involving a great number of growth 
factors, cytokines, and chemokines.6 All cells recruited to the inflammatory 
site contribute to tissue breakdown and are beneficial by strengthening and 
maintaining the defense against infection.6a  
There are also mechanisms to prevent inflammation response from lasting 
too long.7 A shift from antibacterial tissue damage to tissue repair occurs, 
involving both proinflammatory and anti-inflammatory molecules.7 
Prostaglandin E2,8 transforming growth factor-β,9 and reactive oxygen and 
nitrogen intermediates6d are among those molecules with a dual role in both 
promoting and suppressing inflammation. The resolution of inflammation also 
requires a rapid programmed clearance of inflammatory cells: neighboring 
macrophages, dendritic cells, and backup phagocytes do this job by inducing 
apoptosis and conducting phagocytosis.10 The phagocytosis of apoptotic cells 
also promotes an anti-inflammatory response, such as enhancing the 
production of antiinflammatory mediator transforming growth factor- β.11 
However, if inflammation resolution is dysregulated, cellular response 
changes to the pattern of chronic inflammation. In chronic inflammation, the 





macrophages with varying morphology.5 Macrophages and other 
inflammatory cells generate a great amount of growth factors, cytokines, and 
reactive oxygen and nitrogen species that may cause DNA damage.6a If the 
macrophages are activated persistently; they may led to continuous tissue 
damage.12 A microenvironment constituted by all the above elments inhabits 
the sustained cell proliferation induced by continued tissue damage, thus 
predisposes chronic inflammation to neoplasia.1  
 
1.1.2 Cancer Development: An Overview 
Cancer defines malignant neoplasms characterized by metastatic growth. It 
may occur in almost every organ and tissue relating to a variety of etiologic 
factors, such as genomic instability and environmental stress.5 A two-stage 
carcinogenesis model is first conceptualized in a mouse model of skin 
cancer.13 In this model, carcinogenesis is initiated by carcinogen-triggered 
irreversible genetic alteration and then promoted by dysregulated gene 
expression of initiated cells that resulted from epig netic mechanisms and 
host-selective pressure.6a Once the proliferation advantage is obtained, cancer 
cells enter the progression stage in which their population expands rapidly.6b 
This model was subjected to criticism because it oversimplifies and failed to 
apply to all types of cancer.14 
However, cancer development is still accepted as a multistep process, 
during which genetic alterations confer specific types of growth advantage; 
therefore, it drives the progressive transformation from normal cells to 
malignant cancer cells.15 Malignant growth is characterized by several key 
changes: self-sufficiency of growth signals, insensitivity to antigrowth signals, 
escaping from apoptosis, unregulated proliferation potential, enhanced 





accomplished by combined efforts of various signaling processes, and 
moreover it will find out that inflammation may contribute to the formation of 
these cancer phenotypes. 
 
1.1.3 Connecting inflammation and cancer 
Common wisdom says ‘‘most things in life are a double-edged sword’’. 
While they are in our favor at one dose or under one condition; they may be 
disfavor at another dose or under another condition. Inflammation is a part of 
the host response to either internal or external enviro mental stimuli. This 
response serves to counteract the insult incurred by these stimuli to the host. 
This response can be pyrogenic, as indicated by fever. When acute 
inflammation or fever is manifested for a short period of time, it has a 
therapeutic consequence. However, when inflammation becomes chronic or 
lasts too long, it can prove harmful and may lead to disease. How is 
inflammation diagnosed and its biomarkers is not fully nderstood, however, 
the role of proinflammatory cytokines, chemokines, adhesion molecules and 
inflammatory enzymes have been linked with chronic i flammation (Figure 
1.1). Chronic inflammation has been found to mediat  wide variety of 
diseases, including cardiovascular diseases, cancer, diabetes, arthritis, 
Alzheimer’s disease, pulmonary diseases, and autoimmune diseases.16 Chronic 
inflammation has been linked to various steps involved in tumorigenesis, 
including cellular transformation, promotion, survival, proliferation, invasion, 
angiogenesis, and metastasis.17,18 That inflammation is a risk factor formost 






Figure 1. 1 Different faces of inflammation and its role in tumorigenesis. 
 
Al already reported, the links between cancer and inflammation were first 
made in the nineteenth century, on the basis of observations that tumors often 
arose at sites of chronic inflammation and that inflammatory cells were present 
in biopsied samples from tumors,1 but there has been a recent resurgence in 
interest.  
Several lines of evidence20 (Table 1.1) — based on a range of findings, from 
epidemiological studies of patients to molecular studies of genetically 
modified mice — have led to a general acceptance that inflammation and 
cancer are linked. Epidemiological studies have shown that chronic 
inflammation predisposes individuals to various types of cancer. It is estimated 
that underlying infections and inflammatory responses are linked to 15–20% 
of all deaths from cancer worldwide.1 There are many triggers of chronic 





microbial infections (for example, infection with Helicobacter pylori is 
associated with gastric cancer and gastric mucosal lymphoma), autoimmune 
diseases (for example, inflammatory bowel disease is associated with colon 
cancer) and inflammatory conditions of unknown origin (for example, 
prostatitis is associated with prostate cancer). Accordingly, treatment with 
non-steroidal anti-inflammatory agents decreases th incidence of, and the 
mortality that results from, several tumor types.21 
 
Table 1. 1 The evidence that links cancer and inflammation 
1 
Inflammatory diseases increase the risk of developing many types of cancer 
(including bladder, cervical, gastric, intestinal, oesophageal, ovarian, prostate 
and thyroid cancer) 
2 
Non-steroidal anti-inflammatory drugs reduce the risk of developing certain 
cancers (such as colon and breast cancer) and reduce the mortality caused by 
these cancers. 
3 
Signaling pathways involved in inflammation operate downstream of oncogenic 
mutations (such as mutations in the genes encoding RAS, MYC and RET). 
4 
Inflammatory cells, chemokines, and cytokines are present in the 
microenvironment of all tumors in experimental animal models and humans 
from the earliest stages of development. 
5 
The targeting of inflammatory mediators (chemokines and cytokines, such as 
TNF-α and IL-1β), key transcription factors involved in inflammation (such as 
NF-κB and STAT3) or inflammatory cells decreases the incidence and spread of 
cancer. 
6 
Adoptive transfer of inflammatory cells or overexpression of inflammatory 
cytokines promotes the development of tumors. 
 
The hallmarks of cancer-related inflammation include the presence of 
inflammatory cells and inflammatory mediators (for example, chemokines, 





angiogenesis similar to that seen in chronic inflammatory responses, and tissue 
repair. These signs of ‘smouldering’ inflammation20a are also present in 
tumors for which a firm causal relationship to inflammation has not been 
established (for example, breast tumors). Indeed, inflammatory cells and 
mediators are present in the microenvironment of most, if not all, tumors, 
irrespective of the trigger for development. 
In the tumor microenvironment, inflammatory cells and molecules 
influence almost every aspect of cancer progress, including the tumor 
cells’ability to metastasize.22 Thus, whereas there were previously six 
recognized hallmarks of cancer — unlimited replicative potential, self-
sufficiency in growth signals, insensitivity to growth inhibitors, evasion of 
programmed cell death, ability to develop blood vessels, and tissue invasion 
and metastasis23 — cancer related inflammation now emerges as number seven 
(Figure 1.2). In 2000, Hanahan and Weinberg23 proposed a model to define the 
six properties that a tumor acquires. 
 
 





These are unlimited replicative potential, ability to develop blood vessels 
(angiogenesis), evasion of programmed cell death (apoptosis), self-sufficiency 
in growth signals, insensitivity to inhibitors of growth, and tissue invasion and 
metastasis. Kim and colleagues’ findings,24 together with those of other 
studies,22,18 indicate that this model should be revised to include cancer-related 
inflammation as an additional hallmark.23  
The connection between inflammation and cancer can be viewed as 
consisting of two pathways: an extrinsic pathway, driven by inflammatory 
conditions that increase cancer risk (such as inflamm tory bowel disease); and 
an intrinsic pathway, driven by genetic alterations that cause inflammation and 
neoplasia (such as oncogenes) (Figure 1.3).  
The intrinsic pathway was uncovered when addressing why inflammatory 
cells and mediators are present in the microenvironment of most, if not all, 
tumors and therefore are present in cases for which t ere is no epidemiological 
basis for inflammation. This finding raised the question of whether the genetic 
events that cause neoplasia in these cases are responsible for generating an 
inflammatory environment. This question has been addressed only recently, by 
using preclinical and clinical settings in which various oncogenetic 
mechanisms can be assessed.  
The intrinsic pathway is activated by genetic events that cause neoplasia. 
These events include the activation of various types of oncogene by mutation, 
chromosomal rearrangement or amplification, and the inactivation of tumor-
suppressor genes. Cells that are transformed in this manner produce 
inflammatory mediators, thereby generating an inflammatory 
microenvironment in tumors for which there is no underlying inflammatory 





inflammatory or infectious conditions augment the risk of developing cancer 
at certain anatomical sites (for example, the colon, prostate and pancreas).  
 
 
Figure 1. 3 Pathways that connect inflammation and cancer. Cancer and inflammation are 






The two pathways converge, resulting in the activation of transcription 
factors, mainly nuclear factor-kB (NF-kB), signal transducer and activator of 
transcription 3 (STAT3) and hypoxia-inducible factor 1 (HIF1α), in tumor 
cells. These transcription factors coordinate the production of inflammatory 
mediators, including cytokines and chemokines, as well as the production of 
cyclooxygenase 2 (COX2) (which, in turn, results in the production of 
prostaglandins). These factors recruit and activate rious leukocytes, most 
notably cells of the myelomonocytic lineage. The cytokines activate the same 
key transcription factors in inflammatory cells, stromal cells and tumor cells, 
resulting in more inflammatory mediators being produced and a cancer-related 
inflammatory microenvironment being generated. Smouldering cancer-related 
inflammation has many tumor-promoting effects. 
 
1.1.3.1  Mutagenic Potential of Inflammation 
The chronic inflammation microenvironment is predominated by 
macrophages.6 Those macrophages, together with other leukocytes, g nerate 
high levels of reactive oxygen and nitrogen species to fight infection.25 
However, in a setting of continuous tissue damage and cellular proliferation, 
the persistence of these infection-fighting agents is deleterious.6b They may 
produce mutagenic agents, such as peroxynitrite, which react with DNA and 
cause mutations in proliferating epithelial and stroma cells.25,26 Macrophages 
and T lymphocytes may release tumor necrosis factor-α (TNF-α) and 
macrophage migration inhibitory factor to exacerbate DNA damage.27 
Migration inhibitory factor impairs p53-dependent protective responses, thus 
causing the accumulation of oncogenic mutations.28 Migration inhibitory 





Within an ileocolitis-associated mouse cancer model, th  high susceptibility to 
inflammation and cancer in hydroperoxide-reducing ezyme-deficient mice 
suggested that intracellular hydroperoxides might also contribute to tumor 
initiation.30  
 
1.1.3.2 Role of Inflammatory Cells in Tumor Development  
Other than a single mutation, more genetic and epigenetic events are required 
to drive from initiated cells to malignant tumors.23 Some of these events are 
also found to be related to chronic inflammation. For instance, angiogenesis, a 
critical process in tumor progression,31 associates with chronic inflammation, 
such as psoriasis, rheumatoid arthritis, and fibross.23 In addition, the tumor 
inflammatory microenvironment can facilitate the breakage of the basement 
membrane, a process required for the invasion and migration of tumor cells.6a 
A wide population of leukocytes and other types of immune cells infiltrate to 
the developing tumor site and establish the tumor inflammatory 
microenvironment.6c Macrophages, neutrophils, eosinophils, dendritic cells, 
mast cells, and lymphocytes are also found to be key components in the 
epithelial-originated tumors.6c,12,32 The infiltration of immune cells to tumors 
may repress tumor growth.33 However, the increasing concern is that 
inflammatory cells act as tumor promoters in inflammation-associated 
cancers.6a,34,35 Accumulated mutations in epithelial cells lead to dysregulation 
of their growth and migration. These dysregulated epith lial cells may also 
signal to recruit leukocytes.31 In addition, tumor cells may also produce 








1.1.3.3 Key Molecular Players in Linking Inflammation to 
  Cancer 
To address the details of transition from inflammation to cancers and the 
further development of inflammation-associated cancers, it is necessary to 
investigate specific roles of key regulatory molecus involved in this process. 
In fact, in the panoply of molecules involved in can er-related inflammation, 
key endogenous (intrinsic) factors can be identified. These include 
transcription factors (such as NF-kB and signal transducer and activator of 
transcription 3 (STAT3)) and major inflammatory cytokines (such as IL-1β, 
IL-6, IL-23 and TNF-α)36,37,38 (Table 1.2). 
 
Table 1. 2 Key Molecular Players Linking Cancer to Inflammation. 
Potential linkers Functions in linking inflammation to cancer 
Cytokines  
IL-6 Promote tumor growth 
TNF-α 
Induce DNA damage and inhibit DNA repair 
Promote tumor growth 
Induce angiogenic factors 
Chemokines 
Promote tumor cell growth 
Facilitate invasion and metastasis by directing tumor cell 
migration and promoting basement membrane degradation 
NF-Κβ 
Mediate inflammation progress, promoting chronic 
inflammation 
Promote the production of mutagenic reactive oxygen species  
Protect transformed cells from apoptosis 
Promote tumor invasion and metastasis 
Feedback loop between proinflammatory cytokines 





Induce DNA damage and disrupt DNA damage response 
Regulate angiogenesis and metastasis 
COX-2 
Produce inflammation mediator prostaglandins 
Promote cell proliferation, antiapoptotic activity, angiogenesis, 
and metastasis 
HIF-1α 
Promote chronic inflammation  
Induced by proinflammatory cytokines through NF-nB  
Enhance the glycolytic activity of cancer cells  
Contribute to angiogenesis, tumor invasion, and metastasis by 
transactivating VEGF 
STAT3 
Activated by proinflammatory cytokines  
Promote proliferation, apoptosis resistance, and immune 
tolerance 
Nrf2 
Anti-inflammatory activity  
Protect against DNA damage 
NFAT 
Regulate proinflammatory cytokine expression  
Required in cell transformation 
 
For sick of simplicity, between the molecular players involved in 
inflammatory networking cancer, the tumor necrosis factor (TNF-α) and NF-
kB will be described. The TNF-α was first isolated as an anticancer cytokine 
than two decades ago.39 Experience since then has indicated that when 
expressed locally by the cells of the immune system, TNF-α has a therapeutic 
role. However, when dysregulated and secreted in the circulation, TNF-a can 
mediate a wide variety of diseases, including cancer.39 TNF-α has itself been 
shown to be one of the major mediators of inflammation.40 Induced by a wide 
range of pathogenic stimuli, TNF-α induces other inflammatory mediators and 
proteases that orchestrate inflammatory responses. TNF-α is also produced by 





has been linked to all steps involved in tumorigenesis, including cellular 
transformation, promotion, survival, proliferation, i vasion, angiogenesis, and 
metastasis, as outlined below (Figure 1.4). 
 
 
Figure 1. 4 Inflammatory networking in cancer. 
 
On the other hand, NF-kB is a key coordinator of innate immunity and 
inflammation, and has emerged as an important endogenous tumor promoter.36 
NF-kB is crucial both in the context of tumor or potential tumor cells and in 
the context of inflammatory cells. In these cell types, NF-ΚB operates 
downstream of the sensing of microorganisms or tissue damage by the Toll-
like receptor (TLR)–MyD88 signaling pathway, and by signaling pathways 
mediated by the inflammatory cytokines TNF-α and IL-1β. In addition, NF-
kB can be activated as a result of cell-autonomous genetic alterations 
(amplification, mutations or deletions)41 in tumor cells. In tumor cells and 
epithelial cells at risk of transformation by carcinogens, as well as in 





inflammatory cytokines, adhesion molecules, enzymes in the prostaglandin-
synthesis pathway (such as COX2), inducible nitric oxide synthase (iNOS; 
also known as NOS2) and angiogenic factors. 
In addition, one of the important functions of NF-ΚB in tumor cells or cells 
targeted by carcinogenic agents is promoting cell survival, by inducing the 
expression of anti-apoptotic genes (such as BCL2). There is also accumulating 
evidence of interconnections and compensatory pathways between the NF-KB 
and HIF1α systems,42 linking innate immunity to the response to hypoxia. 
There is unequivocal evidence that NF-ΚB is involved in tumor initiation and 
progression in tissues in which cancer-related inflammation typically occurs 
(such as the gastrointestinal tract and the liver).43 The NF-ΚB pathway is 
tightly controlled by inhibitors that function at various stages of the pathway. 
An example is TIR8 (also known as SIGIRR), a member of the IL-1-receptor 
family. TIR8 has a single immuno globulin domain, a long cytoplasmic tail, 
and a Toll/IL-1 receptor (TIR) domain that differs f om that of other members 
of the IL-1-receptor family. Deficiency in the gene that encodes TIR8 is 
associated with increased susceptibility to intestinal inflammation and 
carcinogenesis.44 Thus, the balance of inhibitors and activators tunes the extent 
to which the NF-ΚB pathway operates as an endogenous tumor promoter. 
Support for the connection between cancer and inflamm tion is further 
strengthened by studies of the role of NF-ΚB in tumor-infiltrating leukocytes. 
In established, advanced tumors, which typically have  microenvironment of 
smouldering inflammation,20 tumor-associated macrophages (TAMs) have 
delayed and defective NF-κB activation.45 Evidence suggests that homodimers 
of the p50 subunit of NF-κB (a negative regulator of the NF-κB pathway) are 
responsible for this sluggish activation of NF-κB in TAMs and for the 





‘rheostat’ whose function can be tuned to different levels, a property that 
enables the extent of inflammation to be regulated. Such regulation allows the 
vigorous inflammation (for example, in inflammatory bowel disease) that 
predisposes individuals towards developing cancer to be sustained, and 
enables TAMs to sustain the smouldering inflammatory microenvironment 
present in established metastatic neoplasia.  
Briefly, the mediators and cellular effectors of inlammation are important 
constituents of the local environment of tumors.  
 
1.2 Scope and outline of this thesis 
The study of ligand-macromolecule interactions has a fundamental role for 
the design and the development of new and more powerful drugs. In this 
project, different aspects of interaction and recognition processes between 
ligand and macromolecule has been studied through a combined approach 
based on computational chemistry techniques and NMR spectroscopy. In 
particular, these different aspects regard the employment and elaboration of 
screening methods, the analysis of structural determinants responsible of drug-
macromolecule complex formation and the design of new potential bioactive 
compounds. Several and different proteins, involved in essential cellular 
processes, have been investigated as biological targets taking into account 
their implication in tumor and inflammation initiaton and progress with the 
aim to identify and rationalize new molecules potentially utilizable in therapy.  
As already reported, in some types of cancer, inflamm tory conditions are 
present before a malignant change occurs. Conversely, in other types of 
cancer, an oncogenic change induces an inflammatory microenvironment that 
promotes the development of tumors. Regardless of it  rigin, inflammation in 





proliferation and survival of malignant cells, promtes angiogenesis and 
metastasis, subverts adaptive immune responses, and alters responses to 
hormones and chemotherapeutic agents. The molecular pathways of this 
cancer-related inflammation are now being unraveled, resulting in the 
identification of new target molecules that could lead to improved diagnosis 
and treatment. Between them, in this project, the att ntion was focused on 
targets (Histone deacetilase, HDAC; Nicotinamide Phosp oribosyltransferase, 
NMPRTase or Nampt; microsomal prostaglandin E2 synthase, mPGES-1; 
human synovial Phospholipases A2, hsPLA2; human Farnesoid-X-Receptor, 
FXR; human Pregnane-X-Receptor, PXR; Bile Acid Receptor GPBAR-1, 
TGR5) with different mechanisms of action involved in diverse levels and 
phases of tumor and inflammation process.  
In particular, in the chapter 2 the results obtained for the design, in silico 
screening, and rationalization of binding modes of pan, selective cyclic and 
linear HDAC inhibitors are summarized.  
In chapter 3 the analysis at atomic level of the interactions between 
NMPRTase and triazole-based analogs of APO866 and CHS2883 are reported.  
Although some HDAC inhibitors are already showing therapeutic utility in 
animal models of inflammatory diseases (such as arthritis, inflammatory 
bowel diseases, septic shock, ischemia-reperfusion injury, asthma, ecc.),47 and 
NMPRTase is able to control both cell viability and the inflammatory 
response,48 by regulating NAD availability, it is important to underline that for 
all the compounds described in the chapters 2 and 3 only their antitumor 
activity was evaluated. 
The chapters 4 and 5 are related to the design, in silico screening and 
rationalization of binding modes of mPGES-1 and hsPLA2 inhibitors, key 





in the chapter 4 the design and in silico evaluation of two series of triazole-
based compounds is described in detail; while in the c apter 5, the putative 
binding modes of two marine natural products to human synovial 
Phospholipases A2 were obtained through molecular docking.  
However, even if mPGES-149 is becoming a target for cancer suppression 
thanks to its inhibitory ability to suppress the PGE2 synthesis offering the 
potential for therapeutic benefit without the potential toxicity associated with 
COX-2 inhibition, in the chapter 4, only the potential antiinflammatory 
activities of designed molecules were evaluated. In the chapter 5, the 
antiinflammatory activity of reported compounds was nalyzed in detail, 
although the group II Group IIA Phospholipase A2 (PLA2-IIA) also plays a 
role in tumor progression in vivo, and inhibitors of PLA2-IIA suppress the 
proliferative activity and invasiveness of prostate carcinoma cell lines.50  
The chapters 6 and 7 refer to nuclear receptors FXR, PXR and TGR5 
ligands. In particular, in the chapter 6, a detail r tionalization of the 4-
Methylen sterols antagonist and agonist activity on FXR are PXR respectively 
was reported. On the other hand, in the chapter 7, agonist activity of two well-
known ligands to TGR5 is described. For these compounds will be analyzed 
and described their activity in the controlling of the bile acids metabolism and 
their involvement with dysfunctions connected with it; in fact the described 
nuclear receptors (FXR, PXR and TGR5) are important pharmacological 
targets for a number of diseases, including cancer and metabolic disorders.51 
Finally in the chapter 8, it will be described the use of calculation at 
quantum mechanical level of the NMR parameters (e.g. δ, chemical shifts, and 







1.3 Methodologies employed 
Before starting the discussion concerning the results obtained, it is 
appropriate briefly introduce the methodologies utilized to realize the project.  
 
1.3.1 Molecular docking 
Computational methodologies have become a crucial component in drug 
discovery, from virtual screening for hit identification to lead compound 
optimization. One key methodology is the molecular docking that consists in 
the prediction of ligand conformation and orientation within a targeted binding 
site. The molecular docking is based on the requirement that the 3D structure 
of the macromolecule is known. Many different programs have been 
developed, of which DOCK,52 FlexX,53 GOLD,54120 Autodock,55,56,57 
Autodock Vina,58 and Glide12259 are among the most popular. The mentioned 
tools are based on a range of different concepts, and e ch comes with its own 
set of strengths and weaknesses. One feature most docking programs share, 
however, is that they position a flexible ligand into a rigid binding site. 
Computational feasibility is the main reason for utilizing a rigid 
macromolecule in the docking calculations, as the number of freedom degrees 
that have to be considered grows exponentially withthe number of accessible 
receptor conformations. Most molecular docking software have two key parts: 
(1) a search algorithm and (2) a scoring function.60 For molecular docking to 
be useful in drug discovery, these key parts should be both fast and accurate. 
These two requirements are often in opposition to each other, requiring 
necessary compromises that commonly end in ambiguous results or failure.61  
The search algorithm samples different ligand orientations and 





complicated by the number of freedom degrees contained in the small 
molecule, increasing the conformational space to sample. The search methods 
can be grouped in three categories: systematic methods, random or stochastic 
methods, and simulation methods. The systematic search lgorithms try to 
explore all the degrees of freedom in a molecule, but they face the problem of 
huge number of generated conformations.62 The random methods (often called 
stochastic methods) operate by making random changes to either a single 
ligand or a population of ligands. A newly obtained ligand is evaluated on the 
basis of a pre-defined probability function. Two popular random approaches 
are Monte Carlo and genetic algorithms. About simulations search methods, 
molecular dynamics is currently the most popular approach. However, 
molecular dynamics simulations are often unable to cross high-energy barriers 
within feasible simulation time periods, and therefo  might only 
accommodate ligands in local minima of the energy surface.63 Therefore, an 
attempt is often made to simulate different parts of a protein–ligand system at 
different temperatures.64 Another strategy for addressing the local minima 
problem is starting molecular dynamics calculations from different ligand 
positions. In contrast to molecular dynamics, energy minimization methods are 
rarely used as stand-alone search techniques, as only local energy minima can 
be reached, but often complement other search methods. The scoring function 
aims to evaluate the results of the search algorithm predicting the affinity for 
the biological target. This evaluation is very difficult because the binding 
process is governed by enthalpic and entropic factors and one or of them can 
predominate. Other elements can affect the scoring method, such as limited 
resolution of crystallographic targets, inherent flexibility, induced fit or other 
conformational changes that occur on binding and the participation of water 





functions are currently applied: force field-based, mpirical and knowledge-
based scoring functions.  
Molecular mechanics force fields usually quantify the sum of two energies, 
the macromolecule–ligand interaction energy and internal ligand energy (such 
as steric strain induced by binding). Most force fild scoring functions only 
consider a single protein conformation, which makes it possible to omit the 
calculation of internal protein energy, which greatly simplifies scoring. The 
enthalpic contribution are essentially given by theel ctrostatic and Van der 
Waals terms, and is some software (AutoDock, Gold) take into account the 
hydrogen bond formation between drug and biological target. 
The van der Waals potential energy for the general tre tment of non-bonded 













Equation 1. 1 
 
where ε is the well depth of the potential and σ is the collision diameter of 
the respective atoms i and j. The exp(12) term of the equation is responsible 
for small-distance repulsion, whereas the exp(6) provides an attractive term 
which approaches zero as the distance between the two atoms increases. 
The Lennard–Jones 12–6 function is also used to describ  the hydrogen 
bond in macromolecule-ligand complex, but compared to the Van der Waals 
function, is less smooth and angle dependent. 
 
 
Figure 1. 5 Schematic representation of functions used to model pair
contribute to binding. Interactions are calculated as a function of the distance (
two atoms i and j. a) van der Waals interact
the smoother attractive part of the potential compared to hydrogen bond term). B) hydrogen 
bond potential given by a ‘harder’ 12
for two like (blue) or opposite (black) charges of same magnitude calculated using a distance 
dependent dielectric constant.
 
The electrostatic potential energy is represented as a
Coulombic interactions, as described in equation
 
Equation 1. 2 
 
where N is the number of atoms in molecules A and B, respectively, and q 
the charge on each atom. The functional form o
typically very similar to the
includes van der Waals contributions
Empirical scoring functions work on the sum of several parameterized 
functions to reproduce experimental data. The design of empirical soring 
functions is based on
sum of individual uncorrelated terms. The coefficients of the various terms are 
24 
-wise interactions that 
ion given by a 12–6 Lennard–Jones potential (note 
–10 Lennard–Jones potential. C) electrostatic potential 
 










f the internal ligand energy is 
 protein–ligand interaction energy, and also 
 and/or electrostatic terms. 
 the idea that binding energies can be approximated by a 
Introduction 
 





obtained from regression analysis using experimentally determined binding 
energies and X-ray structural information. 
By using the knowledge-based scoring functions protein–ligand complexes 
are modeled using relatively simple atomic interaction-pair potentials. A 
number of atom-type interactions are defined depending on their molecular 
environment. 
 
1.3.1.2 Autodock: an Overview 
There are numerous molecular docking software applications that utilize 
different searching and scoring algorithms and AutoDock is currently one of 
the most cited of these applications,65 especially in a virtual screening of a 
compound libraries.66 For the purposes of this project the software AutoDock 
3.0.5,55 4.1,56 4.2,57 and AutodockVina58 have been used, where the 
differences between them are related to the speed, macromolecule sidechains 
flexibility, optimization of the free-energy scoring function based on a linear 
regression analysis, AMBER force field, larger set of diverse protein-ligand 
complexes with known inhibition constants; moreover the Lamarckian Genetic 
Algorithm (LGA) is a big improvement on the Genetic Algorithm, and both 
genetic methods are much more efficient and robust than SA in the new 
version of the software. 
The best model obtained with the latest version AutoDock 4.257 in fact, was 
cross-validated with a separate set of HIV-1 protease complexes, and 
confirmed that the standard error is around 2.5 kcal/mol.  
In AutoDock there are different available search methods, but the 
Lamarckian Genetic Algorithm (LGA) has been selected for the aim of this 
study, because it has demonstrated to give the best results compared to the 
other algorithms.55  
 
The vast majority of genetic algorithms mimic
Darwinian evolution
Figure 1.7 note the oneway
phenotype. However, in th
(i.e., one which yields a genotype from a given phenotype
finish a local search by replacing the
search; see the left-hand side of Figure 1.
Figure 1. 6 This figure illustrates genotypic and
and Lamarckian search.
line, and the space of the phenotypes is re
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The result of applying the genotypic mutation
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local minimum, and an inverse mapping
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corresponding genotype. In the case of molecular docking, however, local search is performed 
by continuously converting from the genotype to thephenotype, so inverse mapping is not 
required. The genotype of the parent is replaced by the resulting genotype, however, in 
accordance with Lamarckian principles. 
 
This is called the Lamarckian genetic algorithm (LGA), and is an allusion 
to Jean Batiste de Lamarck’s (discredited) assertion that phenotypic 
characteristics acquired during an individual’s lifetime can become heritable 
traits.68 
The most important issues arising in hybrids (LGA) of Genetic Algorithm 
(GA) and the Local Search (LS) revolve around the developmental mapping, 
which transforms genotypic representations into phenotypic ones.  
The genotypic space is defined in terms of the genetic operators mutation 
and crossover in our experiments by which parents of one generation are 
perturbed to form their children. The phenotypic space is defined directly by 
the problem, namely, the energy function being optimized. The local search 
operator is a useful extension of GA global optimization when there are local 
‘‘smooth-ness’’ characteristics (continuity, correlation, etc.) of the fitness 
function that local search can exploit. In hybrid GA + LS optimizations, the 
result of the LS is always used to update the fitness associated with an 
individual in the GA selection algorithm. If, and only if, the developmental 
mapping function is invertible, will the Lamarckian option converting the 
phenotypic result of LS back into its corresponding genotype become possible. 
The fitness or energy is usually calculated from the ligand’s coordinates, 
which together form its phenotype. The developmental m pping simply 
transforms a molecule’s genotypic state variables into the corresponding set of 





optimization is that the Solis and Wets LS operator searches through the 
genotypic space rather than the more typical phenotypic space. This means 
that the developmental mapping does not need to be inverted. Nonetheless, 
this molecular variation of the genetic algorithm still qualifies as Lamarckian, 
because any ‘‘environmental adaptations’’ of the ligand acquired during the 
local search will be inherited by its offspring. Ateach generation, it is possible 
to let a user defined fraction of the population undergo such a local search. 
The local search frequencies of just 0.06 have found improved efficiency of 
docking, although a frequency of 1.00 is not significantly more efficient.67 
Both the canonical and a slightly modified version f the Solis and Wets 
method have been implemented. In canonical Solis and Wets, the same step 
size would be used for every gene, but we have improved the local search 
efficiency by allowing the step size to be different for each type of gene: a 
change of 1 Å in a translation gene could be much more significant than a 
change of 1° in a rotational or torsional gene. In the Lamarckian genetic 
algorithm, genotypic mutation plays a somewhat different role than it does in 
traditional genetic algorithms. Traditionally, mutation plays the role of a local 
search operator, allowing small, refining moves that are not efficiently made 
by crossover and selection alone. With the explicit local search operator, 
however, this role becomes unnecessary, and is needed only for its role in 
replacing alleles that might have disappeared through selection. In LGA, 
mutation can take on a more exploratory role.  
The LGA yields a maximum number of 256 potential bioactive 
conformations: run, whose number can be increased performing more docking 
calculations. Each conformational solution is the result of a selection. The GA, 
starting from the input geometry, gives rise to a group of n conformations or 





rotational and torsional variables. By the scoring function, each individual is 
labeled by the total interaction energy: fitness. Random pairs of individuals are 
mated using a process of crossover, in which new individuals inherit 
geometrical features from their parents leading to new generation of 
individuals. In addition, some offspring undergo random mutation, in which 
the translational, rotational and torsional variables are mutated randomly. 
Selection of the offspring of the current generation ccurs based on the 
individual’s fitness: thus the better solutions go on into the next generations, 
whereas conformations with a low fitness are discarded. This cycle of 
crossover, mutation to lead new generation is repeat d until the better 
bioactive conformation (run) is given.  
The LS perform an energy minimization of the current found conformation. 
In each generation a fraction of conformations population undergoes the 
geometry optimization, based on the local search frequency. Rapid energy 
evaluation is achieved by precalculating atomic affinity potentials (grid maps) 
for each atom type in the substrate molecule by grid method.69  
These maps are calculated by AutoGrid. In this procedure the protein is 
embedded in a three dimensional grid and a probe atom is placed at each grid 
point (Figure 1.7). The energy of interaction of this single atom with the 
protein is assigned to the grid point.   
An affinity grid is calculated for each type of atom in the substrate, 
typically carbon, oxygen, nitrogen and hydrogen, as well as a grid of 
electrostatic potential, either using a point charge of +1 as the probe, or using a 
Poisson-Boltzmann finite difference method, such as DELPHI.70 The energetic 
of a particular substrate configuration is then found by tri-linear interpolation 








Figure 1. 7 Schematic representation of the grid map. 
 
The electrostatic interaction is evaluated similarly, by interpolating the 
values of the electrostatic potential and multiplying by the charge on the atom 
(the electrostatic term is evaluated separately to all w finer control of the 
substrate atomic charges). The time to perform an energy calculation using the 
grids is proportional only to the number of atoms in the substrate, and is 
independent of the number of atoms in the protein. An estimated free energy 
of binding is used to evaluate the docked ligand conformations. This scoring 
function, based of force field Amber,71 comprises terms above described 
(directional hydrogen bonding, electrostatics, Van der Waals, internal energy) 
and entropic contribution: desolvation and torsional entropy. The latter 
describes the loss of entropy upon interaction with macromolecule followed 





of water molecules from the active site upon the binding of ligand to the 
macromolecular surface and the reorganization of solvent around the complex. 
The scoring function was implemented using the thermodynamic cycle of 
Wesson and Eisenberg. The function is: 
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Equation 1. 3 
 
where the five ∆G terms on the right hand side are coefficient empirically 
determined using a linear regression analysis from a set of protein-ligand 
complexes.55 
For what concern AutoDock Vina,58 this is a new open-source program for 
drug discovery, molecular docking and virtual screening, offering multi-core 
capability, high performance and enhanced accuracy and ease of use. Vina 
uses a sophisticated gradient optimization method in its local optimization 
procedure. The calculation of the gradient effectively gives the optimization 
algorithm a “sense of direction” from a single evaluation. In the spectrum of 
computational approaches to modeling receptor ligand binding molecular 
dynamics with explicit solvent, molecular dynamics and molecular mechanics 
with implicit solvent, molecular docking can be seen as making an increasing 
trade-off of the representational detail for computational speed.72 Among the 
assumptions made by these approaches is the commitment to a particular 





change between, for example, their bound and unbound states. Additionally, 
docking generally assumes much or all of the receptor rigid, the covalent 
lengths, and angles constant, while considering a chosen set of covalent bonds 
freely rotatable (referred to as active rotatable bonds here). Importantly, 
although molecular dynamics directly deals with energies (referred to as force 
fields in chemistry), docking is ultimately interest d in reproducing chemical 
potentials, which determine the bound conformation preference and the free 
energy of binding. It is a qualitatively different concept governed not only by 
the minima in the energy profile but also by the shape of the profile and the 
temperature.73 Docking programs generally use a scoring function, which can 
be seen as an attempt to approximate the standard chemi al potentials of the 
system. When the superficially physics-based terms like the 6–12 van der 
Waals interactions and Coulomb energies are used in the scoring function, 
they need to be significantly empirically weighted, in part, to account for this 
difference between energies and free energies.73  
The afore mentioned considerations should make it rathe  unsurprising 
when such superficially physics-based scoring functio s do not necessarily 
perform better than the alternatives. This approach was seen to the scoring 
function as more of “machine learning” than directly physics-based in its 
nature. It is ultimately justified by its performance on test problems rather than 
by theoretical considerations following some, possibly too strong, 
approximating assumptions 
The general functional form of the conformation-dependent part of the 
scoring function AutoDock Vina is designed to work with is: 
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where the summation is over all of the pairs of atoms that can move relative to 
each other, normally excluding 1–4 interactions, i.e., atoms separated by three 
consecutive covalent bonds. Here, each atom i is assigned a type ti, and a 
symmetric set of interaction functions fti-tj of the interatomic distance rij should 
be defined. 
This value can be seen as a sum of intermolecular and intramolecular 
contributions: 
 
J 	 	 J.728 +	J.78M 
Equation 1. 5 
 
The optimization algorithm attempts to find the global minimum of c and 
other low-scoring conformations, which it then ranks. 
The predicted free energy of binding is calculated from the intermolecular 
part of the lowest-scoring conformation, designated as 1: 
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Equation 1. 6 
 
where the function g can be an arbitrary strictly increasing smooth possibly 
nonlinear function. 
In the output, other low-scoring conformations are lso formally given s 
values, but, to preserve the ranking, using ci tra of the best binding mode: 
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For modularity reasons, much of the program does not rely on any 
particular functional form of fti-tj interactions or g. Essentially, these functions 
are passed as a parameter for the rest of the code.  
In summary the evaluation of the speed and accuracy of Vina during 
flexible redocking of the 190 receptor-ligand complexes making up the 
AutoDock 4 training set showed approximately two orders of magnitude 
improvement in speed and a simultaneous significantly better accuracy of the 
binding mode prediction. In addition, Vina can achieve near-ideal speed-up by 
utilizing multiple CPU cores. However, AutodockVina does not provide very 
good weight of the energetic contribution derived from the hydrogen bond and 
electrostatic interactions, especially when the metal ions are presents.  
 
It is important to underline in this phase of the study description that the 
molecular docking methodology was used for the design of new molecules 
with potential antitumoral and antiflammatory activities as HDAC (see 
paragraph 2.2-2.4, and 2.6) and mPGES-1 (see Chapter 4) inhibitors 
respectively. Alongside this application, in this results description, the 
molecular docking was also used to rationalize the binding modes and the 
mechanism of action of Ugi products CHAP 1 derivatives (paragraph 2.5) as 
HDAC inhibitors, of FX866 and CHS823analogs inhibitors of NMPRTase 
(Chapter 3), of marine natural products acting as inhibitors of hsPLA2 
(Bolinaquinone, BLQ; and Cladocoran A, CLD A), 4-methylensterols as 
ligands of nuclear receptors (Farnesoid-X-receptor (FXR) and the pregnane-X-
receptor (PXR)), and of two molecules with already known pharmacology 






1.3.2 Quantum Mechanical Calculation of NMR Parameters in 
the Stereostructural Determination of Natural Products. 
 
Many molecular properties of organic compounds, such as chemical 
reactivity and catalytic, biological, and pharmacological activities, are 
critically affected not only by their functional groups but also by their spatial 
position. Thus, the disclosure of the relative configuration has a great impact 
in the full understanding of their chemical behaviours. Different approaches to 
determine the exact structure and/or configuration of organic products have 
been devised.74,75,76 The total synthesis has played a primary role in the 
structural assignment and revision but its drawback is represented by the 
additional costs in terms of time and money. For these reasons, a series of new 
and more rapid methods, such as nuclear magnetic resonance (NMR), circular 
dichroism (CD), X-ray crystallography, and mass spectrometry (MS), that 
allow the preservation of the sample under investigation, have shown to be a 
valid alternative to the classical chemical approach. 
In this field, NMR spectroscopy is one of the most employed tool, as some 
NMR parameters (coupling constant, chemical shift (cs)) can provide 
fundamental information on the configurational and conformational 
arrangement of organic molecules. For example, the 3JH-H coupling constants 
between protons separated by three bonds depend on the dihedral angles, 
following the well known Karplus equation.77 Moreover, the Nuclear 
Overhauser Effect (NOE)78 provides information of the 3D spatial 
arrangement of the nuclei, clarifying the geometrical information on the 
relative positions of the atoms in the analysed molecule. Thus, the evaluation 





shifts, and/or nuclear Overhauser effect intensities allows to determine the 
configuration of cyclic compounds with three- to six-membered rings 
presenting a predictable conformational behaviour. Polysubstitued opened 
chains and macrocycles, constitute a more difficult cases of relative 
configurational assignment, because the stereochemial analysis is 
complicated by the geometrical uncertainty of such types of flexible systems.  
For the above situations, different NMR-based methods, such as the J-
based analysis,76,79 the Universal NMR Database (UDB),76,80 and the quantum 
mechanical calculation of NMR parameters,76,81,82 have been proposed for the 
relative (and/or absolute) configurational assignmet of organic molecules. 
The J-based analysis was originally devised by Murata and co-workers and it 
has been shown to be very helpful for the relative configurational assignment 
of two adjacent (1,2) or alternate (1,3) stereocenters belonging to an acyclic 
carbon chain. Briefly, this J-based approach consists in considering the three 
main staggered rotamers (anti, g+ and g-) of the two possible relative 
configurations (threo and erythro) of a stereopair and assigning for each 
rotamers a predicted qualitative (small, medium andlarge) set of 3JH-H and 
2,3JC-H, based on the dependence of scalar couplings on the dihedral angles. 
The comparison of the experimental measured values of homo- and hetero-
nuclear coupling constants with the rotamer predict patterns allows to assign 
the relative configuration of two stereocenters.  
The UDB method is based on the comparison of the proton and carbon 
chemical shifts of a structure having an unknown relative configuration with 
the resonance values of a molecular database formed by fragments of known 
compounds. In particular, the structure under studies could be divided in small 
fragments and its chemical shifts compared with an appropriate reference 





In the last years, great advances have been made in developing QM 
methods of chemical interest able to predict molecular properties. In 
particular, the quantum mechanical calculations of NMR parameters have 
been used as an emerging strategy for the assignment of relative configuration 
of organic molecules, based on the high accuracy in the reproduction of 
experimental NMR properties achieved also at a low demanding level of 
theory.83,84 For further details about theoretical concepts, applications and 
limitations of these NMR-based approaches we refer to our previous review on 
the determination of relative configuration of organic compounds.76 It is 
noteworthy that, besides the development and application of QM approach for 
structural studies, fast empirical methods have been devised to predict NMR 
chemical shifts.85 These empirical methods are based on fast calculation 
algorithms86 that can generate a set of possible structural hypot eses with the 
average deviation between calculated and experimental chemical shifts equal 
to δ = 1.8 ppm for 13C chemical shifts. Such empirical NMR chemical shift 
predictions could be useful with large-sized molecul s or in presence of very 
flexible compounds for which different conformers have to be considered in 
the more time consuming QM calculations. Moreover, these empirical 
methods can be applied as filter to narrow the number of stereoisomers to be 
accurately verified by other methods such as x-ray, total synthesis, QM 
approaches. 
The 13C-based protocol (Figure 1.8), used in this project, consists of four 
fundamental steps: (a) conformational search and a preliminary geometry 
optimization of all the significantly populated conf rmers of each 
stereoisomer; (b) final geometry optimization of all the species at QM level; 
(c) GIAO (gauge including atomic orbital)87 13C NMR calculations of all the 





NMR parameter calculated for each stereoisomer withthose experimentally 
measured for the compound under examination. This protocol has been 
devised for flexible systems considering the importance of the contribution of 
all significant conformers to predict a chemical-physical property and the 
theory level used to calculate the energy of the single geometrical isomers.81,82 
Considering the simple case of a molecule with a couple of two adjacent 




Figure 1. 8 Schematization of protocol used for the determination of relative configuration in 
organic compounds, based on 13C calculation at QM level of theory. 
 
The conformational sampling is performed at empirical theory level,88 
generally through molecular dynamics (MD) or by Monte Carlo Multiple 
Minimum methods (MCMM).89 
A preliminary geometry optimization is run at empirical level (molecular 





conformers for each diastereoisomer, followed by a QM optimization step. On 
the so obtained geometries the 13C NMR chemical shift for each stereoisomer 
is calculated and the theoretical data are extrapolated taking into account the 
Boltzmann-weighted average derived from the energies of the single 
conformers. The calculated values are compared with the experimental NMR 
data and the relative (or absolute) configuration is determined based on the 
best fit between theoretical and experimental data se  given by one of the two 
structural hypothesis. 
Following the same key steps described for 13C-based protocol, the 
calculation of homo- and heteronuclear coupling consta ts can be carried out 
for the conformational and configurational studies of organic molecules. In 
details, each global minimum conformer undergoes a full geometry 
optimization using the DFT theoretical level92 and then, on the obtained 
geometries, the calculation of the J couplings is performed taking into account 
the contributions of the following interactions: Fermi contact (FC), 
paramagnetic spin-orbit (PSO), diamagnetic spin-orbit (DSO), and spin-dipole 
(SD). Based on the Boltzmann distribution of the conformers, the calculated J-
coupling values are extrapolated and then compared to the experimental data 
set, suggesting the relative configuration of the examined compound. For large 
molecular systems, presenting many stereocenters, i is suggested that, given 
the prohibitive computational requirement for a simultaneous consideration of 
all combinations of the possible conformations and configurations, the 
molecule can be dissected into appropriately 2-C fragments prior to the J-
coupling calculations,93 as for the Murata’s method.79 Each reduced subsystem 
is treated like an entire molecule: a geometry optimization step, followed by 
3JH-H and 
2,3JC-H calculations, is performed for each staggered rotamer. It is 





agreement with the experimental values. Differently from the original J-based 
approach proposed by Murata,79 for which it is impossible to distinguish the 
anti erythro from the anti threo arrangement on the basis of the sole evaluation 
of the J coupling values, the quantitative analysis of the calculated vs the 
experimental data allows the relative configurational assignment for the right 
anti rotamer.  
This methodology was applied for the structural studies reported in the 
chapter 8, where the QM/NMR was used as support of the total synthesis of 
natural products (kedarcidin chromophore and palau’mine, paragraph 8.1), 
and in combination with quantitative NMR-derived interproton distances for 
the assigment of the ralative configuration of marine natural sterol conicasterol 
F (see paragraph 8.2). 
 
1.3.3 Quantitative Interproton Distances from Nuclear 
Overhauser Effect (NOE) Data 
The accurate measurement of internuclear distances i  organic molecules 
can be used to determine stereochemical and conformati nal detail of a 
structure. Internuclear distance information can be o tained through a number 
of NMR methods, including Residual Dipolar Couplings (RDC)94 and cross-
relaxation rates, using either inversion-recovery methods95 or NOESY 
methods.  
The nuclear Overhauser effect (NOE), described as the change in 
magnetisation of a spin when a neighbouring spin is irradiated as a result of 
dipolar coupling, can be used to measure such distances. However, the use of 
NOE data in distance measurements has mainly been applied in a semi-





quantitative fashion. Indeed in many cases, their quantitative use is advised 
against as NOE intensities can be perturbed by numerous factors other than 
internuclear distance. These relate to both experimental and molecular 
components including additional cross-relaxation pathw ys or spin diffusion, 
selective polarisation transfer, variation in effective τc (rotational correlation 
time) between spins, accuracy of signal integration and conformational 
flexibility. 96 Nevertheless, various NMR spectroscopy investigations have 
been reported on distance determination within small olecules using NOE 
data, principally utilising the full relaxation matrix analysis.97,98  
Given the improvements in the experimental side of NOE measurements – 
new experimental methods (transient DPFGSE NOESY,99,100,101 zero-quantum 
filtration102 etc.) and hardware improvements – more accurate and clean NOE 
intensities can now be obtained. Not only this, but it was recently shown that 
many of the perturbing factors stated above do not con ribute significantly if 
the molecule of interest is in the fast tumbling reime and if measurements are 
made within the initial rate approximation, (which states that at short mixing 
times only the cross relaxation rate, σIS, between two spins is responsible for 
the magnitude of the NOE enhancement, and that all spin pairs behave as if 
they were isolated two-spin systems).  
Using the method described below, it has been shown that surprisingly 
accurate NOE-derived distances can be obtained.103,104,105  
Various NMR spectroscopy investigations have been reported on distance 
determination within small molecules using NOE data, principally utilising the 
full relaxation matrix analysis106 and using the Initial Rate Approximation, in 







1.3.3.1        The Initial Rate Approximation 
The initial build up of NOE enhancement in all kinet c NOE experiments is 
approximately linear, and this build-up rate leads to the initial rate 
approximation. The initial rate approximation is used to analyse kinetic NOE 
data that is obtained through NOE build-up experiments (selective 1D and 2D) 
to extract internuclear distance information. 
To understand the initial rate approximation, the Solomon equations107 
must first be revisited as in for a two-spin system (Equation 1.8) 
 PQR PST 	 −UQQR − QRV − WQXXR − XRV 
Equation 1. 8 
 
where Iz and Sz correspond to the intensities of the I peak and S peak 
respectively at time t, and Sz
0 and Iz
0 correspond to the respective equilibrium 
intensities of these peaks. RI is the total relaxation rate of spin I, and σIS is the 
cross relaxation rate between two spins I and S. 
The initial conditions (after Sz inversion) for a NOESY experiment with a 
two-spin system are Iz = Iz
0 and Sz = -Sz
0, which yields the following initial 
rates of NOE growth as shown in Equations 1.9-10 for 1D and 2D108 
experiments respectively. 
 
PQYPS 	 ZWQXXRV 
Equation 1. 9 P[\]^_``ab]PS 	 −WQX\V 






where across(τm) is the intensity of the cross peak, and a0 is the intensity of 
the diagonal peak at τm=0. 
 
The initial rate approximation assumes that only the cross-relaxation rate 
constant between spins I and S is responsible for the size of the NOE 
enhancement, i.e. other forms of relaxation have no effect, and that all spin 
pairs behave as if they were isolated two-spin system  (the Isolated Spin Pair 
Approximation (ISPA)). If more than two spins are considered, the subsequent 
evaluation gets increasingly more complicated. Cross- elaxation rates can thus 
be determined from the initial slope of the build-up curves, where the initial 
rate approximation assumes that there is a linear dpendence of the NOE 
build-up on the mixing time of the experiment. The cross-relaxation rates can 
then be used to calculate internuclear distances as will be explained below. It 
has been found, however, that the initial rate approximation only holds true for 
the shortest mixing times when used in this fashion. In order to maximise the 
utility of NOE distance measurements, it is highly desirable that longer mixing 
times (and hence more intense NOEs) be used i.e. th initial rate 
approximation needs to be extended as much as possible. 
However it can be seen to fail due to a number of factors. At short mixing 
times, cross-peak intensities in 2D experiments and peak intensities in 1D 
experiments are relatively small, and this is the region of lowest signal-noise, 
making accurate measurements more difficult, especially for medium to long 
range distances whose NOEs are fundamentally weaker. Unfortunately, these 
distances are often those of most interest, so the ability to include data from 
longer mixing times (where the signal-noise is better) in calculations is 





than cross-relaxation (e.g. spin-rotation, chemical shift anisotropy, 
quadrupolar relaxation) can cause problems and so can the three spin 
effect/spin diffusion, all of which can affect the accuracy of quantitative 
distance measurements made. 
It has been shown that this approximation can be ext nded to longer mixing 
times in 2D NOESY experiments by taking the ratio of cross-peak to the 
diagonal peak in the same experiment.109,110 This compensates for the non-
linearity of the NOE build-up rate due to external relaxation so that the initial 
rate approximation is valid and linear over a wider range of mixing times. 
Previous methods involved the scaling of each individual target resonance 
relative to experiments carried out at zero mixing time. Problems resulting 
from variations from experiment to experiment are reduced in this new method 
as scaling between the target and NOE resonances ocur within each separate 
experiment. Hu and Krishnamurthy110 then demonstrated that this practice 
could be applied to 1D NOE data, specifically to that obtained using the 
DPFGSE NOE pulse sequence. They refer to this method as peak amplitude 
normalisation for improved cross-relaxation (PANIC). They used the Solomon 
equations (Equation 1.8) as a basis to explain their process as follows. 
After solving the Solomon equations for the conditions of a DPFGSE NOE 
experiment, Hu and Krishnamurthy showed that the NOE enhancement at spin 
I as a fraction of the equilibrium magnetisation can be displayed as in 
Equation 1.11: 
 
defgab 	 QY ab − QY ab^hijV 																																





Equation 1. 11 
 
where		l 	 opQ − pXZ + qWQXZ   and  mn 	 pQ + pX + l/Z and 
mZ 	 pQspXAlZ  and κ is the scaling factor (0<<κ <1) that accounts for signal 
loss from relaxation during the spin echo sequence of the DPFGSE. M0 is the 
equilibrium z-magnetisation for spins I and S (assumed to be equal) and (τm)ref 
corresponds to the mixing time of a reference spectrum, acquired with spin S 
aligned along the +z axis, so that spin I shows no NOE enhancement. 
Equation 1.11 can be simplified by substituting the exponential terms with 
their Taylor series and ignoring all 2nd and higher order terms, which we 
assume to have little contribution, to give Equation 1.12: 
 
defgab ≈ ZkWQXab 
Equation 1. 12 
 
This provides the basis for the method used prior t Hu and 
Krishnamurthy’s extension. However, it involves acquiring a DPFGSE NOE 
experiment at zero mixing time and a simple 1D pulse-acquire experiment to 
determine the value of κ, and it only remains valid up until short mixing times 
of ca. 200ms. Hu and Krishnamurthy110 went on to detail a more accurate 
method for determining cross-relaxation rates that also takes into account the 
irradiated peak intensity. This extends the initial rate approximation so that it 
can be used at longer mixing times. Much of the non-linearity at these times 
evolves from external relaxation, but by also considering the target 







dS\^uhSab 	 jYXab − jYXab^hijV  
 
≈ −ZkWQXl 5hAmnab + hAmZab6 
Equation 1. 13 
 
Dividing Equation 1.13 into the NOE enhancement, Equation 1.12 and 
simplifying by ignoring all 3rd order and higher terms, the effect of external 
relaxation can be seen to cancel to yield Equation 1.14. 
 
vefgab ≈ WQXab 
Equation 1. 14 
 
where ζNOE(τm) is the NOE enhancement normalised against the irradiated 
signal in the same spectrum. 
Cross-relaxation rates can then be measured by a line r regression analysis. 
It is no longer necessary to determine the scaling factor, or to normalise 
against equilibrium magnetisation, leading to a simpler data analysis. As well 
as this, the initial rate approximation is extended to remain linear at longer 
mixing times. Hu and Krishnamurthy110 have thus demonstrated that by taking 
the ratio of two NOE intensities, it is possible toc rrect for external 
relaxation. 
Under conditions valid for the initial rate approximation, it is only the 
internuclear distance, rIS between spins I and S that has an effect on the size of 





measuring the NOE enhancement between the two spins, a direct measure of 
σIS is achieved, and this value is directly proportional to the internuclear 
distance as described below in Equation 1.15. 
 
WQX 	 w^QXAx 
Equation 1. 15 
 
where, w 	 yzVq{|Z ℏZ~qnV y xa]nsqZa]Z − a]| 
 
In the above equation the only unknown is τc, the molecular correlation 
time, which is not the easiest of values to measure. By assuming that the 
molecule of interest is rigid and tumbling isotropically, it can be approximated 
that all components of the system will have the same correlation time. In doing 
so, a relative calibration can now be made using the NOE intensity from a pair 
of protons of known internuclear distance, e.g. methyl ne protons – the 
reference - and comparing this to the unknown distance’s NOE intensity as in 
Equation 1.16.111 
 
iQXSi^hiS 	  ^QX^^hi
Ax
 
Equation 1. 16 
 
where fI{S}(t) is the NOE intensity of interest at mixing time t, and fref(t) is 
the reference NOE intensity at mixing time t.  
Equation 1.16 can be rearranged to express the unknown internuclear 






^QX 	 ^^hi iQXSi^hiS 
An/x
 
Equation 1. 17 
 
Accurate distances can be obtained from this method as internuclear 
distance is thus proportional to the inverse sixth power root of the function, 
which means that the effect of experimental errors, spin diffusion and 
motional effects are greatly reduced. Not only this, but by taking the ratio of 
two NOE intensities, external relaxation is being corrected for, as described 
above, so that this method can be used for data collected at relatively long 
mixing times. 
Wang et al.112 determined interproton distances of three dolichodial-like 
diastereomers, each of which have three stereocenters sing 2D NOESY data 
sets obtained with a 2 second mixing time. They estimated interproton 
distances from NOE volumes using Equation 1.18, a form of the initial rate 
method as described above. 
 
^ 	 ^^hix ^hi 
n/x
 
Equation 1. 18 
 
where V and Vref are the volumes of the unknown and reference (geminal) 
cross-peaks respectively and r and rref are the corresponding interproton 
distances.  
Andersen et al.113 also investigated the quantitative use of 2D NOESY data 
for small molecules. They reported the effects of preparatory delay (d1) 





overcome this. Preparatory truncation delay, where the delay is below the 
normal value of 5 times T1, means that not all signals will have fully relaxed 
back to their equilibrium states, and in 2D NOESY spectra, this can result in 
diagonal asymmetry, a problem for accurate data analysis.  
Unfortunately, truncation is desirable as small molecu es have long T1 
values, and so collection of 2D NOESY data can be a l ngthy process if the 
normal pulse sequence is used. Andersen et al. estimated cross-relaxation rates 
in truncated NOESY data by taking the average of tw diagonal cross-peaks 
after they have been normalised by their diagonal-pe k as in Equation 1.19. 
 
dQX + _^T dXQdQQ + _^T dXX 	 WQXab 
Equation 1. 19 
 
where ηIS and ηSI are the cross-peak cross-section intensities and ηII and ηSS 
are the diagonal peak cross-section intensities. 
This normalisation accounts for cross-peak leakage, which is assumed to be 
well approximated by the net leakage at either of the corresponding diagonal 
peaks. In this case, the term leakage accounts for the eduction in the NOE 
caused by external relaxation. They found that cross- elaxation results with 
truncation agree with non-truncated experimental data, lthough they were 
neither as precise nor as accurate. By examining the differences between 
internuclear distance data derived from each spectrum dimension (f1 and f2 
spectral projections) they found that f2 spectral projections were most useful 
for well-resolved resonances, as long as corrections were made for t1 streaks. 





difficult by the fact that NOE enhancements using the standard NOESY 
experiment are almost non-existent.  
However, 1D ROESY data can also be used to produce quantitative 
distance data in these cases. Such an example is that of the natural diterpene 
derivatives investigated by Forgo et al.114 They determined distances by 
obtaining the cross-relaxation rate for a pair of protons from the slope of the 
NOE build up curve over a range of mixing times. They then used Equation 
1.20 to determine the corresponding distance. In order to do this, the rotational 




Z ~q ћZ^x  a]n + qZ a]Z −
nnVa] 
Equation 1. 20 
 
These NOE observed distances were subsequently compared with solid-
state X-ray crystallography distances for the equivalent compounds, and the 
correlation was observed to be very good, with differences of only 0.1-0.2Å 
between corresponding distances. 
 
1.3.3.2    Method for quantitative interproton distance 
determinations  
Under conditions valid for the initial rate approximation, and assuming that 
the molecule of interest is in the fast tumbling regime, it is only the 
internuclear distance, rIS, between spins I and S that has an effect on the size of 
the NOE enhancement between the respective spins. Thi  means that by 





σIS is achieved, and this value is directly proportional to the internuclear 
distance as described below in Equation 1.21. 
 
WQX 	 ^QXAx 
Equation 1. 21 
 
where,  	 yzVq{|Z ℏZ~qnV y xa]nsqZa]Z − a]| 
 
Assuming that the values of µ0, γ (magnetogyric ratio) and ω (Larmor 
frequency) are essentially fixed for a given homonuclear experiment, and if we 
further assume that τc (rotational correlation time) is comparable for each spin 
pair in a given selective inversion experiment, then k can be assumed to be 
identical for each spin pair within a given selective nversion experiment. This 
leads to Equation 1.22, where the ratio of the intensi ies of a pair of NOE 
signals, ηIS:ηref, can be assumed to be proportional to the ratio of the respective 
internuclear distances. 
dQXd^hi 	  ^QX^^hi
Ax
 
Equation 1. 22 
 
where ηIS is the NOE intensity of interest at mixing time t, and ηref is the 
reference NOE intensity at mixing time t. Thus, by measuring ηIS and ηref, one 
needs only to know one distance e.g. rref, in order to calculate the unknown 
distance, rIS. 
To prove this methodology, Butts103,104,105 and co-workers had chosen the 
stryctinine molecule (Scheme 1.1) because it is a rigid molecule, with a well 





structure116 data are available, so it is well characterised aninternuclear 






























Scheme 1. 1 Molecular structure of strychnine (1). 
 
The initial reference distance used was the H15a-H15b NOE distance 
calibrated to 1.76Å (assumed intermethylene distance) and distances were 
propagated through the entire dataset by the following method in Figure 1.9. 
The analysis employing equation 1.22 to determine int rproton distances is 
illustrated for H15a of strychnine in CDCl3.  
The selective (1D) transient DPFGSE-NOESY spectrum of H15a is shown 
in Figure 1.10 and shows the clean, well-resolved NOE peaks with a very flat. 
For convenience, the absolute values for the NOE intensities were measured 
relative to the irradiated (negative) peak for which the integral was arbitrarily 
assigned a value of -1000. 
The NOE intensity for the H15 methylene protons H15a-H15b (η = 216.2) 
corresponds to an estimated distance of ~1.76 Å, and hence the intensities of 
the remaining observed NOEs from H15a to H13 (η= 60.4), H14 (η = 25.8), 
H16 (η = 31.7), and H8 (η = 1.3) can be used to determine their corresponding 

















Figure 1. 9 Distance determination method. 
 
In this way a list of interproton distances was obtaining analyzing both 1D 
and 2D NOESY/ROESY experiments. In this case, mean errors in interproton 
distances as low as 3% can be obtained from 1D-, 2D NOESY or ROESY 
experiments when these are conducted in the fast-tumbling regime and inside 
the Initial Rate Approximation (IRA). 
At distances >4 Å, signals from artifacts and NOEs become comparable in 
intensity and thus distance determinations become significantly less reliable 
under the conditions described. The interproton distances are most accurate 
when measured in a non-viscous solvent, but perturba ions due to solvent 
viscosity and deviation from the Initial Rate Approximation were addressed by 
using a mixing time of around half of the mixing time observed to give 
maximum NOE intensity in a single 1D-NOESY build-up curve – whether this 
rule-of-thumb can be applied generally to small molecu es is unclear. 
Repeat for all 
H 
irradiations 
H15a-H15b calibrated to 1.76 Å 
Distances to remaining observed 
NOEs from HA obtained (H15a-Hx) 
H15a-Hx distances used for 
calibration in Hx irradiation 
Distances to remaining observed 
NOES from Hx obtained (Hx-Hy) 
Hx-Hy distances used for 







Figure 1. 10 1D-NOESY spectrum of H15a of strychnine in CDCl3. 
 
These so obtained datasets were combined and plotted against their 
computationally determined values (See an example in Figure 1.11). The slope 
of the line-of-best fit in Figure 1.13 is essentially unity (1.012), reflecting the 
accuracy of this NOE-based method in determining interproton distances 
across a range of separations in strychnine.  
The precision is also surprisingly high, as the aver g  absolute error is 
3.3% (0.09Å) with a standard deviation of 3.1% (0.11 Å) for distances up to 
4.5 Å. These error values compare very well with those obtained from X-ray 
crystallography, where mean interproton distance errors of 1.4–4.3% (std 
1.2%–4.3%) arise from the numerous structure determinatio s of strychnine 
reported with R2 values of 1.5%–3.7%. 
Where possible the use of 1D-NOE/ROE data is recommended, rather than 





reduce the level of post processing of spectra, which in turn minimizes 
perturbation of the weakest NOEs. 
 
 
Figure 1. 11 Example of computed interproton distances v rsus those established by 1D-NOE 
measurements. 
 
The most modern implementations of DPFGSE-based transient NOE 
experiments should be employed and incorporation of zero-quantum filtration 
is beneficial to the quality of spectra obtained, but in these experiments zero-
quantum filtration did not substantially affect the distances determined. The 
effects of structural dynamics have not been considered, however the accuracy 
of the data obtained herein offers significant optimism for comparably 
accurate dynamical analysis of NOE measurements in flexible systems and we 
are currently investigating these. 
In conclusion, it can be seen that the described method produces very 
accurate interproton distances in comparison to computed structures when 
experiments are collected in less viscous solvents such as CDCl3 and d6-





addressed by reducing the mixing time to correspond t  around half that of the 
mixing time observed to give maximum NOE intensity, or by increasing the 
temperature of the sample. The effects of spin diffusion are therefore 
negligible under the conditions used in these cases. Moreover, it is interesting 
to note that Neuhaus and Williamson96 describe an r-3 rather than an r-6 
relationship for internal motions faster than overall tumbling (methyl groups in 
particular) when considering protein structure determination.  
 
This kind of approach in combination with the Quantum Mechanical 
Calculations of 13C Chemical Shifts was used and described for the 


















Design, virtual screening and rationalization  












2.1 HDAC as drug target 
Gene expression is highly regulated by post-translation l modifications of 
histone proteins, including acetylation, methylation, phosphorylation, 
ubiquitylation, sumoylation, ADP-ribosylation, glycosylation, biotinylation 
and carbonylation.117 In particular, histone acetyl groups from lysine or 
arginine residues118 located on the amino-terminal tails of histones proteins 
(H2A, H2B, H3, and H4) are removed by metalloenzymes called Histone 
Deacetylases (HDACs)117 (Figure 2.1)  
 
 
Figure 2. 1 The acetylation state of lysine amino acids are governed by the equilibrium 
activities of acetyltransferase enzymes and deacetyl s  enzymes. In the context of gene 
expression, the lysine residues of histone proteins are key substrates for acetylation. 
 
Histones comprise nucleosomes, which are the basic packaging units of 
chromosomes.119 By binding to genomic DNA, the accessibility of genes to 
transcriptional proteins is altered by histone lysine acetylation. As a result, 
HDAC proteins are generally associated with repression of transcription and 
reduced gene expression120. HDAC proteins comprise a family of 18 members 
in humans and are separated into four classes based on their size, cellular 
localization, number of catalytic active sites, and homology to yeast HDAC 
proteins. Class I includes HDAC1, HDAC2, HDAC3, and HDAC8. Class II 
consists of six HDAC proteins that are further divied into two subclasses. 
Class IIa includes HDAC4, HDAC5, HDAC7, and HDAC9, which each 





HDAC10, which both contain two active sites, although only HDAC6 has two 
catalytically competent active sites. HDAC11 is thesole member of class IV, 
based on phylogenetic analysis.121 Class I, II, and IV HDAC proteins operate 
by a metal ion-dependent mechanism, as indicated by crystallographic 
analysis.122 In contrast, class III HDAC proteins, referred to as sirtuins 
(SIRT1-7), operate by a NAD+-dependent mechanism unrelated to the other 
HDAC proteins.123 The metal-dependent HDAC proteins are the targets of he 
HDAC inhibitors discussed in this chapter. 
Due to their fundamental role in gene expression, HDAC proteins have 
been associated with basic cellular events (transcriptional regulation,124 
intracellular transport,125 metabolism, cell proliferation) and disease states, 
including cell growth, differentiation, and cancer fo mation126 (activation of 
oncogenes and transcription deactivation of tumor suppressor genes.127,128). 
HDAC’s, in fact, have been recently highlighted as promising targets in the 
epigenetic therapy as a consequence of their ability to influence transcriptional 
events for the treatment of several disorders included cancer.  
The great potential of HDAC inhibitors as anticancer drugs seems to be 
related in fact, to the transcription and expression of oncogenes which are 
proved to be silent in cancer pathology.  
Since this epigenetic event is associated with carcinogenesis and tumor 
progression, HDAC inhibitors (HDACi) have been considered promising 
anticancer agents,129 and in fact it has been observed that overexpression of 
HDACs is correlated to cancerous pathologies,130 and the different isoforms of 
HDAC are expressed in several tumor tissues with specific biological function 







Table 2. 1 Expression of HDACs in tumor tissues. 
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On the other hand, while individual members of class I and II HDAC 
proteins are linked to cancer formation, the role of each isoform in 
carcinogenesis is unclear. Particularly, the molecular mechanism connecting 
HDAC activity to cancer formation is not yet defined. Targeting of class I 
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HDAC inhibitors (HDACi) bear great potential as new antitumor drugs; 
indeed, they can induce differentiation, growth arrest, and apoptosis in 
transformed cell cultures. Consistent with their clni al effects, inhibitors of 
HDAC proteins suppress tumor cell proliferation, induce cell differentiation, 
and upregulate crucial genes associated with anti-ccer effects.132  
Although a large number of HDACi have been obtained from both natural 
sources and through chemical synthesis, and despite the fact that some are in 
clinical trials—such as valproic acid (4 in Figure 2.3),133 MS-275 (7 in Figure 
2.3),134—there are only two HDAC inhibitors currently on the market: 
vorinostat (Zolinza, 17 in figure 2.4)135 and depsipeptide FK228 (Romidepsin, 
13 in Figure 2.3).136 Both of these were approved by the US Food and Drug 
Administration (FDA) for the treatment of cutaneous T-cell lymphoma 
(CTCL).137 Therefore, HDACi drugs represent a promising next generation of 
anti-cancer therapeutics.  
However, the HDAC involvement and the therapeutic use of HDACi are 
not restricted to cancer, as several studies have also shown that these enzymes 
have a role in autoimmune diseases,138 inflammatory regulation139 central 
nervous system disorders140 and development. Interestingly, most of the 
intracellular pathways involved in these processes share common 
intermediaries that are regulated by HDACs, suggesting a central role for these 
enzymes as regulators of seemingly unrelated physio-pathological conditions. 
Supporting this concept, HDACi have emerged as potential therapeutic tools 
for the treatment of autoimmune diseases138,141 cystic fibrosis142 and regulation 
of immune tolerance.143 In contrast to the rapidly increasing knowledge of the 
role of HDACs in cancer and the use of HDACi in trea ing this and other 
pathological conditions, still little is known about the role of specific HDACs 
in immune cells and the functional consequences of their inhibition by 
 
HDACi. Although the pro
are still only in the very early stages of being resolved, it is starting to
that HDACi have some promising anti
animal models of inflammatory
have so far been reported to influence inflammatory conditions are now
summarized in Figure
Figure 2. 3 Structures of HDACi with reported antiinflammatory activity.
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In general, HDAC inhibitors have a standard, modular construction with 
structural similarities to the HDAC acetyllysine sub trate (Figure 2.1). 
HDAC inhibitors typically consist of a metal-binding moiety that 
coordinates to the catalytic metal atom (Zn2+) within the HDAC active site and 
a capping group that interacts with the residues at the entrance of the active 
site (Figure 2.4).  
 
 
Figure 2. 4 Pan-inhibitors TSA and SAHA. 
 
In addition, a linker that is structurally related to the carbon chain present in 
the acetyl-lysine substrate appropriately positions the metal-binding moiety 
and capping group for interactions in the active site. Crystallographic 
evidence122 with TSA bound in the active site of a bacterial homologue of 
class I HDAC proteins (HDLP) confirms that the hydroxamic acid coordinates 
to the zinc atom at the bottom of the active site, th  linker lies in a confined 
hydrophobic channel, and the aromatic capping group interacts with the amino 






Figure 2. 5 TSA binds inside the pocket making contacts to residues at the rim, walls and 
bottom of the pocket. a) Space-filling representation of TSA in the active-sit  pocket; b) 
Closeup stereo view of the structure of the HDLP-Zn2+-TSA complex TSA is in white; c) 
Schematic representation of HDLP-TSA interactions. TSA is in black and the protein is in red. 
HDLP residues are labelled in red with their counterparts in HDAC1 indicated in black; d) 
Surface representation of the HDLP-TSA interface in a similar orientation to b.  
 
The majority of HDACi drugs in and out of clinical trials inhibit all HDAC 
isoforms nonspecifically (so called paninhibitors). SAHA and TSA are the 
canonical pan-inhibitors (Figure 2.4), influencing the activity of HDAC1–9 
with roughly equivalent potency.145 Selective HDAC inhibitors, which affect 
either a single HDAC isoform (isoform-selective HDACi) or several isoforms 
within a single class (class-selective HDACi), would be ideal chemical tools to 





selective HDAC inhibitors would aid in defining the molecular mechanism 
connecting HDAC activity to cancer formation.129a In addition, it is possible 
that a class-selective or isoform-selective HDAC inhibitor would provide a 
more effective chemotherapy compared to pan-inhibitors.  
In this chapter, the application of molecular docking will be described for 
the design, virtual screening and rationalization of binding modes of small 
libraries of compounds as potential HDAC inhibitors. In particular, this 
methodology was successfully applied for the identification of new potential 
cyclic (mono and bis amides, calixareni, see paragrph 2.2 and 2.4 
respectively) and linear (hydroxamic tertiary amines, see paragraph 2.3) 
HDAC pan-inhibitors; and for the rationalization of the binding modes of Ugi 
products (see paragraph 2.5).  
Because, clinical studies show that pan-HDAC inhibitors may also cause 
numerous side effects:146 bone marrow depression, diarrhoea, weight loss, 
taste disturbances, electrolyte changes, disordered clotting, fatigue, and 
cardiac arrhythmias. Thus, the next step in the development of HDAC 
inhibitors is to target selectively individual HDAC isoforms, with the aim of 
interfering with critical oncogenic function in cancer cells and without 
affecting normal cells. On this basis, in the last paragraph the work-flow of the 
different stages involved in the structural characterization, design and 
synthesis of new selective HDAC inhibitors will be d scribed (see paragraph 
2.6) 
All docking calculations described in this chapter, were performed using 
the software Autodock 3.05. For all molecular docking studies of pan-
inhibitors (paragraphs 2.2-2.5) the histone deacetylase-like protein (HDLP) 
reported by Finnin122 (Figure 2.5) and optimized by Maulucci147 et al. was 





electrostatics, the partial charges of the zinc ion and of the amino acids 
involved in the catalytic center (Ala169, His170, Asp168, Asp258) have been 
calculated at DFT B3LYP level and 6-31G(d) basis set using the ChelpG148 
method for population analysis (Gaussian 03 Software Package).149  
For what concern the design of potential HDAC selectiv  inhibitor, the 
homology models for HDAC1, HDAC3 and HDAC6 (See Figure 2.6) were 
used in molecular docking calculations, along with the X-ray structures (See 
Figure 2.6) of HDAC2 (3MAX),150 HDAC4 (2VQM),151 HDAC7 (3C0Z)152 
and HDAC8 (3F0R,153 and 1VKG);154 also in this case, the partial charge of 
Zn2+ and of the amino acids constituting the catalytic center were derived by 
DFT calculations m0515 level by the 6-31+G(d) basis set and ChelpG 






Figure 2. 6 Molecular surface of the Histone Deacetylase proteins (Class I and II) represented 
by molecular surface and colored according to the hydrophobicity (dodger blue=hydrophilic, 
orange red=hydrophobic). The figure highlights the two fundamental phenylalanine at the top 






2.2 Synthesis of new mono and bis amides projected as 
potential histone deacetylase (HDAC) inhibitors 
In this paragraph, it is reported the design, virtual screening, synthesis and 
biological evaluation of new collection of new potential HDAC inhibitors, 
whose cytotoxic properties are also described.156 In particular with the aim to 
further increasing the in vivo stability of the potential HDAC binders, instead 
of the cyclopeptide framework, it was used a heterocyclic moieties or open 
chain tertiary amines, bearing a terminal functionalized aliphatic chain of 
appropriate length. As metal binder domain, it was selected the amide function 
present in other potent HDAC inhibitors of natural origin, like azumamides.8 
Concerning the retrosynthetic plan of the molecules, it was immediately 
recognized the possibility of applying, as key step o close the cycles, the 
RCM reaction, which has emerged as a powerful tool f r the construction of 
carbocyclic and heterocyclic ring systems. On the basis of this assumption, 
and in consideration of the commercially availability of the building blocks, it 
were designed seven molecules (Scheme 2.1), five of which (18, 19, 20, 23, 
24) showing, as cap group, cyclic structures of different size, and bearing 
variable length functional tails; the other two (21-22) mainly reproduced, in 
some extend, the open versions of the previous ones.  
The first step was a docking study on the designed molecules to obtain a 
prediction of their histone deacetylases inhibitory activity, through virtual 
screening process. Prior to the docking calculations, a conformational search 
on the cyclic 157 compounds by means of molecular dynamics was performed 
at different temperatures (400 K, 600K and 800K) using the MMFFs158  force 
field included in the MacroModel software package.159 On the so obtained 





vacuo at DFT B3LYP level, using the 6-31G(d) basis et (Gaussian 03 
Software Package).160 Subsequently, the charges of 1-7 were calculated with 









































Scheme 2. 1 Molecular structures of 18-24 compounds. 
 
Docking studies were performed on optimized 18-24 compounds with the 
HDLP binding pocket,122 using AutoDock 3.0.5 software,55 which has been 
successfully used in the interpretation of the inhibitory activity of several 
HDAC ligands.156,161 In addition to the compounds optimized as described 
above, we used as model receptor the HDLP active site refined at QM level,147 
in order to improve the calculations with the aim to obtain a good qualitative 
accordance between theoretical KDcalc and biological assays results. According 




Figure 2. 7 3D model of the HDLP.
 
The results obtained, reported in Table 2.2, showed satisfactory K
for all compounds, even if among them, 
better binding properties for
 
Table 2. 2 Calculated (K
 18 
KDcalc 1.78 x 10-8 
 
Concerning all cyclic molecules, (
strong interactions between the recognition binding domain, represented by 
the hetero cyclic framework, and the hydrophobic surface of HDLP active site. 
For sake of simplicity, here the detailed docking results for cmpounds 
7 will be only described. 
HDAC 
71 
-D)161a acting as molecular recognition domain (Figure 
 
 
compounds 23 and 24 showed a little 
 HDLP receptor surface. 
D) activities of 1-7 compounds. 
19 20 21 22 23
4.09 x 10-8 7.81 x 10-8 2.74 x 10-8 3.65 x 10-7 8.88 x 10
 












The docking studies indicate that the linker chain and the cap group of 24 
and 18 fill equivalent spaces (hydrophobic pocket D: His170, Ala197, Leu265, 
Phe198, and Phe200, see Figure 2.8). Moreover, the linker chain exerts a set of 
interactions with the tubular hydrophobic pocket and the zinc- coordinating 
carboxylate group, forming hydrogen bonds with Hε2 of H131. 
 
 
Figure 2. 8 (A) 3D model of the interaction between 18 and the HDLP binding site. The 
protein is represented by molecular surface and sticks and balls. 18 is depicted by sticks (by 
atom type: C green, polar H white, N dark blue, O red). (B) 3D model of the interaction 
between 24 and the HDLP binding site. The protein is represented by molecular surface and 
sticks and balls. 24 is depicted by sticks (by atom type: C sky blue, polar H white, N dark 
blue, O red). 
 
The cap group portion of both compounds is accommodated in a shallow 
groove, establishing Van der Waals interactions and hydrogen bonds with the 
receptor counterpart, formed by His170, Aala197, Phe198 and Phe200 
residues. The cap group extends its hydrophobic conta ts thanks to the phenyl 
ring, which is accommodated in the deep pocket D (Tyr264, Leu265, Ser266, 
Lys267, see Figure 2.8); however, the macrocycle siz  seems to slightly 
modulate the activity, as emerged by directly comparing 18 with 24; this last, 
in fact, in virtue of its higher dimension of the cycle (13 C atoms vs 15, 





suboptimal hydrophobic interactions are responsible for a predicted increase in 
the binding affinity to the receptor of about 10-fold (KDcalc of 18 1.78 x 10
-8 vs 
KDcalc of 24 1.82 x 10
-9). 
Furthermore, comparing docking results of 19 and 23 (Figure 2.9), 
presenting the same cap group but differing for the linker length, it is possible 
to suppose that this last should be of 9 carbon atoms in order to have the 
optimal fit with receptor surface. 
Figure 2. 9 (A) 3D model of the interaction between 19 and the HDLP binding site. The 
protein is represented by molecular surface and sticks and balls. 19 is depicted by sticks (by 
atom type: C violet, polar H white, N dark blue, O red). (B) 3D model of the interaction 
between 23 and the HDLP binding site. The protein is represented by molecular surface and 
sticks and balls. 23 is depicted by sticks (by atom type: C pink, polar H white, N dark blue, O 
red). 
 
Finally, compound 20, which presents the same linker of 23, but an entirely 
aliphatic cap group (Figure 2.9), showed to be not able to establish strong 
hydrophobic interactions with the protein counterpart, being totally lacking of 






Figure 2. 10 3D model of the interaction between 20 and the HDLP binding site. The 
protein is represented by molecular surface and sticks and balls. 20 is depicted by sticks (by 
atom type: C dark red, polar H white, N dark blue, O red). 
 
For the analysis of linear compounds 21 and 22, the small difference of their 
KDcalc values, could be ascribed to their different aromatic rings content. In 
fact, the two aromatic rings, present in compound 21, showed to correctly 
accommodate in the A and D hydrophobic pockets of the enzyme, increasing 
the stability of the drug-receptor complex. (Figure 2.11).  
 
 





Prompted by the virtual screening results, the synthesis of the designed 
molecules was undertaken with the aim to verify the qualitative accordance 
between the theoretical and the experimental data, using a combination of 
solution and solid phase techniques to synthesize the compounds and, a ring 
closing metathesis (RCM) reaction as the key synthetic step to obtain the 
rings. A cytotoxicity assays was then performed on the synthesized molecules 
and the analysis of the results, reported in Table 2.3, was disappointing for 
some compounds but, at the same time, allowed to make some considerations 
on virtual screening outcome. 
 
Table 2. 3 Biological (IC50 ) activities of compounds 18-24 on HEK-293, J774A.1 and WEHI-
164. Control cells viability was designated as 100%, and results were expressed as the 
concentration of tested compounds able to induce the 50% of mortality in cells (IC50). Results 
are expressed as mean ± s.e.m. from at least three-ind pendent experiments 







































For example, the predicted negative response for some f the designed 
molecules (in good qualitative accordance with the experimental data) can be 
ascribed to unfavorable structural features, such as the lack of aromatic rings 
in compound 20, while, the unsuitable size of the aliphatic chain spacer in 19 
could account for the absence of cytotoxicity, in coherence with its slightly 





24, the biological results were in disagreement with the virtual screening 
response. In fact these two compounds, despite the best affinity properties 
displayed in docking studies, did not exert the expected higher potency in 
antiproliferative assay, probably due to unfavorable pharmacokinetic 
parameters – such parameters are in fact not quantifiable in the computer 
simulation approach.  
On summary in this paragraph it was reported the development of a new 
collection of potential HDAC inhibitors and a partil rationalization of their 
biological behaviour through molecular docking calculations. Four of the 
seven synthesized molecules showed a satisfying level of antiproliferative 
activity and all of them are currently investigating for their ability to inhibit 
HDAC enzyme. 
 
2.1.1. Computational details 
Molecular mechanics/dynamics (MM and MD) calculations were performed 
using the Macromodel 8.5 software package159 and the MMFFs162 force field 
at several temperatures (400, 600 and 800K). The solv nt effects are simulated 
using the analytical Generalized-Born/Surface-Area163 (GB/SA) model 
mimicking the presence of H2O. All the structures were minimized using a 
Polak-Ribiere Conjugate Gradient (PRCG, 50000 steps, convergence threshold 
0.005 kJ mol−1 Å−1). Autodock 3.0.555 was used for all docking calculations. 
HDLP122 (histone deacetylase-like protein) is a metalloprotein, so a 
nonbonded model for metallic center according to the nonbonded Zn 
parameters of Stote164 (Zinc Radius=1.10 Å, well depth=0.25 kcal/mol) was 
used. In order to have an accurate weight of the electrostatics, we derived the 
partial charge of Zn=1.175 and of the aminoacids involved in the catalytic 





by the 6-31G(d) basis set and ChelpG method148 for population analysis 
(Gaussian 03 Software Package).160 For what concerns the ligands, the 
geometries were optimized atDFT B3LYP level using the 6-31G(d) basis set. 
Subsequently, the charges of compounds 1-7 were calculated with the ChelpG 
method148 at the B3LYP/6-31G+(d) level. The above calculated charges were 
used for docking calculations. For all the docking calculations a grid box size 
of 66 x 64 x 48 with spacing of 0.375 Å between thegrid points, centred 
between Zn2+ and His170 (x=49.75, y=5.0, z=101.491) and covering the 
catalytic centre surface of HDLP was used. For all the docked structures, all 
bonds were treated as active torsional bonds except th  amide bonds. In order 
to achieve a representative conformational space during the docking 
calculations, six calculations consisting of 256 runs were performed, obtaining 
1536 structures (256 x 6). The Lamarckian genetic algorithm was used for 
dockings. An initial population of 450 randomly placed individuals, a 
maximum number of 4.0 x 106 energy evaluations, and a maximum number of 
3.0x 106 generations were taken into account. A mutation rate of 0.02 and a 
crossover rate of 0.8 were used. Results differing by less than 3.5 Å in 
positional root-mean-square deviation (RMSD) were clustered together and 
represented by the result with the most favourable fre  energy of binding. All 
the 3D models were depicted using the Phyton software:165 molecular surfaces 





2.3 Design, synthesis, and biological activity of new 
hydroxamic tertiary amines as histone deacetylase 
(HDAC) inhibitors. 
Following the results of a collection of new mono and bis amides reported 
in the previous paragraph, here, it will be described the design, docking 
studies, synthesis, and biological evaluation of new g neration of hydroxamic 
tertiary amines.167 With this second series of compunds reported below, it is 
explored the efficiency of non-peptidic linear compounds presenting the 
hydroxamic group as metal binder and two differently substituted arms as cap 
group.  
In particular for the design of a small set of hydroxamic tertiary amines, it 
was respect the well established168 structural features of a standard HDAC 
inhibitor: I) a hydrophobic region (cap group) invol ed in the molecular 
recognition process; II) a ZnII chelating element (metal binder); and III) a five 
to seven-atoms spacer (linker) between the cap group and the metal binder. 
Specifically, the same linker chain, presenting thehydroxamic group, was 
conjugated with different aromatic moieties in order to optimize the size and 
the chemico-physical properties of the cap groups (25-34, Scheme 2.2).  
For the modeling studies, Autodock 3.0.5 software55 and the optimized 
HDLP model147 (see previous sections pdb code 1C3R)122 (Figure 2.12) as 
model enzyme, which has been successfully used in the interpretation of the 





Scheme 2. 2 Structures of compounds 25-34. 
 
The calculated affinity, expressed as the most favourable HDAC free energy 
of binding, and the three dimensional models of thecomplex between 




Figure 2. 12 Molecular surface of the Histone Deacetylase Like Protein represented by 
molecular surface colored according to the hydrophobicity (A) (dodger blue=hydrophilic, 
























































The docking calculations point out that all the designed molecules fill the 
equivalent space on the surface protein, and that they are able to occupy the 
catalytic binding site coordinating the fundamental zinc ion (Figures 2.13 and 
2.15), exhibiting thus a potential antagonist activity.  
Concerning the molecules with the same arms (25-27, and 29), predicted 
energy evaluation suggests a good ligand efficiency170 (binding energy for 
heavy atom molecular ∆G/NHA) and strong interactions between the cap 
group and the hydrophobic surface of the HDLP active site (See Figure 2.13-
2.15). In particular, 29 is the most promising compound among this subset of 
molecules.  
In analogy with 25-27 it forms three hydrogen bonds with the aminoacids 
of the catalytic site (namely His131, 132 and 170) by the hydroxamic portion 
(See Figure 2.14), and, furthermore, it also projects the oxigen atoms of the 
arms in close contact with the NH of Phe198. Moreover, even if compound 27 
establishes a cation-π interaction with Lys19, only compound 29 is able to 
generate π- π interactions with the Phe141 and Phe198 on the protein surface. 
On the other hand, the different arm present in 33 and 34 is not involved in 
further interactions with the macromolecule in comparison to 26 and 27, and 
because the majority of the hydrophobic contacts are maintained (See Figure 
2.14), these arms may be considered equivalent.  
Moreover, as compound 31 is a hybrid of 27 and 29, it exhibits as expected 
an intermediate value of calculated free energy of binding with respect to 
them, presenting different π-π interactions with the Phe200 and Tyr297 on the 
protein surface, and a different and less efficient pattern of hydrogen bonds 






Figure 2. 13 (A) Superimposition of the compounds 25-34 in the HDLP binding site. The 
protein is represented by molecular surface and 25-24 are represented by tube, and coloured 
as: 25, yellow; 26, cyan; 27, light blue; 28, green; 29, red; 20, light green; 31, pink; 32, purple; 
33, blue; 34, orange. (B) Calculated Free Energy of Binding expr ssed as kcal/mol of 
compounds 25-34 for HDLP. 
 
On the contrary, compound 30 favorably combines the features of 26 and 29, 
showing the best calculated free energy of binding among the all investigated 
molecules thanks to the efficient hydrophobic, hydrophilic and electrostatic 







Figure 2. 14 Three-dimensional models of the complexes between compounds 25-34 and 
HDLP molecule. The side chains of amino acids and the compunds are represented by tube. 
 
On the contrary, the 28 and 32, presenting the most encumbering arms of our 
set of compounds show the worst ligand efficiency170 values (Figure 2.15), 
because the bigger dimensions of the cap group does n t balance the gain in 






Figure 2. 15 Ligand efficiency of 25-34 with the HDLP enzyme. 
 
On the basis of the above rationale, it was virtually evaluated the influence of 
the cap group dimension on the HDAC activity of a small set of hydroxamic 
tertiary amines, where the hydrophobic and/or the arom tic stacking 
interactions seem to be among the main driving forces of the target-ligand 
complexes formation. In fact, the molecular docking results revealed that the 
simultaneous and efficient interactions of 30 with both the enzyme surface and 
the tubular binding pocket, due to the proper selection of its arms, are critical 
for the potential antagonist activity. Prompted by the above in silico results, 
the synthesis of the designed molecules was undertaken in order to verify the 
qualitative accordance between the theoretical and the experimental data.  
In particular for the synthesis of compounds 25–34, the N-Fmoc-
hydroxyamine 2-chlorotrityl resin was used for the production of the 
hydroxamic acids by solid-phase organic synthesis (SPOS).171 Alkylation of 
the primary amine with the aldehydes (5 equiv) on slid phase was performed 
in a two-step procedure to minimize dialkylation,172 employing (MeO)3CH 





compounds were cleaved from the resin by a single-step treatment with a 
solution of TFA/TIS/CH2Cl2.  
Inhibition of HDAC activity in HeLa nuclear extracts by compounds 25-34 
and Trichostatin A (TSA, 5) a well known HDAC inhibitor, was measured 
using a fluorescence-based assay. The IC50 values of compounds 25-34 are 
reported in Table 2.4. 
 
Table 2. 4 In vitro HDAC-inhibitory activity (IC50 ± sd) of compounds 25-34 and TSA 
Compound IC50 (µM)
 [a] 
25 1.00 (±0.08) 
26 0.64 (±0.064) 
27 0.19 (±0.017) 
28 1.20 (±0.11) 
29 0.47 (±0.037) 
30 0.07 (±0.004) 
31 0.58 (±0.047) 
32 0.97 (±0.078) 
33 0.18 (±0.016) 
34 0.17 (±0.008) 
TSA[b] 0.022 (±0.002) 
[a] Mean values of at least two-independent assays are reported. Standard 
deviations are in parenthesis. [b] TSA was used as a control for these 
experiments. 
 
On summary, differently decorated tertiary amines baring hydroxamic 
acids as chelating element have been successfully developed as a new class of 
potential HDAC inhibitors, and a rationalization of their biological behavior 
has been pursued through molecular docking calculations. In particular, a good 





was found, and in fact, all the synthesized compounds displayed a 
considerable HDAC inhibition activity. In particular, as predicted by docking 
calculations, compound 30 showed the highest inhibitory activity in the 
nanomolar range (IC50 0,07 µM 30 vs 0,022 µM TSA, 5), using TSA as 
reference compound. Bearing in mind the biological results and the 
descriptions of the 3D models of 30 with HDLP discussed above, in this 
paragraph a complete a rationalization of the molecular docking results related 
to linear tertiary amines based inhibitors was offered. In particular, the 
presence of hydrophobic and bulky aromatic substituents as cap group, 
necessary for hydrophobic interactions, and π-π stacking, seems to be the 
driving force of the target-ligand complex efficiency. Alongside the 
intermolecular interactions, the in silico results have also revealed the critical 
role and influence of the nature and dimension of the arms on the potential 
HDAC activity. Such evidences are also confirmed by calculated and 
experimental 28 inactivity.  
 
2.3.1. Computational Details 
As previously reported, for docking calculations the optimized HDLP147 
DFT/B3LYP was used. Moreover, in the docking calculations the zinc ion was 
treated with the Stote164 parameters: radius of 1.10 Å, and well depth of 0.25 
kcal/mol. The molecular docking calculations were performed by Autodock 
3.0.555 on quad-core Intel Xeon 3.4 GHz, using a grid box size of 66 x 64 x 
48, with spacing of 0.375 Å between the grid points, and centered at 49.75(x), 
5.0 (y), 101.491 (z), covering the active site of the HDLP  To achieve a 
representative conformational space during the docking studies and for taking 
into account the variable number of active torsions, 6 calculations consisting 





Lamarckian genetic algorithm (LGA) was employed for d cking calculations, 
choosing an initial population of 450 randomly placed individuals. The 
maximum number of energy evaluations and of generations was set up to 5 x 
106 and to 4 x 106 respectively. Results differing by less than 3.5 Å in 
positional root-mean-square deviation (RMSD) were clustered together and 
represented by the most favorable free energy of binding. Illustrations of the 






2.4. Conformationally Locked Calixarene-Based HDAC 
Inhibitors 
In the last decade several examples of calixarene drivatives able to interact 
with molecules of biological interest, have been repo ted.175 In particular, 
Hamilton has designed calixarene derivatives able to bind to protein surfaces 
and to block biologically important protein–protein interactions.176 
Interestingly, the treatment of nude mice bearing human tumors with 
peptidocalix[4]arene derivatives, able to selectively bind to platelet-derived 
growth factor (PDGF), resulted in a significant inhibition of tumor growth and 
angiogenesis.176c In addition, it was demonstrated that calixarene-based 
therapeutic agents do not show any toxic eff ect in mice tests.176c,177  
Recently, it was demonstrated a surface recognition of tissue and microbial 
transglutaminases by peptidocalix[4]arene diversomers.178 Larger 
calix[8]arene derivatives have shown competitive inhibition of recombinant 
human tryptase.179 Water-soluble p-sulfonatocalixarenes have shown 
interesting biological activities, including anti-viral, anti-bacterial, and anti-
thrombotic activity.180 Recently, Ungaro and coworkers have reviewed the 
properties of calixarene-based multivalent ligands in lectin binding and 
inhibition, DNA condensation, and cell transfection.181  
On this basis, it was decided to investigate the use of calix[4]arene scaffold 
to construct novel inhibitors of Histone deacetylase enzymes (HDACs) and, in 
this paragraph, it was reported the result of this study.169 In this field, Nature 
provides a number of related cyclic scaffolds with HDAC inhibitory 
activity.168 
Regarding the structural features of HDACi, Ghadiri has recently shown that 





On the basis of these structural considerations,183 we envisioned that 
preorganized calix[4]arenes184 locked in the cone conformation, by propoxy 
groups at the ndo rim, and endowed with the appropriate functional groups at 
the exo rim to bind to the receptor surface (Figure 2.16, top) should be ideal 
candidates as potential HDAC inhibitors.  
Concerning the functional groups, first, a carbon aliph tic chain entering the 
binding channel E (channel linker, Figure 2.16, top) and bearing a metal 
binder for the Zn2+ coordination is required (Figure 2.16, bottom). Second, 
hydrophobic arms (cap groups, Figure 2.16, bottom) able to fit the four 
external hydrophobic pockets A-D (Figure 2.16, top) n the enzyme surface 
should be necessary.  
To direct the synthesis toward derivatives with higher activity, it was 
performed a molecular docking study of a significant set of designed 
calix[4]arenes variously substituted at the exo rim with aliphatic or aromatic 
groups of different size and hydrophobicity (Figure 2.16). 
In accordance with the current synthetic possibilites, the amide linkage185 
was selected to attach the above moieties at the upp r rim of calixarene 
scaffold.  
Molecular docking studies were articulated in the following steps: I) choice 
of the metal binder group and length of the linker chain, II) choice of the cap 
groups by gradually increasing the length of an amide aliphatic chain (from 
one to five carbon atom), and III) choice of aromatic cap groups by gradually 
increasing the size of the aromatic system (from one t  four condensate rings). 
 
Figure 2. 16 (A) A-D: Hydrophobic pockets on the HDLP (Histone Deacetylase Like Protein) 
surface. E: Zn2+ binding channel.
for HDAC inhibition. 
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Figure 2. 17 Variation of the final calculated inhibition constan  (KDcalc) as a function of 
different alkylic and aromatic groups connected at the amide linker at the upper rim of 
calix[4]arenes 35-45. 
 
As it is possible to observe in Figure 2.17, the KDcalc values are strictly 
dependent on the size of the arms. In particular, it is possible divide the curve 
in three different zones: low, medium, and high theoretical activity. 
Interestingly, the low zone corresponds to amidocalix[4]- arenes 35-40 bearing 
alkylic arms, whereas the medium and high zone of Figure 2.17 correspond to 
the series of amidocalixarenes 41-45 bearing aromatic arms of increasing size. 
In the best arrangement of the low zone obtained with the propylic arms 
(derivative 37, Figure 2.18c) it is important to note that the carboxylate group 
(metal binder) is of primary importance because of its network of interactions: 
it coordinates the zinc ion in a bidentate fashion and establishes hydrogen 
bonds with Hε2 of His131 and Hε2 of His132.  
The six element chain (channel linker) makes stabilizing hydrophobic 
contacts with the zinc-containing tubular pocket. The aromatic rings of calix 
scaffold establish π stacking with Tyr196, Phe200 and Tyr297 and van der 





surface (Figure 2.18c). The propylamido arms are core tly accommodated in 
the D and C hydrophobic pockets (constituted by Leu265, Ser266, Lys267, 
His170, Ala197, Phe198, Phe200, and by Pro22, Phe141, Tyr264, Tyr297, 
His298, Phe338, respectively). In the latter instance, a stabilizing H bond also 
occurs between the C=O of Tyr264 and the NH of propylamido arm.  
Moreover, additional van der Waals interactions betwe n one propoxy 
group at the lower rim and the macromolecular counterpart (pocket A), 
contribute to the calculated stability of calixarene-enzyme complex. 
Comparing the putative three-dimensional models of 35-40, even if all the 
Zn2+ binding channel interactions are maintained, it appears clear that the 
different length of alkylic arms translates in suboptimal hydrophobic 
interactions with the enzyme surface leading to a decrease in the calculated 
binding affinity.  
The linker chain of 35-45 fits into the 11 Å binding channel and the 
carboxylate moiety binds to the Zn2+ ion, at the bottom of the channel, in a 
bidentate fashion establishing hydrogen bonds with Hε2 of His132 for 41-45, 







Figure 2. 18 3D model of the interaction between amidocalix[4]arenes 35-40 with alkylic 
arms and the HDLP binding site. The protein is represented by molecular surface, while 
compounds 1-6 are depicted by sticks (by atom type: C yellow, polar H white, N dark blue, O 
red). A-D: Hydrophobic pockets on the HDLP surface. 
 
The aromatic arms of 41 and 42 occupy the pockets B, C, and D, while in 
the other models (43-45) the analogous arene moieties fill the pockets A, B, 
and C (Figures 2.19c-e). This different arrangement d pends on the size of the 
aromatic group. As shown in Figure 2.19a and 2.19b the smaller benzene or 
naphthalene rings of 41 and 42 (Figures 2.19a and 2.19b) easily accommodate 





Lys267, Ala197, Phe198 and Phe200, and establish van der Waals interactions 
with the protein counterpart (Figures 2.20a-d). 
Moreover, in the case of compound 42 an amide function forms an 
additional hydrogen bond with NH of Leu265 (Figures 2.20c and 2.20d), 
while two similar additional hydrogen bonds with Nε1 of His170 and OH of 
Tyr91 (Figures 2.20e and 2.20f) are observed for compound 45. On the other 
hand, the bulkier anthracene, phenanthrene or pyrene rings of the others ligand 
form a π-stacking interaction with Tyr91 (pocket A) for 43 and 44; Phe134 
(pocket B) for 10; Tyr264 (pocket C) for 43 and 44; Tyr297 (pocket C) for 9 
(see Figures 2.20e-f). Moreover, these aromatic rings establish cation-π 






Figure 2. 19 3D model of the putative binding mode of amidocalix[4]arenes 41-45 with 
aromatic arms and the HDLP binding site. The protein is represented by molecular surface, 
while compounds 41-45 are depicted by sticks (by atom type: C yellow, polar H white, N dark 







Figure 2. 20 Front view (A, C, and E) and back view (B, D, and F) of 3D model interactions 
between amidocalix[4]arenes 41, 42 and 45 and the HDLP binding site. In the front view (A, 
C, and E), the protein is represented by molecular surface, while compounds 41-45 are 
depicted by sticks (by atom type: C yellow, polar H white, N dark blue, O red). In the back 
view (B, D, and F) the protein and compounds 41-45 are depicted by sticks coloured by blue 





In particular, it was considered the most promising candidate 43 (Figure 
2.21) to pin down the main features of new potential calixarene-based HDACi.  
 
 
Figure 2. 21 3D model of the putative binding mode of amidocalix[4]arene 43 and the HDLP 
binding site. The protein is represented by its molecular surface (gray), while 43 is depicted as 
a CPK (top) or stick model (bottom) (colored by atom type: C, yellow, polar H, white; N, dark 
blue; O, red). 
 
The linker chain of 43 fits into the 11 Å binding channel, and the 
carboxylate moiety binds to the Zn2+ ion, at the bottom of the channel, in a 
bidentate fashion establishing hydrogen bonds with Hε2 of His132; moreover, 
an amide function forms an additional hydrogen bond with Nδ1 of HIS170. 
The aromatic arms of 43 occupy the pockets A, B, and C establishing van der 
Waals interactions with the enzyme counterpart, a π-stacking interaction with 
TYR91 (pocket A) and TYR264 (pocket C), and a cation-π interaction with 
LYS19 (pocket A).  
The docking results show that the influence of the groups at the upper rim is 
mainly related to hydrophobic or aromatic stacking i teractions, which seem 





To verify the above in silico results, it was decided to check the key points 
of the predicted curve represented in Figure 2.17: the most active candidate of 
the low zone (37), the intermediate (41), and three derivatives of the high 
zone, namely, 42, 43, and 45. The five derivatives 37, 41, 42, 43, and 45 were 
synthesized easily obtained starting tetraaminocalix[4]arene, already locked in 
the cone conformation by the four propoxy groups at the endo rim according.  
In vitro evaluation of inhibition of HDAC activity in HeLa nuclear extracts 
was performed by a fluorescence-based assay. The IC50 values of compounds 
37, 41, 42, 43, 45, and Trichostatin A (TSA, 5), a well-known HDAC 
inhibitor, are reported in Table 2.5.  
As predicted by the docking studies, alkyl derivatie 3 was the less active 
compound (IC50 > 10 µM) followed by phenyl derivative 7 (IC50 ) 5.10 µM). 
On the other hand, 8, 9, and 11, bearing larger aromatic rings, displayed higher 
inhibitory activities (IC50=0.14-0.86 µM), although with less pronounced 
differences with respect to the predicted ones. 
Probably the calculated differences fall within the accuracy limit of the 
docking method. In any case, results confirm that topology, size, and 
hydrophobicity of the aromatic arms are the most important determinants for 
biological activity of this novel class of calix[4]arene inhibitors. In summary, a 
classic in silico screening of a new class of potential HDAC inhibitors was 
applied obtaining a good predictions of their inhibitory activity before 
proceeding to their synthesis. 
In this way, it was possible to design a new class of amidocalix[4]arenes 
permanently locked in a cone conformation with convergently predisposed 
interacting moieties. The in silico evaluation of their binding ability toward the 
HDAC active site allowed us to direct the synthesis only to the most promising 









41 5.10 (±1.00) 
42 0.14 (± 0.02) 
43 0.14 (± 0.02) 
45 0.86 (±0.10) 
TSA 0.02 (±0.009) 
[a]values are means of three independent experiments. Standard deviation 
values were < 20% and are reported in parenthesis. 
 
The subsequent synthesis and enzyme inhibition evaluation fully confirmed 
the theoretical prediction that arylamidocalix[4]- arenes bearing large aromatic 
arms constitute moderately active HDACi. Considering that the calixarene 
frameworks had shown no hint of toxicity in several in vivo biological 
tests,176c,177 this work suggests an additional application of a sc ffold already 
used in the fields of biomolecular recognition. Future work will be directed 
toward the in silico screening of nonsymmetrically substituted 
arylamidocalix[4]arenes that could give an even better fitting on the different 
enzyme hydrophobic A-D pockets. The influence of the “coneblocking” 
groups at the lower rim will also be evaluated as well as the possibility to 







2.4.1. Computational Details 
The molecular docking calculations were performed on a two dual-core 
Intel Xeon 3.4 GHz, using Autodock 3.0.5 software55 using a already 
described QM optimized HDLP model. For all the docking studies a grid box 
size of 66 x 64 x 48 with spacing of 0.375 Å between the grid points, and 
centered at 49.75 (x), 5.0 (y) and 101.491 (z), covering the four hydrophobic 
pockets (A-D) on the HDLP surface was used. For all the docked structures, 
all bonds at the upper rim were treated as active torsional bonds. In order to 
achieve a representative conformational space during the docking calculations, 
from three to ten calculations consisting of 256 runs were performed, 
obtaining 768/2560 structures. The Lamarckian genetic algorithm was used for 
dockings. An initial population of 600 randomly placed individuals, a 
maximum number of 5.0 x 106 energy evaluations, and a maximum number of 
6.0 x 106 generations were taken into account. A mutation rate of 0.02 and a 
crossover rate of 0.8 were used. Results differing by less than 3.5 Å in 
positional root-mean-square deviation (RMSD) were clustered together and 
represented by the result with the binding energies. All the 3D models were 
depicted using the Python software:165 molecular surfaces are rendered using 





2.5. Synthesis, Biological Evaluation, and Molecular Docking 
of Ugi Products Containing a Zinc-Chelating Moiety as 
Novel Inhibitors of Histone Deacetylases 
In this paragraph, it is reported the use of molecular docking to rationalize 
the binding mode of three enantiomers pairs of linear peptides161a HDAC 
inhibitors (67, 73, and 74, Scheme 2.5) derivatives of CHAP 1 (36, Scheme 
2.3). 1 is an analogue of trapoxin B in which epoxyketone is replaced with 
hydroxamate, leading to a compound that reversibly nhibits HDAC at 
nanomolar concentrations, with a superior in vivo stability compared to 
trapoxin B.187 In a SAR study on CHAP derivatives it has been shown that the 
presence of two hydrophobic amino acids, such as the bisphenylalanine 
moiety, is fundamental for the interaction with two lipophilic binding sites of 
HDACs.188  
With the aim of probing binding interactions on the outer rim of HDAC 
enzymes, it was decided to focus on the bis-phenylalanine region markedly 
simplifying 1, generating a diamide scaffold by an Ugi reaction (Scheme 
2.3).189 This led to a peptidomimetic structure displaying a tertiary amide, 
making it possible to investigate the role of an additional substituent (R3). 
Furthermore, it was also investigated different side chains (R1, R2), analyzing 
their influence on HDAC activity. 
With this strategy in mind, different building blocks (isocyanides, 37-39, 
aldehydes, 40-43, amines, 44-46, and carboxylic acids containing the alkyl 
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The key reaction in the synthesis of the proposed HDACs inhibitors is the 
Ugi reaction, which leads to the R-aminoacylamide displaying an ester 
function. The methyl ester is then transformed into the corresponding 










Scheme 1.  
 
The Ugi reaction was performed in classical conditions (MeOH, 2 M, 48 h, 
r.t.), leading to the R-aminoacylamides in moderate yields (17-44%). Several 
attempts to optimize the transformation (37, 44, 40, 47) were made; in detail, 
temperature (reflux), solvent (trifluoroethanol), reaction times (up to 7 days), 
and molar ratios (excess of 44 and 40) were varied, alongside preforming the 
imine intermediate. Yet, none of these strategies proved better, in respect to 
the presence of starting materials, byproduct, and yiel s of the desired product. 
The hydrolysis of the methyl esters (49-57) to the corresponding carboxylic 
acids (58-66) was performed with LiOH in THF/water. The hydroxamic acids 
(65-75) were prepared by subsequent reaction with TBDMS-protected 
hydroxylamine, EDCI, and TEA in CH2Cl2, and final deprotection with TBAF 
in THF. To probe the structure-activity relationship of the metalchelating 
R1NC R2CHO
R3NH2 HOOC COOMen
47 n = 3





































Scheme 2. 5 Reagents and conditions: (a) MeOH, rt, 17-44%; (b) LiOH, THF, H2O, rt, 
75-99%; (c) o-(tert-butyldimethylsilyl)hydroxylamine, TEA, EDCI, CH2Cl2, rt; (d) 





group, analogues of 67 and 74 were also synthesized, replacing the 
hydroxamates with benzamides.  
Benzamides were synthesized (76 and 77), coupling the corresponding 
carboxylic acids to o-phenylenediamine using standard peptide chemistry 






Scheme 2. 6 Reagents and conditions: (a) o-phenylene diamine, DCC, THF, rt, 23-24%. 
 
To test the activity of the synthesized compounds, it was opted for a 
screening that evaluated cytotoxicity in a cell line previously reported to be 
sensitive to HDAC inhibitors.190 For each compound viability was evaluated 
with the MTT assay (Table 2.6), which measures mitochondrial activity. Most 
compounds possessing the hydroxamates moiety displayed a cytotoxic activity 
comparable to that of SAHA (17), chosen as a reference compound. The only 
exception was represented by 38, which was unable to induce a significant 
level of cell death at a concentration of 10 µM. To confirm the mechanism of 
action, a cellular HDAC activity assay was then performed in the same cell 
line concentrating on SAHA, 67 and 74.  
All three compounds inhibited HDAC activity at a con entration of 10 µM, 
validating the mechanism of action. The rank order of potency of the three 
compounds was SAHA (IC50 0.5 µM ± 0.1 µM) > 67 (1.2 µM ± 0.1 µM) > 39 
(4.4 µM ± 0.5 µM). This rank order of potency mirrored the rank order of 









































no R1 R2 R3 R4 
Viability (% of 
control) 











































Bn Benzamide 74.0±4.2 
SAHA     33.8±0.4 
Viability is evaluated at a concentration of 10.0 µM and data are expressed as mean ± 













To rationalize and to identify the structural features of the active molecules, 
we performed molecular docking studies on 
structurally dissimilar, and on 
with the HDLP binding pocket (PDB code 1C3R
AutoDock 3.0.5 software
 
Figure 2. 22 3D model of the HDLP. The protein is represented by molecular surface and 
sticks and balls 
 
For this docking calculations
between theoretical 
HDLP active site refined at QM level, 
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method for population analysis (see 
efficacy of such QM integration in the docking procedure has provided very 
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on both possible configurations (R and S) for compounds 67, 73, and 74, to 
evaluate if one or both enantiomers could be actually interacting with the 
biological target. In the three-dimensional model (Figure 2.23a) of the S-67, it 
is important to note that the hydroxamic moiety (metal binder) is of primary 
importance for its interactions network: it coordinates the zinc ion in a 
tridentate fashion and establishes hydrogen bonds with Hε2 of His132 and OH 
of Tyr297 (not shown). The heptanediamide chain (linker) makes stabilizing 
hydrophobic contacts with the zinc-containing tubular pocket. The cap group, 
formed by three rings, establishes noncovalent interac ions with the 
hydrophobic cavities C and D on the HDLP surface (Figure 2.23a). In 
particular, the cyclohexylamino ring is correctly accommodated in the D 
hydrophobic pockets (Leu265, Ser266, Lys267, His170, Ala197, Phe198, and 
Phe200). The N1-[1-(phenylmethyl)ethyl] is accommodated in a shallow 
groove, establishing van der Waals interactions with the macromolecular 
counterpart, formed by Ala197 and Phe200 residues, while the N1-
(phenylmethyl) ring accommodates in the C hydrophobic pockets (Pro22, 
Phe141, His21) of the enzyme. 
 
  
Figure 2. 23 (A) 3D model of the interaction between 67S and the HDLP binding site. The 
protein is represented by molecular surface and sticks and balls. 67S is depicted by sticks (by 





between 67R and the HDLP binding site. The protein is represented by molecular surface and 
sticks and balls. 67R is depicted by sticks (by atom type: C orange, polar H sky-blue, N dark-
blue, O red). 
 
Figure 2.23b depicts the 3D model of the interaction between R-67 and the 
target; the metal binder, linker chain, and the cap group of the two docked 
enantiomers (R- and S-67) fill equivalent spaces, but the two rings 
(cyclohexylamino and N1-[1-(phenylmethyl)ethyl]) of the cap group are in 
inverted positions on the HDLP surface with respect to S-67 (Figure 2.23b). In 
particular, the cyclohexylamino ring interacts with the Ala197, and Phe200 
residues, while the N1-[1-(phenylmethyl)ethyl] is accommodated in D pocket 
(Leu265, Ser266, Lys267, His170, Ala197, Phe198, and Phe200); in the mean 
time, the N1-(phenylmethyl) remains interacting with the aminoacid of the C 
hydrophobic pocket (Pro22, Phe141, His21). The different arrangement of the 
R-67 and the suboptimal hydrophobic interactions are respon ible for a 
predicted decrease in the binding affinity to the receptor of about 2.5-fold 
(KDcalc of S-67 4.45 × 10
-8 vs KDcalc of the enantiomer 1.04 × 10
-7). The same 
approach was used for 74. Bearing in mind the 3D model of the interactions 
between 67 and the HDLP binding site described above, the octanedi mide 
chain of S-74 fits into the 11 Å channel (Figure 2.24a), the NHOH group binds 
to the Zn2+ ion, at the bottom of the channel, in a tridentate fashion and 
establishes hydrogen bonds with Hε2 of H132, Oδ2 of Asp258, and OH of 







Figure 2. 24 (A) 3D model of the interaction between 74S and the HDLP binding site. The 
protein is represented by molecular surface and sticks and balls. 74S is depicted by sticks (by 
atom type: C blue, polar H sky-blue, N dark blue, O red). (A)  3D model of the interaction 
between 74R and the HDLP binding site. The protein is represented by molecular surface and 
sticks and balls. 74R is depicted by sticks (by atom type: C light-blue, polar H sky-blue, N 
dark blue, O red). 
 
The cap group, formed by four aromatic rings, establishes hydrophobic 
interactions with the cavities (A, C, and D). The N1-[1-([1,1'-biphenyl]-
methyl)]ethyl] group accommodates in pocket C (Pro22, Phe141, Tyr264, 
Tyr297). The N1-[(2-phenylethyl)amino]ethyl] ring accommodates in pocket D 
(Leu265, Ser266, Lys267, His170, Ala197, Phe198, and Phe200), while the 
N1-(phenylmethyl) occupies pocket A (Pro22, Tyr91, Glu92, and Phe141). 
Figure 2.24b depicts the putative three-dimensional model of R-74-HDLP 
complex. Comparing this model with the S enantiomer binding mode, the only 
difference is the R1-R3 arrangement on the enzyme surface; in particular, the 
pockets A and D are occupied by the N1-(phenylmethyl) and the N1-[1-([1,1' -
biphenyl]-methyl)]ethyl] moieties, respectively, while the N1-[(2-
phenylethyl)amino]ethyl] ring interacts with the Phe198, Phe200, and Tyr91 
amino acids. The minor efficiency of such interactions are responsible of a 
small decrease in the binding affinity to the target (of about 5-fold: KDcalc of S-






In both the enantiomers R and S of 73, the lack of a hydrophobic and bulky 
group on R3 is responsible for a predicted decreased histone deacetylase 
inhibitory activity (KDcalc of S-73 2.44x 10
-7 vs KDcalc of the enantiomer 3.87 
x10-7), because their expected noncovalent interactions are lost. In the first 
model (Figure 2.25a), the N8-[2-[(2-phenylethyl)amino], and N8-1-
(phenylmethyl) ethyl groups are placed in D (Leu265, Ser266, Lys267, 
His170, Ala197, Phe198, and Phe200) hydrophobic cavity, but the hydroxamic 
moiety (metal binder) coordinates the zinc ion in amonodentate fashion. In the 
three-dimensional model of R-73, the R1 and R2 substituents are placed in the 
same hydrophobic cavity found for the S-enantiomer but with an inverted 




Figure 2. 25 (A) 3D model of the interaction between 73S and the HDLP binding site. The 
protein is represented by molecular surface and sticks and balls. 73S is depicted by sticks (by 
atom type: C light-green, polar H sky-blue, N dark blue, O red). (A) 3D model of the 
interaction between 73R and the HDLP binding site. The protein is represented by molecular 
surface and sticks and balls. 73R is depicted by sticks (by atom type: C green, polar H sky-
blue, N dark blue, O red). 
 
Keeping in mind the biological results and the descriptions of the 3D 





docking results related to compounds containing NHR1COCHR2NR3 as cap 
group was offered. 
In particular, the influence of the hydrophobic and bulky group on R1, R2, 
and R3, in turn related especially to hydrophobic interactions, and to aromatic 
stacking, seem to be the driving forces of the target-li and complexes. Such 
evidence is confirmed by calculated and experimental 73 inactivity. In light of 
the above results and thanks to the good qualitative accordance between the 
results of biological essays and the prediction of the molecular docking 
calculations, there is a complete rationalization of the putative binding mode 
for 67, 73, and 74 enantiomers pairs. In particular, a new scaffold was proven 
to be an efficient cap group model in the rational design of new linear HDAC 
inhibitors, and the critical features necessary for the optimal contact modes 
with HDLP binding pocket were determined. 
 
2.5.1. Computational Details 
Molecular docking calculations were performed on a two dual-core Intel Xeon 
3.4 GHz, using Autodock 3.0.5 software55 using the already described 
optimized HDLP model. 
The charges of the ligands were optimized at DFT level using the B3LYP 
functional and the 6-31G+(d) basis set, as implemented in Gaussian 03 
Package software.160 For all the docking studies, a grid box size of 66  x 64 x 
48 with spacing of 0.375 A between the grid points and centered at 49.75 (x), 
5.0 (y), and 101.491 (z) covering the four hydrophobic pockets (A-D) on the 
HDLP surface was used. For all the docked structures, all bonds were treated 
as active torsional bonds. To achieve a representative conformational space 
during the docking calculations, 10 calculations consisting of 256 runs were 





algorithm was used for dockings. An initial population of 450 randomly 
placed individuals, a maximum number of 10.0 × 106 energy evaluations, and 
a maximum number of 8.0 × 106 generations were taken into account. A 
mutation rate of 0.02 and a crossover rate of 0.8 were used. Results differing 
by less than 2.5 Å in positional root-mean-square deviation (rmsd) were 
clustered together and represented by the free energy of binding. All the 3D 
models were depicted using the Python software165 molecular surfaces are 






2.6. Structural Basis for the design and synthesis of selective 
HDAC inhibitors 
In this paragraph, it was traced out the structural elements responsible of 
selective binding for the therapeutically relevant different HDAC isoforms. 
The structural analysis has been carried out by molecular modeling, docking in 
the binding pockets of HDAC1-4 and HDAC6-8, thirty five inhibitors 
presenting a well defined selectivity for the different isoforms. As proof of 
evidence, it was reported the design, synthesis and biological evaluation of 
three selective inhibitors.191 The experimental data suggest that the obtained 
structural guidelines can be useful tools for the rational design of inhibitors 
against selected HDAC isoforms. 
In literature, studies devoted to develop selective l gands for specific 
isoforms are reported, even though such studies only consider a restricted 
number of isoforms.192 Moreover, most of the published works focused on 
selective ligands are only based on biological profiles, lacking the structural 
investigation aimed to disclose the ligand and protein elements potentially 
responsible of class and isoform selectivity.193 
On this basis, here, it was traced out the structural elements responsible of 
selective binding in the whole landscape of the therap utically relevant HDAC 
isoforms (Scheme 2.7).  
In particular, it was tried to rationalize a number of experimental 
observations and tried to systematically add new insights for a targeted design 
of selective inhibitors of the different HDAC isoforms, focusing our attention 
on HDAC1-4, and HDAC6-8. HDAC9-11, for which few information so far 





HDAC5, missing a concrete ligand inhibitory profile,129 have not been 
considered in this investigation. 
 
 
Scheme 2. 7 Work-flow of the different stages involved in the structural characterization, 
design and synthesis of new selective HDAC inhibitors. 
 
The structural analysis reported below was performed by molecular 
docking calculations, using as ligands pan and class selective HDAC inhibtors 
reported in the literature (5, 7, 9, and 78-109, Scheme 2.8), presenting a well 
defined profile of HDACs inhibition. Based on the obtained structural 
guidelines, we designed (110-112, Scheme 2.8), synthesized and 






































































































































































































































































Scheme 2. 8 Molecular structures of compounds 5, 7, 9, and 78-112. 5 and 78, pan inhibitors. 
9, 7, 79-80, class I selective inhibitors. 81-90, HDAC1,2 selective inhibitors. 91-97, HDAC8 
selective inhibitors. 98 and 99, HDAC4 selective inhibitors. 100-109, HDAC6 selective 






2.6.1. Structural analysis 
All the considered compounds in the present analysis were analyzed by 
molecular docking calculations on HDAC1-4 and HDAC6-8 (Scheme 2.8). 
Some enzyme calculation parameters related to the electrostatic and Van der 
Waals terms of binding energy were refined, following the successful strategy 
adopted for the structural studies on azumamide E and two stereochemical 
variants.147 This strategy allowed to reach a good qualitative accordance 
between theoretical KDcalc and biological assays results, and it was also 
validated by its useful application to the study of other HDAC ligands.161,169 In 
particular, for the electrostatic contribution, the partial charges of the zinc ion 
and the amino acids constituting the catalytic site of each isoforms were 
calculated at DFT/M05194 theory level by using the 6-31+g(d) as basis set and 
the ChelpG method148 for the population analysis and were used in the 
subsequent docking calculations. Similarly, for thevan der Waals term the 
well depth and zinc radius proposed by Stote and Karplus were applied.164  
 
2.6.1.1. Common structural features of all isoforms 
As well defined by previous studies,168,183 the general structure of HDAC 
inhibitors can be dissected (5, Scheme 2.5) in: a cap group involved in the 
molecular recognition process with surface amino acids; a linker, usually 
hydrophobic; a zinc-chelating group. Each structural moiety contributes to the 
binding event and biological activity of the small molecules. In particular, a 
fundamental structural element to inhibit these biological targets is the metal 
binder. Many chelating agents, such as hydroxamic ac ds, carboxylate, α-
hydroxy-ketone were introduced, and theoretical andexperimental evidence 





enzymes. Class I and II proteins present a considerable sequence similarity in 
the catalytic site. By comparing homology and experim ntal models, it 
possible to observe the presence of two parallel phenylalanine units 
delineating the channel which accommodates the acetyl t d lysine of the 
histone (Table 2.7, and Figure 2.6).  
 
Table 2. 7 Residue number of two phenylalanines constituting he hydrophobic channel, 
which accommodates the substrate. 
 Phe 
HDAC1 150 205 
HDAC2 155 210 
HDAC3 144 200 
HDAC4 168 227 
HDAC6 140 200 
HDAC7 679 738 
HDAC8 152 208 
 
As revealed by docking calculations on all considere  HDACs, the 
switching from a linear carbon chain (5, 9, 79, 22-108) to an aromatic linker 
(7, 78, 80-95, 109) causes an increased affinity with the targets, thanks to 





2.6.1.2 General features and differences of Class I and II 
In the reported 
present a CO of a glycine and side chain of a tyrosine pointing inside the 11 Å 
channel: Gly149 and 
Gly143 and Tyr298 for HDAC3, and Gly151 and Tyr306 for HDAC8. The 
class I isoform selective compounds 
the linker and the metal binder (Figure 
functionality can establish a hydrogen bond with the carbonyl of the glycine. 
Moreover, the hydrophobic channel of class II proteins does not display 
acceptors and donors of hydrogen bonds. In this perpective, the linker could 
be modified inserting hydroge
interactions with these two residues constituting the hydrophobic channel, 
sustaining selectivity for class I HDACs. 
 
Figure 2. 26 Three-dimensional model of the interactions betwe
protein (a) and 82 are represented by tube and their atoms are coloured by atom type: C, gray; 
polar H, white; N, dark blue; O, red). For 
ion is represented in orange cpk. The figure
between the NH of the amide functionality and the carbonyl of the Gly154
represented by molecular surface. The figure shows the coordination of zinc ion (represented 
in red cpk) and the accommodation of metal binder appendage in the internal cavity.
 
The analysis of crystal structures of bacterial homologues (HDLP) of 
class I122 along with human HDAC2 and HDAC8 reveals the presence of a 14 
HDAC 
117 
analysis, it was observed that HDAC1-3 and HDAC8 
Tyr303 for HDAC1, Gly154 and Tyr308 for HDAC2, 
7, 81-89 present an amide bond between 
2.26). The NH of the amide 
n bond acceptors and donors in order to give 
 
en 82 and HDAC2. The 
82, carbon and bonds are depicted in green. The zinc 












Å internal cavity at the bottom of the 11 Å hydrophbic channel, close to the 
zinc active site.161f The high sequence similarity of HDAC1 and HDAC3 with 
HDLP, HDAC2 and HDAC8 confirm for all class I HDACs the presence of 
the 14 Å internal cavity is expected. The homology models obtained in this 
study of HDAC1 and HDAC3 in fact showed the presence of the internal 
channel observed in HDLP, HDAC2 and HDAC8, also in agreement with 
previously reported homology modelling studies.195 With one exception 
(HDAC8), the residues forming the 14 Å internal cavities are identical across 
the different proteins of class I. Recently, 2-amino benzamides were proposed 
as metal binders, and compounds presenting this functionality showed 
selectivity for class I enzymes.196 In particular, in agreement with reported 
experimental data, the analysis of docking results on the compounds 
presenting a benzamide as metal binder (7,197 Scheme 2.8) revealed a 
preference for class I enzymes, in particular for HDAC1 and HDAC2. The 
coordination of the enzyme prosthetic group by the NH2 of benzamide requires 
a side accommodation of phenyl ring, unlike the common metal binders, such 
as hydroxamic acid, carboxylate group, α-hydroxy-ketone. The consequence is 
the requirement of a side room at the bottom of the 11 Å channel, offered by 
the 14 Å internal cavity.  
In literature it is reported that natural cyclopeptides198 are selective 
inhibitors of class I proteins, and the most important of these ligands were 
considered in our studies. For example, the azumamide E147 and apicidine199 
(79 and 9, Scheme 2.8) show selectivity for class I, with significant affinity for 
HDAC8 and superior affinity for HDAC1-3. From the rported theoretical 
analysis of cyclopeptides and the other ligands, it was found that the 





surface at the entrance of 11 Å hydrophobic cavity, establishing Van der 
Waals interactions and hydrogen bonds (Figure 2.27).  
 
 
Figure 2. 27 Three-dimensional model of the interactions between 79 and HDAC1. The 
protein is represented by molecular surface and ribbons. 79 is depicted by tube. C atoms and 
bonds are shown in yellow and the remaining atoms are coloured by atom type: polar H, 
white; N, dark blue; O, red). The figure highlights that the phenyl group is located in a 
hydrophobic pocket and the tetrapeptide core interac s with a shallow cavity on the receptor 
surface. The green dashed line indicates a hydrogen bond. 
 
These interactions contribute to the complex stabili y, favouring the 
binding for the HDACs of class I over the isoforms of class II. Such 
observation is suggested from the docking analysis of the binding mode of 
azumamide E and apicidine with HDACs of class II, showing that the 
macrocycle does not interact with macromolecular counterparts on the surface 
of HDAC4, HDAC6 and HDAC7, thus not contributing to the affinity for the 
protein. The pan inhibitors TSA (5) and NVP-LAQ824 (78),200 for example, 
did not present this structural bulky cap group, highlighting the role of the 





other analyzed class I selective ligands, the cyclopeptides presented a wider 
cap group, which established more extended contacts with proteins surface. As 
reported in the previous section, the proteins of class II present two 
phenylalanines to form the channel leading to the active site (Table 2.7, and 
Figure 2.6), like the isoforms of class I. By this analysis of the homology and 
experimental models of class II isoforms, we observed that the distance of the 
aromatic side chains of these two residues is about 8.5 Å. This distance is 
larger than that one found in the class I isoforms (≈ 7 Å), thus the linker 
moiety could establish tighter interactions with hydrophobic channel of 
HDAC1-3 and HDAC8 with respect to HDAC4, HDAC6 and HDAC7.  
 
2.6.1.3 HDAC1 
The differences between HDAC1 and HDAC2 are very small due to an 
85% sequence identity and 93% sequence similarity, which confer very similar 
shapes for all the protein regions. The comparison of the three-dimensional 
models of HDAC1 and HDAC2 reveals some small differences, which could 
be exploited to discriminate the recognition of these two isoforms. By this 
investigation it was observed a tighter access to the catalytic site of HDAC1 
compared to HDAC2 (Figure 2.28), due to the different spatial arrangement of 
residues leading to the zinc ion and bordering the 11 Å channel. In particular, 
this diverse orientation reflects the replacement of Met233, Pro361 and 







Figure 2. 28 View of the top of the ≈11 Ǻ channel. The HDAC1 and HDAC2 are represented 
by molecular surface coloured in white and red, respectively. The figure highlights the 
difference in shape and dimensions of the tube like channel, leading to the zinc ion. 
 
As reported above, all proteins of class I present an internal hydrophobic 
pocket at the bottom of the channel accommodating the substrate. It was 
observed that the amino acids constituting this internal cavity are identical or 
conservatively substituted, but differences in the surrounding amino acids of 
these internal cavities can be pointed out. In particular, bulkier residues in 
HDAC3 and HDAC8 (see below) prevent the accommodatin of the chelating 
agent with an appendage. Indeed, in the case of HDAC1 and HDAC2 the 
docking results on 7 highlighted that the metal binder is well harboured and 
the zinc is coordinated by the CO and NH2 functionalities. This docking 
studies show (Figure 2.29) that the phenyl ring interacts with the surrounding 
hydrophobic residues and along with the bidentate coordination increases the 
affinity for HDAC1 and HDAC2. These findings are inagreement with 
published biological assays,197 which show the selectivity of MS275 (7) for 
HDAC1 with this preference: HDAC1 > HDAC3 and HDAC1 >> HDAC8, 




Figure 2. 29 Three-dimensional model of the interactions between 
acids are represented by tube and coloured by atom type (C, grey; polar H, white; N, dark 
blue; O, red). 7 is depicted by stick (orange) and balls coloured as for the protein. The figure 
highlights that the phenyl group is located in the internal
interactions. 
 
The insertion of a substituent on the benzamide leads to a further 
discrimination among HDACs of class I. Indeed, HDAC1 and HDAC2 were 
able to harbour a substituent on the benzamide (
thiophene or phenyl.
same considerations for compound 
benzamide interacting with the internal cavity, and strengthening the 




7 and HDAC1. 
 cavity, establishing hydrophobic 
81-89, Scheme 2
202 The reported docked pose (Figure 2.30
90203 where the phenethyl replaces the 





.8), such as 
) suggests the 
 
Figure 2. 30 Three-dimensional model of the interactions between 
amino acids are represented by tube and coloured by atom type (C, grey; polar H, white; N, 
dark blue; O, red). 90 is depicted by st




As outlined in the previous section, many structural elements of compounds 
having high affinity for HDAC1 are similar for the isoform 2. By comparing 
the models of HDAC1 and HDAC2, structural differencs, even though small, 
are detectable. As described above, residues bordering the 
present a different spatial arra
Tyr209 in HDAC2, in turn depending on the presence of Leu228, Asn356 and 
Leu359 in HDAC1 and Met233, Pro361 and Met364 in HDAC2. On the basis 
of this different arrangement, a deeper cavity is present for HDAC2 com
to the shallower cavity of isoform 1, formed by amino acids His183, Tyr209, 
Phe210 and Leu276. Together with this first discrimination, and even though 
HDAC 
123 
90 and HDAC1. The 














the amino acids constituting the 14 Å internal cavity are identical for HDAC1 
and 2, differences could be found in the neighbouring esidues. In details, it 
was observed that the Val19 (HDAC1) is substituted by the Ile24 in HDAC2, 
influencing the arrangement of surrounding residues. In particular, it was 
observed a different disposition of Met35, Phe114 and Leu144 giving rise to a 
larger room compared to HDAC1 (Figure 2.31).  
 
 
Figure 2. 31 View of the bottom of the side channel. The HDAC1 and HDAC2 are 
represented by molecular surface coloured in red anwhite, respectively. The figure 
highlights the difference in shape and dimensions of the internal channel, near to the catalytic 
site of the enzymes. 
 
This can justify the observed slightly preference (about 10 fold)183,203 of 
benzamides for HDAC1 vs. HDAC2, due to closer contacts with the internal 
cavity of isoform 1. On this basis, it was designed and tested new potential 
selective ligands for HDAC2 taking into account thecombination of a metal 
binder able to interact with the 14 Å internal cavity and of an adapted capping 








As shown in the previous two sections, the relevant structural elements to 
discriminate isoforms of class I are appendages of metal binder, able to 
interact with the internal cavity at the bottom of the 11 Ǻ channel. By the 
analysis of the amino acids surrounding the internal cavity close to the 
catalytic site, it was observed that in HDAC3 Tyr107 replaces Ser113 in 
HDAC1 and Ser114 in HDAC2. In the isoform 3 the presence of the bulkier 
side chain of Tyr107, forces the Leu133 to point towards the center of the 
internal cavity. This shift of Leu133 causes a steric clash preventing the 
accommodation of bulky metal binders. The reported docking results on 81-90 
highlighted that the metal binder was not well accommodated in the internal 
cavity, as experimentally confirmed.168,195,198,203 Thus, the design of an adapted 
chelating agent able to match the HDAC3 macromolecular counterparts and to 
give effective contacts, is necessary for gaining selectivity toward this 
isoform. The reported docking results allowed to appreciate differences on the 
protein surface near the catalytic site. In particular, it was observed the 
presence of Phe199 in HDAC3 and Tyr204 and Tyr209 in HDAC1 and 
HDAC2, respectively. In the isoforms 1 and 2 the OH group of tyrosine 
establishes a hydrogen bond with the CO of Leu271 in HDAC1 and Leu276 in 
HDAC2. This hydrogen bond is absent in HDAC3, giving rise to a larger and 
deeper hydrophobic cavity delimited by the amino acids Ile171, His172, 
Phe199, Phe200, Gly267 and Cys268 (Figure 2.32).  
 
 
Figure 2. 32 Three dimensional model of the complex between
represented by molecular surface and sticks. 
are shown in pink and the remaining atoms are repres nt d by atom type: polar H, white; N, 
dark blue; O, red. 
 
This cavity can accommodate larger ligand moiety favouring the selectivity 
toward the isoform 3, in addition to the affinity. Moreover, 
pocket delimited by amino acids Phe88, Asp93, Gly143 and Phe200, as for 
HDAC1. In this regard, the insertion of an aromatic ring on the capping 
moiety in order to establish 
with Asp93, a hydrogen bon
contacts with Asp93, may contribute to increase the affinity for HDAC3. 
 
2.6.1.6 HDAC8
The resolved X-ray structures of HDAC8 complexed with 
have suggested structural elements to selectivity bind this 
bound to 91, HDAC8 shows a shift from the normal position of Phe152, which 
is located along the hydrophobic 11 
that can contain hydrophobic groups protruding from the linker moiety, 




 7 a d HDAC3. The protein is 
7 i  depicted by sticks. The C atoms and bonds
it was
π-π interactions with Phe200, and anion




Ǻ channel. This shift creates a sub pocket 
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204 and 91205 
 
strong interactions contribute to the complex stability and favour a selective 
binding to HDAC8. Compounds 
structural considerations obtained from 
docking calculations showed, as expected, high selectivity for HDAC8 thank 
to the interactions with the induced hydrophobic cavity. By comparing the 
amino acids constituting the internal cavity found in all isoforms of class I, 
was observed that HDAC8 presents Trp141, in place of a leucine in HDAC1
3. The presence of the bulky side chain of Trp141 hinders the appropriate 
accommodation of chelating portions endowed
HDAC1-3. Indeed, 
Trp141 limited the accommodation of the benzamide, causing the NH
coordinate the zinc ion in a monodentate manner (Figure 
compounds 81-90 endowed of larger appendages, the prosthetic group of the 
enzyme is not coordinated. 
 
Figure 2. 33 Three dimensional model of the complex between
represented by molecular surface and sticks. 
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91 bound to HDAC8, and molecular 
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2.33). Moreover, for 
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On the other hand, well tailored chelating moieties can afford selectivity for 
isoform 8, as showed by compounds 
azetidin-2-one contained in 
correct coordination of the zinc binding region of HDAC8 (Figure 
 
Figure 2. 34 Three-dimensional model of the interactions between 
pdb archive code). The amino acids are represented by tube, and coloured as: gly, white; asp, 
red; phe, brown; his, light blue; leu, green; cys, yellow; trp, dark bro
zinc ion is represented in dark orange cpk. The 
coloured as: C, blue; polar H, white; N, dark blue; O, red; S, yellow. The figure highlights the 




Based on docked poses of all considered ligands (Scheme 2
trace out the structural elements responsible for the selectivity of HDAC4. In 
particular, aryl pyrrolyl hydroxamide (APHA, 
compounds207 are reported as selective HDAC4 inhibitors. These comp unds 
show a lower general HDAC affinity compared to TSA, but present higher 
HDAC 
128 
96 and 97.192a Indeed, the N
96 and 97 interacts with Trp141, allowing a 
96 and HDAC8 (3FOR, 
wn; tyr, light brown. The 
96 is depicted by blue tube and the atoms 
nternal cavity.  
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selectivity for this enzyme. It was observed that substitution of chlorine with 
fluorine at phenyl C3 position improved the selectivity for HDAC4 from 78-
fold to 176-fold over class I.207 Moreover, non-halogenated or differently 
substituted APHA derivatives did not show any selectivity towards this 
isoform, highlighting the importance of the position f the halogen in the 
capping group. The described theoretical model showed that the halogen is 
involved in a hydrogen bond with the side chain of Tyr170 (Figure 2.35). 
Moreover, there is an interaction between NH group f Phe168 with the 
electron π system of the halogenated phenyl ring, along with a π-π interaction 
of C-halogen bond with CO of Phe168 that can contribu e to the specific 
recognition for HDAC4. The reported theoretical investigation also suggested 
that the presence of an aromatic linker in 98 and 99 gives rise to π-π 
interactions with side chains of Phe168 and Phe227 (Figure 2.35). 
 
 
Figure 2. 35 Three-dimensional model of the interactions between 25 and HDAC4. The 
protein is represented by ribbon and the zinc ion is depicted in dark orange cpk. The side 
chains of His158, His159 and Tyr170 (light green), and 25 (white) are shown by tube. The 







It was also observed that the hydroxamic acid of 98 and 99 coordinated the 
zinc ion, but also established hydrogen bonds with the Nε2 of His158 and 
His159 by the OH and NH groups, respectively (Figure 2.35). In all other 
analyzed isoforms 98 and 99 did not show these two interactions, except one 
hydrogen bond with the catalytic site of HDAC3. As reported above,207 a 
moderate biological activity has been shown for these HDAC4 selective 
inhibitors, thus structural modifications are required to increase the affinity of 
new candidate molecules. From this analysis, hydrophobic cavity delimited by 
residues His198, Phe226, Phe227, Leu299 may host a larger group, able to 
establish a hydrogen bond with the NH of His198, in replacement of the 
methyl group in the 98 and 99. From the docked poses of 98 and 99 we 
observed the cap group near a small pocket formed by Pro165, Met166, 
Gly167, Tyr170, and Cys169.  
Thus, along with a halogen, a hydrophobic group canbe inserted to 
establish Van der Waals contacts with the described pocket on protein surface. 
The reported comparison of electrostatic potential m ps of all considered 
isoforms on the surface around the channel leading to the zinc ion revealed 
that HDAC4 displayed a positive charged area, whereas the other proteins 
presented negative or neutral regions (Figure 2.36). Thus, the cap moiety can 
be elongated to favour electrostatic interactions with side chains of positively 
charged amino acids.  
 
 
Figure 2. 36 Molecular surfaces of HDAC1
 
2.6.1.8 HDAC6
As already reported in previous st
ligands,192d,192e,193a here it was
length is a crucial structural element for 
coordination, the linker length is responsible of correctly directing the 
extended interactions of the capping moiety with the macromolecular 
counterparts. HDAC6 presents a wider entrance of the binding pocket 
conducting to the prosthetic group, formed by several non
selective inhibitors (
structural moieties and can assume an extended conformation
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Figure 2. 37 Three dimensional model between 
by ribbon and the zinc ion is represented in dark orange cpk. The side chains of Phe140 and 
Phe200, and 101 are depicted
The atoms are coloured as: 
lines indicate hydrogen bonds.
 
In the case of other considered HDAC isoforms, due to the small
of the hydrophobic channel, the cap groups are not well accommodated in the 
surface cavities giving fewer contacts with amino acids, and suggesting a 
consequent lower contribution to the complex stability. Moreover, in 
described docked pose
between cap group and amino acids on the surface of HDAC1
HDAC8, but this entropic loss is not compensated by extended interactions 
with the macromolecular counterparts. These theoretical f
experimental observations that all selective inhibitors for HDAC6, tubacin 
(100),208 mercaptoacetamides (
108)209presented longer spacers, differently from class I elective
HDAC 
132 
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 in tube, respectively coloured in green and light green, and red. 
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whose optimal linker length is six carbons.168,183,147,161 As recently reported 
(109, Scheme 2.8),210 the right combination of linker length with a large and 
rigid cap group can also dictate the selectivity for the isoform 6. The 109 
presents a shorter linker length compared to the other selective HDAC6 
compounds (100-108), but the tolyl linker combined with the tricycle confers a 
bent conformation to 109, favouring tight interactions with the rim of 
hydrophobic channel of this isoform. On the contrary, the docked poses of 109 
in the binding cavity of HDAC1-4, HDAC7 and HDAC8 shows steric clashes 
with amino acids on the proteins surface, leading to unfavourable ligand-
enzyme binding.  
 
2.6.1.9 HDAC7 
Up to date, there are not selective inhibitors of HDAC7. Thus, the docking 
results of compounds 5, 7, 9, and 78-108, the structural features of the 
catalytic domain and of the surface pockets of HDAC7 may suggest 
interesting elements for designing selective inhibitors of this isoform. In detail, 
the unique sequence of HDAC7 gives rise to a novel zinc binding motif. This 
protein domain is formed by a β-hairpin positioned by two antiparallel β-
strands (β3 and β4) and the loop between helices α1 and α2, which outlines a 
distinct and only groove contiguous to the opening of the active site 
channel.211 This enlarged active site of HDAC7 could be able to harbour a 
well tailored metal binder, conferring selectivity and improving the affinity of 
new inhibitors for this enzyme. Selective inhibitors 81-90 presented a metal 
binder with an appendage able to interact with the 14 Ǻ internal cavity of class 
I proteins. These docking results on HDAC7 showed that these selective 
inhibitors did not coordinate the prosthetic group of the enzyme and did not 





bioactive conformation of 7 is bound to the zinc ion in a monodentate fashion. 
On the contrary, the remainder docked inhibitors, presenting a classical 
chelating agent without decorative appendages, coordinate the zinc ion. Thus, 
in the hypothesis to design selective binders of HDAC7, new protuberances 
decorating the metal binder should be projected to selectively match the active 
site of HDAC7. It could be suggested to insert two flexible appendages 
flanking the metal binder of the putative ligand. It was observed a deep 
hydrophobic pocket near the Phe679, which is a constituting residue of 
hydrophobic channel harbouring the acetylated lysine. This cavity is delimited 
by the amino acids His531, His541, Pro542, Glu543, Ile628 and Phe679 
(Figure 2.38), and it is a peculiarity of HDAC7. The docked poses of 5, 7, 9, 
and 78-109 did not show interactions with this macromolecular counterpart by 
their cap groups. Thus, a capping moiety, able to es ablish contacts with this 
unique pocket on the surface, can be another structural element addressing 
selectivity for this enzyme. 
 
 
Figure 2. 38 Three dimensional model of HDAC6. The protein is represented by molecular 






2.6.2. Proof of concept: Design, synthesis and biological 
evaluation of selective HDAC2 inhibitors 
 
2.6.2.1 Design of 110-112 
On the basis of the previous analysis aimed to find the structural elements 
responsible for a specific recognition of HDAC isoforms, three molecular 
probes (110-112, Scheme 2.8) were designed for the selective inhibition of 
HDACs. In particular, this design relied on the useof the weak carbonyl group 
as chelating agent in order to emphasize the contribution to selective binding 
by the other structural moieties. The design was focused on a metal binder 
with three different appendages in order to probe the influence on the class I 
and isoform selectivity. The three compounds (110-112, Scheme 2.8) were 
docked on all considered HDACs. As revealed by the theoretical investigation, 
the metal binder showed a Class I recognition preference. In fact, the structure 
of the metal binder presents an appendage able to establish contacts with the 
internal cavity near the catalytic site. Moreover, changing the structure of the 
decorative element of the metal binder, it was observed isoform selectivity as 
predicted by the investigation of 5, 7, 9, and 78-109. Indeed, compound 110 
selectively reached the catalytic site of HDAC2. In all other isoforms, 110 was 
not able to coordinate the zinc ion, suggesting an exclusive binding to HDAC2 
as confirmed by the biological assays (see below). In particular, the carbonyl 
moiety coordinates the zinc ion, whereas the NH of the amide group, as 
suggested by our analysis, establishes hydrogen bonds with the CO of Gly154 







Figure 2. 39 Three-dimensional model of the interactions between 110 and HDAC2. The 
protein is represented by molecular surface and the zinc ion is depicted in dark orange cpk. 
The side chains of amino acids are represented by tube, and coloured as: gly, white; asp, red; 
phe, brown; his, light blue; leu, green; cys, yellow; arg, dark blue; met, olive. The 110 is 
depicted in purple tube and the atoms are coloured as: C, purple; polar H, white; N, dark blue; 
O, red.  
 
The naphthalene was accommodated in the 14 Ǻ internal cavity, giving 
hydrophobic interactions with the surrounding protein amino acids: Met35, 
Phe114, Gly143, Leu144, Gly305, Tyr308 (Figure 2.39). The aromatic linker 
interacted by π-π contacts with the hydrophobic channel conducting to the zinc 
ion. One of the two furans was accommodated in a shallow pocket delimited 
by residues His183, Tyr209, Phe210 and Leu276, and it also established π-π 
interactions with Tyr209 (Figure 2.39). The other furan ring established anion-
π interaction with Asp104. The arrangement of these two aromatic groups of 
the capping moiety, induced by the rim shape of the c annel, favoured the 
coordination of the zinc. It is noteworthy that we d signed this cap group in 
order to discriminate between the isoforms of class I. Indeed, besides the 
HDAC1 and HDAC2 selectivity driven by the metal binder, it was observed 
that this cap group interacts differently with HDAC1 and HDAC2, leading to a 
preference towards isoform 2. In the theoretical model obtained by docking 
calculations, it was observed that the interactions f the cap group with the 





binder to the zinc, predicting absence or at least scarce biological activity. 
Compound 111 and 112 presented a different appendage of the metal binder, 
which caused a different affinity and selectivity for the investigated isoforms. 
In compound 111, the reduced dimensions of the metal binder caused fewer 
interactions with the internal cavity, justifying a lower affinity for the HDAC2. 
Moreover, the modification of metal binder structure gave rise to a possible 
binding to the HDAC8, as suggested by our calculations. The same 
considerations can be made for the 112. Respect to 110 and 111, compound 
112 presents a methylene between the chelating agent and the linker. This 
structural modification does not favour the interactions given by the linker and 
the cap group with HDAC2. Indeed 112 showed a lower binding affinity with 
HDAC2, with respect to the other compounds.  
These designed small molecules were synthesized and tested by biological 
assays on all considered HDAC isoforms. 
Compounds 110-112 displayed significant selectivity in the in vitro 
inhibition tests against the HDAC1-4 and HDAC6-8 (Table 2.8). As expected, 
all compounds were not able to inhibit class II HDACs, and showed a 
selective isoform binding among proteins of class I. As predicted by the 
docking studies, 110 showed selectivity on HDAC2, thus confirming that the 
structure of cap group and metal binder is an important determinant for the 
biological activity towards isoform 2.  
In particular, the capping moiety allowed to discriminate between HDAC1 
and HDAC2. Compared to 110, compound 111 presented a lower activity 
against HDAC2 in agreement to the docking results, due to the less extended 
interactions given by the pyrrolidine with the internal hydrophobic cavity. 






Table 2. 8 In vitro inhibitory activity of 110-112 against HDAC1-4 and HDAC6-8 (IC50, M)
a 
 HDAC subtype 
compound 1 2 3 4 6 7 8 
110 - 8.06 x 10-5 - - - - - 
111 - > 100 µM - - - - 
2.96 x 
10-5 
112 - - 
4.58 x 
10-5 
- - - 
6.26 x 
10-5 











aValues are the means of three experiments. Compounds 110-112 were tested in 10-dose IC50 mode 
with 3-fold serial dilution starting at 100 µM. TSA was tested in a 10-dose IC50 with 3-fold serial 
dilution starting at 10 µM, and starting at 20 µM with Class2A substrate. IC50 values were extracted by 
curve-fitting the dose/response slopes. Screening was performed by Reaction Biology Corp. 
(www.reactionbiology.com/). 
 
Concerning compound 112, the experimental data confirmed the 
theoretically expected (see Proof of concept) lower/absent selectivity of 
binding to HDAC2 as theoretically foreseen. Moreover, thank to the cap group 
an inhibitory activity on HDAC1 was not detected. Compound 112 showed a 
comparable inhibition of HDAC3 and HDAC8. 
In summary, 110 is a selective inhibitor of HDAC2, even though at modest 
potency. The evaluated inhibitory activity on these nzymes is in line with the 
theoretical findings, confirming the predicted struc ural observations.  
 
2.6.3 Computational Details 
2.6.3.1 Homology modeling 
The amino acid sequences of Human HDAC1 (Genbank Accession Number 
Q13547,482aa), HDAC2 (Genbank Accession Number AAH-31055,488aa), 





(Genbank Accession Number BAA22957,1097aa), and HDAC6 (Genbank 
Accession Number Q6NT75,1215aa), were extracted from the NCBI protein 
sequence database. The BLAST (Basic Local Alignment Search Tool)212 
search was performed to find homologous proteins in the PDB database, 
applying the BLOSUM62213 (BLOcks of amino acid SUbstitution Matrix) 
matrix. The search of homologous proteins was run by the Chimera 1.5.3 
package.174 The resulting alignments were examined and modified manually. 
HDAC1 and HDAC3 have additional segments in their C-terminal domains 
that are about 50-110 amino acids long. When these portions of the sequences 
were subjected to a BLAST search, no alignment was pos ible, and no similar 
sequences (other than themselves) were found. Moreove , the function of these 
residues was proposed to recruit other enzymes to large protein complexes that 
may regulate their activities.195,214 Thus, they may have less influence on the 
substrate/inhibitor binding. Due to the lack of struc ural information on these 
portions, they were omitted in the model building. The three-dimensional 
structure of HDAC2 chain A (PDB code: 3MAX)150 and HDAC4 (PDB code: 
2VQM)151 were used as templates for human HDAC1 and HDAC3 and 
HDAC6 homology models building, respectively. HDAC6 differs from other 
HDACs, for the presence of two catalytic domains (HDAC6 CD I and HDCA6 
CD II) sharing 46% sequence identity and 60% similarity. In general, CD1 and 
CD2 show the same relevant amino acid residues in the active site, whereas 
more differences can be observed in the loop regions. A recent study, using 
natural and synthetic substrates, showed that the second catalytic site is the 
major functional domain of HDAC6.215 In particular, the authors demonstrated 
that the inhibition of HDAC6 can be solely ascribed to the interaction of 
ligands with the second binding domain. Moreover, rcently, docking studies 





HDAC6.210 The resulting alignments were used as input for the automated 
homology modeling program MODELER.216 The number of generated loops 
was set to five along with high optimization level for models and loops. The 
generated models of HDAC1, HDAC3 and HDAC6, showing the lowest 
energy and minor number of restraint violations, were selected. On the 
obtained homology models, hydrogen atoms were added by using the 
graphical interface Maestro version 6.0, Schrödinger, LLC, New York, NY, 
2003. The charges of side chains were assigned consideri g their pKa at 
physiological pH of 7.4. The geometry of the added hy rogen atoms by OPLS 
force field217 and steepest descent method (500 steps and converge c  
threshold 0.5 kJ mol-1 Å-1) by using the MacroModel 8.5.159 The quality of the 
obtained models for HDAC1, HDAC3 and HDAC6 were valid ted using the 
software PROCHECK (see below).218  
Sequence alignment of HDAC1 and the template HDAC2, 93.46 % of identity. (*) 
indicates identity; (:) denotes strongly similar amino acids and (.) highlights weakly 
similar. 
 
HDAC1       TRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRP  
HDAC2       AKKKVCYYYDGDIGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRP  
            :::*********:************************************* 
 
HDAC1       HKANAEEMTKYHSDDYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGL  
HDAC2       HKATAEEMTKYHSDEYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGL  
            ***.**********:*********************************** 
 
HDAC1       FEFCQLSTGGSVASAVKLNKQQTDIAVNWAGGLHHAKKSEASGFCYVNDI  
HDAC2       FEFCQLSTGGSVAGAVKLNRQQTDMAVNWAGGLHHAKKSEASGFCYVNDI  
            *************.*****:****:************************* 
 
HDAC1       VLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFP  
HDAC2       VLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFP  
            ************************************************** 
 
HDAC1       GTGDLRDIGAGKGKYYAVNYPLRDGIDDESYEAIFKPVMSKVMEMFQPSA  
HDAC2       GTGDLRDIGAGKGKYYAVNFPMRDGIDDESYgqIFKPIISKVMEMYQPSA  






HDAC1       VVLQCGSDSLSGDRLGCFNLTIKGHAKCVEFVKSFNLPMLMLGGGGYTIR  
HDAC2       VVLQCGADSLSGDRLGCFNLTVKGHAKCVEvVKTFNLPLLMLGGGGYTIR  
            ******:**************:********.**:****:*********** 
 
HDAC1       NVARCWTYETAVALDTEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTN  
HDAC2       NVARCWTYETAVALDcEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTp  
            *************** *********************************  
 
HDAC1       EYLEKIKQRLFENLRML  
HDAC2       EYMEKIKQRLFENLRML  







Figure 2. 40 Ramachandran plot of HDAC1 calculated by PROCHECK using a hypothetical 
resolution of 2 Ǻ. 
 
 
Figure 2. 41 Superimposition (rmsd = 0.1 Å, calculated by DaliLite 3.1
and HDAC2 (yellow). The proteins are represented in ribbons.
 
Sequence alignment of HDAC3 and the template HDAC2, 63.54 % of identity. (*) 
indicates identity; (:) denotes strongly similar amino acids and (.) highlights weakly 
similar. 
 
HDAC3       KTVAYFYDPDVGNFHYGAGHPMKPHRLALTHSLVLHYGLYKKMIVFKPYQ 
HDAC2       KkVCYYYDgDIGNYYYGqGHP
            *.*.*:** *:**::** ********: :**.*:*:****:** :::*::
 
HDAC3       ASQHDMCRFHSEDYIDFLQRVSPTNMQGFTKSLNAFNVGDDCPVFPGLFE 
HDAC2       ATaEEMtKYHSDEYIkFLRsIrPdNMSeYSKQMQrFNVGEDCPVFdGLFE 
            *: .:* ::**::**.**: :
 
HDAC3       FCSRYTGASLQGATQLNNKICDIAINWAGGLHHAKKFEASGFCYVNDIVI 
HDAC2       FCQlsTGGSVaGAVKLNRQqtDMAVNWAGGLHHAKKsEASGFCYVNDIVL 
            **.  **.*: **.:**.:  *:*:*********** ************:
 
HDAC3       GILELLKYHPRVLYIDIDIHH
HDAC2       AILELLKYHqRVLYIDIDIHHGDGVEEAFYtTDRVMTVSFHKYGEY
            .******** ***************:**** *************:* ***
 
HDAC3       TGDMYEVGAESGRYYCLNVPLRDGIDDQSYKHLFQPVINQVVDFYQPTCI 
HDAC2       TGDLrDIGAgKGKYYAVNfPM
            ***: ::** .*:**.:*.*:******:** ::*:*:*.:*:::***:.:
 




1) of HDAC1 (green) 
 
MKPHRIrMTHNLLLNYGLYRKMeIYRPHK 

























HDAC2       VLQCGADSLSgDRLGCFNLTVKGHAKCVEvVKTFNLPLLMLGGGGYTIRN  
            *********. ********:::**.:*** **:**:***:*******:** 
 
HDAC3       VARCWTYETSLLVEEAISEELPYSEYFEYFAPDFTLHPDVSTRIENQNSR  
HDAC2       VARCWTYETAVaLDceIpNELPYNDYFEYFGPDFkLHiSpSN-MtNQNTp  
            *********:: ::  *.:****.:*****.***.** . *. : ***:  
 
HDAC3       QYLDQIRQTIFENLKML  
HDAC2       EYMEKIKQrLFENLRML  



































Figure 2. 42 Ramachandran plot of HDAC3 calculated by PROCHECK using a hypothetical 
resolution of 2 Ǻ. 
 
Figure 2. 43 Superimposition (rmsd = 0.2 Å, calculated by DaliLite 3.1
and HDAC3 (red). The proteins are represented in ribbons. 
 
Sequence alignment of catalytic domain II of HDAC6 and the template HDAC4, 47.76 % 
of identity. (*) indica
highlights weakly similar.
 
HDAC4         PRFTTGLVYDTLMLKHQCTCG/H
HDAC6_II      ----
                  
 
HDAC4         RGRKATLEELQTVHSEAHTLLYGTNPLNRQKKLLGSLASVFVRLPCGGVG 
HDAC6_II      TPRPATEAELLTCHSAEYVGHLRATEKMKT
                * **  ** * **  :.    :.   :  : *   :*           
 
HDAC4         VDSDTIWNEVH
HDAC6_II      -NFDSIYICPSTFACAQLATGAACRLVEAVLSGEVLNGAAVVRPPGHHAE 
               : *:*:    : ..*:**.*.. .**  * :**: ** ***********
 
HDAC4         ESTPMGFCYFNSVAVAAKLLQQR
HDAC6_II      QDAACGFCFFNSVAVAARHAQTISGHALRILIVDWDVHHGNGTQHMFEDD 
              :.:. ***:********:  *     . :***************: * .*
 
HDAC4         PSVLYMSLHRYDDGNFFPGS
HDAC6_II      PSVLYVSLHRYDHGTFFPMGDEGASSQIGRAAGTGFTVNVAWNG





1) of HDAC2 (yellow) 
 






























HDAC4         GDAEYLAAFRTVVMPIASEFAPDVVLVSSGFDAVEGHPTPLGGYNLSARC  
HDAC6_II      GDADYLAAWHRLVLPIAYEFNPELVLVSAGFDAARGD--PLGGCQVSPEG  
              ***:****:: :*:*** ** *::****:****..*.  **** ::*..  
 
HDAC4         FGYLTKQLMGLAGGRIVLALEGGHDLTAICDASEACVSALLGNELDPLPE  
HDAC6_II      YAHLTHLLMGLASGRIILILEGGYNLTSISESMAACTRSLLG---DPPPL  
              :.:**: *****.***:* ****::**:*.::  **. :***   ** *  
 
HDAC4         KVLQQRPNANAVRSMEKVMEIHSKYWRCLQRTTS----------------  
HDAC6_II      LTLPRPPLSGALASITETIQVHRRYWRSLRVMKVEDREGPSSSKLVTKKA  
               .* : * :.*: *: :.:::* :***.*:  .                  
 
HDAC4         --TAGRSLIEAQTCENE---------------------------------  
HDAC6_II      PQPAKPRLAERMTTREKKVLEAGMGKVTSASFGEESTPGQTNSETAVVAL  
                .*   * *  * .::                                  
 
HDAC4         -------------------------------------------------- 
HDAC6_II      TQDQPSEAATGGATLAQTISEAAIGGAMLGQTTSEEAVGGATPDQTTSEE  
                                                                 
 
HDAC4         -------------------------------------------------- 
HDAC6_II      TVGGAILDQTTSEDAVGGATLGQTTSEEAVGGATLAQTTSEAAMEGATLD  
                                                                 
 
HDAC4         -------------------------------------------------- 
HDAC6_II      QTTSEEAPGGTELIQTPLASSTDHQTPPTSPVQGTTPQISPSTLIGSLRT  
                                                                 
 
HDAC4         -------------------------------------------------- 
HDAC6_II      LELGSESQGASESQAPGEENLLGEAAGGQDMADSMLMQGSRGLTDQAIFY  
                                                                 
 
HDAC4         -------------------------------------------------- 
HDAC6_II      AVTPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQENWVCLSCYQVYCGR  
                                                                 
 
HDAC4         -------------------------------------------------- 
HDAC6_II      YINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKNIAHQN  
                                                                 
 
HDAC4         ---------- 












Figure 2. 44 Ramachandran plot of HDAC6 calculated by PROCHECK using a hypothetical 
resolution of 2 Ǻ. 
 
Figure 2. 45 Superimposition (rmsd = 0.7 Å, calculated by DaliLite 3.1
and HDAC6 (white). The proteins are represent
 
2.6.3.2 Docking calculations
The homology models for HDAC1, HDAC3 and HDAC6 were used in 
molecular docking calculations, along with the X
(3MAX),150 HDAC4 (2VQM),
In particular, the crystal structure of HDAC8 complexed with CRAA
(1VKG)154 was also considered in the calculations, in order to explore the 
large sub-pocket created by the shift of Phe152 upon ligand binding, and 
located in the hydrophobic active site channel. Molecular docking studies were 
performed using AutoDock 3.0.5
are metalloproteins, so a non
the non-bonded Zn2+
= 0.25 kcal/mol) were used. In order to have an accurate weight of the 
electrostatics, the partial charge of Zn
HDAC 
148 
1) of HDAC4 (purple) 
ed in ribbons.  
 
-ray structures of HDAC2 
151 HDAC7 (3C0Z)152 and HDAC8 (
.55 HDACs (histone deacetylase
-bonded model for metallic center acco
 parameters of Stote164 (Zinc Radius = 1.10 Å, well depth 












catalytic center by DFT calculations m05194 were derived level by the 6-
31+G(d) basis set and ChelpG method148 for population analysis (Gaussian 03 
Software Package).155 By using the same theoretical level, the partial charges 
of 110-112 were achieved and were used in the subsequent docking 
calculations. All ligands structures were built using the graphical interface 
Maestro version 6.0, Schrödinger, LLC, New York, NY, 2003, and their 
geometries optimized through MacroModel 8.5159 and using the MMFFs force 
field.158 For the 109, the tertiary amine on the tricyclic ring system was 
protonated and the two enantiomers were considered in our theoretical studies. 
Monte Carlo Multiple Minimum (MCMM) method (10000 steps) of the 
MacroModel module was used in order to allow a fullexploration of the 
conformational space. The so obtained geometries were optimized using the 
Polak-Ribier conjugate gradient algorithm (maximum derivative less than 
0.001 kcal/mol). A GB/SA (generalized Born/surface area) solvent 
treatment163 was used, mimicking the presence of H2O in the geometry 






















A Novel Potent Nicotinamide 







3.1. A Novel Potent Nicotinamide Phosphoribosyltransferase 
Inhibitor Synthesized via Click Chemistry 
The inhibition of NAD synthesis or salvage pathways ha  been proposed as 
a novel target for antitumoral drugs. Two molecules with this mechanism of 
action are at present undergoing clinical trials 113 (APO866)219 and 114 
(GMX1777) (Scheme 3.1),220 In searching for similar novel molecules, the 
most promising triazole-based compound was identifid between a library of 
185 novel APO866 analogues221 and, by molecular docking, a rationale of 
inhibition mechanism via was provide  
While the pharmacological fight against cancer has m de great advances in 
the last 20 years, novel molecules to fight this disease are still urgently needed. 
Many cancers still present unmet therapeutic needs, and chemoresistance is an 
importantphenomenon within the context of fast cell division and high 
mutation rates. Furthermore, side effects and safety are major concerns with 
antitumoral drugs. Although targeted biotechnology-based agents (e.g., 
monoclonal antibodies and vaccines) have and are being developed for a 
number of cancers, it is obvious that small-molecul drugs will result in lower 
costs and might be able to combat a wider range of tumors. Furthermore, the 
development of novel agents might also allow researchers to discover 
synergisms that will reduce the doses required for single agents used in 
combination, increasing efficacy while reducing side effects. For this to occur 
it is imperative that novel targets be exploited and that, for each target, a 
number of therapeutic agents (for example, with different pharmacokinetic 
profiles or different organotropisms) become available to the clinician.  
In this context, it has recently been proposed that interfering with NAD(P) 





pyridine nucleotide, that is, tumoral cells with a high division rate.222 While 
the general perception is that NAD(P) is mainly used as an enzymatic cofactor 
(and, as such, its depletion should be slow as it participates mainly in redox 
reactions), it is now accepted that a number of enzymes consume NAD(P). For 
example, NAD is the substrate for a specific subclass of histone deacetylases 
(sirtuins),223,224,225 as well as mono- and poly-ADP ribosylating enzymes (e.g., 
PARPsa).225,224 Furthermore, NAD-(P) is also the precursor for a number of 
Ca2+-releasing second messengers (e.g., cADPR, NAADP) and as such is 
consumed by enzymes such as CD38.226,227 Eukaryotic cells possess several 
mechanisms to replenish NAD levels, including a de novo pathway from 
tryptophan and at least two salvage/recycling pathwys.228,229 The most 
important of these latter two pathways relies on the enzyme nicotinamide 
phosphoribosyltransferase (NMPRTase or NAMPT), which converts 
nicotinamide into nicotinamide mononucleotide (NMN), which is 
subsequently converted to NAD by NMN adenyltransferas  (NMNAT).  
Beyond its well-described role in cellular metabolism, intracellular 
nicotinamide adenine dinucleotide (NAD) levels have be n shown to affect the 
enzymatic activity of a series of NAD-dependent enzymes, influencing 
biological responses such as cell survival and inflammation. Nicotinamide 
phosphoribosyl transferase activity has been shown to be essential for 
maintaining adequate intracellular NAD levels, suggesting that this enzyme 
may in fact play a central role in modulating the activity of a wide range of 
NAD-dependent enzymes.230 Several recent observations concur with this 
hypothesis and suggest that by regulating NAD availbil ty, NMPRTase is 
able to control both cell viability and the inflammatory response. Nampt may 
thus represent a novel pharmacological target with valuable anti-inflammatory 







Figure 3. 1 NAD metabolism and regulation of cellular functions.  
 
NMPRTase has been exploited as a target for developing a potential 
antitumoral drug (113, initially known as FK866 and now renamed 
APO866).219 This compound has an IC50 for cytotoxicity of approximately 
1nM against several cancer cell lines, and when evaluated preclinically it has 
been demonstrated to possess very promising antitumoral actions against both 
solid tumors and leukemia cells.219,231 Phase I clinical trials have been 
completed, and this compound is at present in phase II alone or in combination 
with other antitumoral drugs.232 A second compound, 114 (CHS 828, now 
renamed GMX1777) (Figure 3.1), is in early clinical development. This 
compound, originally screened as an antihypertensiv drug,233 showed very 
high cytotoxic activity.234 Furthermore, its action, as for 113, can be reverted 
by adding nicotinamide, the true substrate for NMPRTase.219,234 It was 
recently attempted to replace the amide of 113with a 1,4-disubstituted triazole 
using click chemistry, as it has been postulated that is substitution can 
generate a nonclassic bioisostere.235 To surprise, the true bioisostere (115) was 





pyridine derivative (116) maintained nanomolar potency even while being 




































Scheme 3. 1 NMPRTase inhibitors in clinical trials (113 and 114) and analogues of FK866 
used to draw the original hypothesis (115, 116, and 117). 
 
This observation suggests that the 1,4-disubstituted triazole ring is 
compatible with the binding pocket of the enzyme (Scheme 3.1). It was then 
performed molecular docking calculations on nicotinamide 
phosphoribosyltransferase (NMPRTase) and 113, 115, and 116. Tong et al. in 
2006 elucidated the X-ray crystal structure of the uman NMPRTase-1 
complex (PDB code: 2GVJ) with a 2.1 Å resolution.236 The authors clarified 
the molecular mechanism for the substrate specificity of this enzyme, defining 
the binding mode of 113 and the structural basis for its specificity for 
NMPRTase. The structure revealed a tunnel at the interface between chains A 
and B that is a potential binding site for inhibitors. The first step of the 





In accordance with that reported by Tong et al.,236 water molecule 645 was left 
in the NMPRTase active site during the molecular docking calculations with 
Autodock3.0.5 software.55 Moreover, to improve the accuracy of calculated 
dissociation constant (KDcalc), it was performed energy and geometry 
optimizations of 113, 115, and 116 and computed the charges of the molecules 
at the quantum mechanical (QM) level (see computation l details). In analogy 
with the rationalization of the NMPRTase inhibitor pharmacophore elucidated 
by Tong et al.,236 the described calculated model for 113 maintains all of the 
principal interactions with the enzyme: (1) the pyridine ring of the inhibitor is 
sandwiched between the side chains of Phe193 and Tyr180, and it forms a 
cation-π with Arg196; (2) the carbonyl oxygen atom and the amide nitrogen of 
the amide bond form two hydrogen bonds with the hydroxyl of Ser275 and the 
water molecule, respectively. Moreover, the lead comp und establishes 
hydrophobic interactions with the amino acids of the tunnel formed at the 
dimer interface, namely, Glu376, Asn377, Arg349, Ile378, Val330, Val350, 
Ala379, Ile351, and Ile309. In particular, the phenyl ring forms a π-stacking 
interaction with Tyr188 on the shallow groove of the NMPRTase surface. All 
of the above-mentioned interactions (Figure 3.2a) contribute to the 1-enzyme 
complex calculated stability (KDcalc=1.23x 10
-9M) and strengthen the reported 
model. Analyses of other compounds were conducted by taking into account 
the similarities and/or differences with the binding mode of 113. The 1,4-
disubstituted triazole rings of compounds 115 and 116 are able to form a 
hydrogen bond with the OH of Ser275 but cannot form it with the water 
molecule; this is a drawback that may be associated with the lower activities of 







Figure 3. 2 Superimposition of the crystallized 113 structure and the structures calculated 
by molecular docking in the catalytic site of NMPRTase. The true crystallized 113  structure is 
present in all panels (light blue), superimposed with the calculated 1 (a, blue), the calculated 3 







The difference in activity between the true bioisostere (115) and the 
triazolyl pyridine derivative (116) is due to the different topological position 
of the pyridine ring (Figure 3.2b). The presence of the double bond between 
the triazole and pyridine ring causes the loss of π-π stacking with Phe193 and 
Tyr180, suggesting decreased activity. On the other hand, 116 has the same 
topological position of the pharmacophoric points of 113 cocrystallized with 
the enzyme (Figure 3.2c), and moreover the phenyl ri g forms a cation-π 
interaction with Lys189 on the NMPRTase surface (KDcalc=1.89 x 10
-9 M). In a 
set of unpublished data, it was also synthesized a compound bearing a 
sulfonamide group (117, Scheme 3.1) in place of the amide moiety of 113.  
For what concern 117, the sulfonamide group should theoretically be more 
prone to form a hydrogen bond due to its higher acidity with respect to the 
amide group. Yet, this compound (either for inability of the drug to cross the 
plasma membrane or inability to enter the binding pocket) was inactive. This 
failure led it to exploit the compatibility of the triazolyl pyridine with the 
active site of NMPRTase to explore the possibility of generating more active 
analogues. 
Indeed, the triazolyl pyridine also presents the grat advantage of allowing 
us to capitalize on the simplicity of the click chemistry reaction.237,238 Its 
amenability to solution phase parallel synthesis is also an advantage, as it 
allows the screening of a high number of analogues in a fast and reliable 
manner.239,240,241 This, in turn, allows probing of the active site and the rim of 
the enzyme in more detail. On this basis, 185 triazolyl pyridines was 
synthesized, using a fast and versatile solution-phase parallel combinatorial 





displays an IC50 for cytotoxicity in vitro of 3.8±0.3 nM and an IC50 for NAD 
depletion of 3.0±0.4 nM. 
To investigate the activity of the synthesized compunds (Schemes 3.2 and 
3.3), it was we decided to exploit a neuroblastoma cell line that had already 
been characterized as sensitive to 113.235 Full concentration response curves 
were generated, and most compounds were found to have IC50 values in the 
nanomolar range (See Table 3.1). 
Compound 120 inhibited the growth of most cell lines tested, with 
nanomolar potency (GI50) in cell lines derived from leukemia, lung, CNS, 
colon, melanoma, ovarian, renal, and prostate cancers. To surprise, this 
compound appeared truly cytotoxic in melanoma cell lines, while in the others 
it was mainly cytostatic. This might suggest potential areas of therapeutic use. 
Compound 120 was also further modified to gather additional structural 
information. In this context, the ester (131) as a possible bioisostere of the 
amide group and the carbazole (132), to rigidify the 2-aminobiphenyl scaffold, 
were synthesized and the phenyl ring at the 2-position of aniline (21, 22) with 
commercially available ortho-substituted anilines (Figure 3.4) was substituted 
to explore the role of the o-phenyl. Compound 132 (the rigidified analogue) 
displayed nanomolar potency (37.4±17 nM), albeit with a loss of potency of 
approximately 10-fold compared to 120. Compound 134 displayed a decrease 
of approximately 50-fold (Table 3.1). Compound 131 did not display any 
activity. Yet, no conclusion can be drawn for this lack of efficacy as it may be 
also due to instability of the ester in the medium. The investigations on the 
induction NAD depletion have revelead that as expected, 113 depleted the 
cellular NAD pool with an IC50 of approximately 1 nM. Similarly, compound 
120, compound 132 (the rigidified analogue), and compounds 123 and 121 





Although enzymatic assays have not been performed, biological data suggest 









119  n = 6
120 n = 7























122 n = 6
123 n = 7
124 n = 8
125 n = 6
126 n = 7
127 n = 8
128 n = 6
129  n = 7
130  n = 8  










































(IC50 : nM) 
NAD levels 
(% of control) 
at 1 µM 
NAD levels 
(% of control) 
at 300 nM 
NAD levels 
(% of control) 
IC50 
118 nd 31.0 ± 13.2 87.8 ± 4.6 / 
119 56 ± 13 26.2 ± 12.0 88.2 ± 2.8 / 
120 3.8 ± 0.3 11.6 ± 6.19 9.9 ± 7.1 3.0 ± 0.4 
121 14.6 ± 3.6 13.0 ± 6.2 35.6 ± 16.7 84.4 ± 6.7 
122 nd 16.8 ± 6.9 83.8 ± 2.0 / 
123 97 ± 17 23.0 ±9.5 11.0 ± 5.6 49.2 ± 1.8 
124 157 ± 50 32.3 ± 6.5 77.3 ± 14.4 / 
125 nd 28.0 ±7.6 86.1 ± 6.2 / 
126 72 ± 12 30.0 ± 9.7 75.2 ± 5.3 / 
127 82 ± 8 13.1 ± 7.0 74.7 ± 7.3 / 
128 120 ± 25 24.7 ± 6.0 81.3 ± 4.6 / 
129 37 ± 7 17.7 ± 8.7 87.9 ± 1.4 / 
130 78 ± 9 22.6 ± 8.6 79.5 ± 5.9 / 
131 nd / 74.7 ± 7.3 / 
132 37.4 ± 17.5 / 12 ± 8.0 17.1 ± 0.1 
133 nd / 87.9 ± 1.4 / 
134 205 ± 17.6 / 79.5 ± 5.9 / 
aViability was evaluated via the MTT method. Values are mean + S.E.M. of 8-12 
determinations. NAD levels were first screened at a fixed concentration (n=10) and, if 
the compound displayed activity at 300 nM a full con entration-response was performed. 
Values are mean + S.E.M. n.d. not determined as full toxicity was not reached at 
concentrations up to 1 µM. 
 
The main observations that lead to this statement are as follows: (1) both 





(2) both 113 and 120 induce autophagy; (3) the cytotoxic effects of 113 and 
120 can be rescued by extracellular NAD application but cannot be rescued by 
nicotinamide. The metabolic instability of the pyridine moiety is one of 
themain problems of the two known inhibitors of NMPRTase in clinical trials 
(1 and 2), which leads to the need for continuous infus on.242  
On this basis, molecular docking studies were performed on the compounds 
with nanomolar potency, 120 and its rigid analogue 132, using the model 
described in the Introduction. The three-dimensional model of the interactions 
between NMPRTase and 120 highlights its ability in reproducing the binding 
mode of 113 (Figure 3.3a). Except for the loss of the hydrogen bo d with the 
water molecule common to all the triazole derivatives, the other 
pharmacophoric interactions are maintained: π stacking of the pyridine ring 
with Phe193 and Tyr180, cation-π with Arg196, and hydrogen bonds with the 
hydroxyl of Ser275. The biphenyl group on 120 remarkably contributes to the 
stability of the drug-target complex (KDcalcd8 = 4.31 x 10
-9 M) occupying a 
shallow groove on the NMPRTase surface formed by Gly185, Tyr188, and 
Lys189 and interacting with Ile378, Ala379, Val399, and Arg349. The alkyl 
chain interacts with His191, Val242, Ile350, and Arg31. In the calculated 
model, analogue 132presents a binding mode very similar to that of 113 
(Figure 3.3b), maintaining the interaction with the Phe193 and Tyr180 
aromatic ring and the hydrogen bond with the OH of Ser275. Additionally, the 
loss of the cation-π interaction of the pyridine ring with Arg196 is balanced by 
the presence of the carbazole, which gives a cation-π interaction with Lys89 
and π stacking with Tyr188 (KDcalcd20 = 3.07 x 10-9 M). Moreover, such a rigid 
group allows better hydrophobic interactions with Glu376, Asn377, Arg349, 
Lys189, Ala379, and Ile378, and a part of it places on the shallow groove on 






Figure 3. 3 Three-dimensional model of the superimposition in the catalytic site between the 
true crystallized 113 structure and the calculated structures for compound 120 (a) or 
compound 132 (b, c). The crystallized 113 structure, 120, or 132 are depicted in light blue, 
green, and purple sticks, respectively. The NMPRTase A and B chains are represented by gray 
sticks (a, b) and by molecular surface colored according to electrostatic potential. Positive 





The described docking calculations would therefore suggest that the triazole 
ring, the pyridine ring, and the hydrophobic tail are related to hydrogen bonds, 
hydrophobic interactions, and aromatic stacking that constitute the driving 
forces of the target-ligand complexes. Molecular docking calculations also 
suggest that the triazole group must be linked directly to the pyridine ring, as 
confirmed by the loss of activity of 115 and that the hydrophobic tail can be 
increased for a wider interaction with the amino acids on the target surface, as 
observed for 120 and 132. Obviously, such speculations will require further 
analogues to be synthesized and tested to verify this hypothesis. 
 
3.1.1 Computational Details 
Molecular docking calculations were performed on a two dual-core Intel 
Xeon 3.4 GHz, using Autodock 3.0.5 software.55 For all FK866 analogues a 
quantum mechanical optimization of the energies andthe geometries was 
performed in vacuo at the DFT B3LYP level, using the 6-31G(d) basis set, and 
on so optimized structure, the charges were calculated t the DFT B3LYP 
level using the 6-31+G(d) basis set and ChelpG148 method for population 
analysis, as implemented in Gaussian 03 Package software.160 For all the 
docking studies a grid box size of 50 x 66 x 76 with spacing of 0.375 Å 
between the grid points, and centered at 14.93 (x), 5.56 (y) and 2.17 (z), 
covering the tunnel at interface of the dimer was used. For all the docked 
structures, all bonds were treated as active torsional bonds, except the amide 
bond. In order to achieve a representative conformation l space during the 
docking calculations, ten calculations consisting of 256 runs were performed, 
obtaining 2560 structures (256 x 10). The Lamarckian genetic algorithm was 
used for docking calculations. An initial population f 650 randomly placed 





maximum number of 5.0 x 106 generations were taken into account. A 
mutation rate of 0.02 and a crossover rate of 0.8 were used. Results differing 
by less than 2.5 Å in positional root-mean-square deviation (RMSD) were 
clustered together and represented by binding energy. All the 3D models were 
depicted using the Python software,165 molecular surfaces are rendered using 



















Microsomal Prostaglandin E2 Synthase-1: 







4.1 Structure-based discovery of mPGES-1 inhibitors 
In this chapter, it will be described the design and virtual screening of two 
series of triazole obtained for directing the click hemistry synthesis as 
potential inhibitors of microsomal prostaglandin E2 synthase (mPGES)-1 
enzyme. The reported results, in fact, prove the effici ncy of the triazole group 
as a new scaffold useful in the rational design of ew promising candidates as 
antiinflammatory drugs with potential action on other enzymes within the 
arachidonic acid cascade, such as 5-LO or FLAP. In fact, interference with 5-
LO or FLAP, the key enzymes in the formation of leukotrienes (LTs) from 
arachidonic acid, is considered a valuable characteristic of a given mPGES-1 
inhibitor, because dual suppression of PGE2 and LT formation might be 
superior over single interference in terms of higher anti-inflammatory efficacy 
as well as in terms of reduced side effects.243 
Non steroidal anti-inflammatory drugs (NSAIDs) reprsent so far the pivot 
of inflammation therapy as a consequence of their potent effect in the 
suppression of prostaglandins (PGs), prominent bioactive mediators involved 
in key physiological functions244 and also implicated in several pathologic 
conditions like inflammation and tumorigenesis.245   
However, especially for long-term treatments - like those required for 
chronic pathologies such as rheumatoid arthritis - heir use comprises severe 
side effects; in particular NSAIDs are well known to be endowed with relevant 
gastric toxicity246 due to the efficient suppression of constitutively generated 
PGE2 involving the COX-1 pathway with gastro protection fu ction. Not long 
ago, the introduction of coxibs in therapy was initially considered as a solution 
of all the problems connected with the use of NSAIDs, as these selective 
COX-2 inhibitors showed to exhibit potent anti-inflammatory activity without 





evidences indicated their implication in serious cardiovascular accidents.247 In 
this perspective, there is an ever growing need for the research of safer anti-
inflammatory drugs. Recently, great attention has been focused on the 
microsomal prostaglandin E2 synthase (mPGES)-1 enzyme responsible for the 
conversion of the COX-derived unstable peroxide PGH2 into PGE2; this 
enzyme is over-expressed in several inflammatory disor ers248 as well as in 
many human tumors.249,250,251  
Elevated levels of mPGES-1, in fact, are often observed concomitantly with 
COX-2 over-expression. In fact, in vitro studies have demonstrated that 
mPGES-1 is localized at the perinuclear membrane and endoplasmic reticulum 
and is in general functionally coupled with COX-2,252 thereby enabling 
efficient generation of PGE2 during inflammation.252 Moreover, recent studies 
have shown that mPGES-1 expression can be specifically induced by 
lipopolysaccharide (LPS) in rat peritoneal macrophages,253 interleukin-1b (IL-
1b) and tumor necrosis factor (TNF)-a in a human lung carcinoma cell line, 
A549 with or without induction of COX-2.254 However, studies with these 
diverse stimuli have clearly shown that mPGES-1 canalso be functionally 
activated in the absence of induced COX-2 levels,254 providing evidence that 
these two enzymes can be independently regulated. This latter observation is 
important from the standpoint of drug targeting. It suggests the possibility that 
the enzymatic activity of mPGES-1 can be pharmacologically targeted with 
resultant suppression of PGE2 production by mechanisms that circumvent the 
toxicity associated with inhibition of COX-2 activity. 
To date, a limited number of compounds have been described that inhibit 
mPGES-1 activity in vitro (Figure 4.1). None as yethave been developed as 
anti-cancer agents. There are several examples of compounds that were 
developed to target COX-2 but also found to inhibit mPGES-1 activity as well. 
 
For example, NS-398 inhibits mPGES
866, ~3 nM,256 IC









Figure 4. 1 Structures of known compounds that have mPGES
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crystallographic structure of closed conformation of mPGES-1, the open form 
of the protein constitutes a model for the productive enzyme. Therefore the 
absence of three-dimensional (3D) X-ray crystal structure of open mPGES-1 
conformation with a substrate or an inhibitor bound has represented the major 
difficulty for the rational design of new specific inhibitors, making the 
classical receptor-based approach quite challenging. In fact, despite many 
efforts spent in this area, only very few effective n vivo mPGES-1 inhibitors 
has been reported in the literature, therefore the discovery of potent inhibitors 
of this interesting target would be of great relevance for the development of a 
new generation of anti-inflammatory agents with potential safer profile. By 
means of an in silico screening, we describe here the development of fast 
synthetically accessible triazole-based261,262,263,264,265,266,267,268  compounds, 





4.2 Structure-Based Discovery of Inhibitors of Microsomal 
Prostaglandin E2 Synthase-1, 5-Lipoxygenase and 5-Lipoxygenase-
Activating Protein: Promising Hits for the Development of New 
Anti-inflammatory Agents 
In this paragraph, it will be described the results of the rapid in silico 
screening on a small set of triazole derivates thathas disclosed three new 
potential anti-inflammatory drugs: (I) compound 143 displaying selectivity for 
mPGES-1 with an IC50 value of 3.2 µM, (II) compound 159 that dually 
inhibits 5-lipoxygenase and mPGES-1, and (III) compund 146 apparently 
acting as 5-lipoxygenase-activating protein inhibitor (IC50 = 0.4 µM). from 
for directing the click chemistry synthesis of the most promising mPGES-1 
inhibitor 4.269  
The lack of a 3D X-ray crystal structure of open mPGES-1 conformation 
has stimulated many efforts for identifying the key characteristics of mPGES-
1 inhibitors, based on QM calculations,270 SAR271,272 and 3D-QSAR 
analysis,273,274,275,276 multistep ligand-based strategy,277 high-throughput (HTS) 
screening,278 molecular modeling and dynamics simulation279 and site-direct 
mutagenesis studies.280 As reported by Friesen et al.258 these efforts have led 
to the identification of several classes of mPGES-1 inhibitors: fatty acids and 
PGH2 analogues,
281 indole and 43 (MK-886, Scheme 4.2) analogues,282 
phenantrene imidazoles,278 nonacidic agents,277 and other inhibitors. 
Considering the well-known characteristic of indole-based agents—the 
simultaneous contributions to the inhibitory activity on mPGES-1 of 
hydrophobic and electrostatic effects—and the ring size of fatty acids and 
PGH2 analogues as starting point, we designed new triazole nucleus templates 
as potential scaffolds for anti-inflammatory drugs. We designed a small set of 





account both the synthetic accessibility and the compatibility of R1 and R2 
groups with the binding requirements of the pocket situated in the region at the 









































































































































Scheme 4. 1 Chemical structures of compounds 140-165 utilized for molecular docking 
Studies 
 
In particular, it was gradually increased the length, size, and hydro- and 
lipophilicity of R1 and R2 with the aim to optimize their chemophysical 





inhibition, it was performed an i  silico screening by molecular docking using 
AutoDock 3.0.5 software55 of a small set of molecules. For reported docking 
calculation, it was used the MGST-1 structure solved by Holm et al. in 2006283 
in which significant amino acid conservation in comparison to mPGES-1284 
(38% of homology sequence) can be recognized. Recently, the structure based 
drug design targeting mPGES-1 was facilitated by the work of Hamza et 
al.,279,280 who have described the PGH2 binding to the mPGES-1-GSH 
complex. More precisely, as also demonstrated by site direct mutagenesis, the 
natural ligand at the interface of each mPGES-1 mono er establishes a strong 
salt bridge between its carboxylate group and the highly conserved Arg110 in 
the MAPEG family and interacts with Arg70, Asn74, Arg73, Glu77, Tyr117, 
Leu121, Arg122, Arg126, Thr129, Arg110, His72, Lys26, Leu69, and Ile125. 
Taking into account the considerations above, it was referred to the sequence 
alignment of these two MAPEG super family members fo  the rationalization 
of the small molecules binding mode (Table 4.1).279  
 
Table 4. 1 List of the corresponding amino acids present both in mPGES-1 
























The data shown in Figure 4.2 indicate the best calcul ted affinities for 
compounds presenting one H-bond acceptor group and a lipophilic substituent 
of adequate dimensions.170d For the sake of simplicity, it was report the most 
promising candidates derived from the in silico screening, 143 and 20 (Figure 
4.3), to trace the features of new potential anti-inflammatory drugs. From the 
analysis of the results, both compounds disclosed a similar binding mode at 
the interface of the target monomer. The reported proposed poses are in agreement 
with the model reported by Hamza et al.279 In fact, the compounds interact with 
residues considered critical for PGH2 binding, such as the hydrogen bonds with the 
carboxy group in 143 and 159 with the highly conserved Arg113 in MGST-1 
(Arg110mPGES-1), guaranteeing, at least in theory, the enzyme binding specificity, as 
well as van der Waals and other interactions with residues of the active site—the 
cation-π interactionwith Lys67, Arg72, and Arg196 for 4 and with Lys67 and Arg196 
for 20. The above in silico results suggested the synthesis of the molecules 143, 145-
147, 150, 153, 154, 156, 157, 159-163, and 165, all within the lowest free energy of 
binding and a good ligand efficiency (Ebinding < 9 kcal/mol and ∆G/NHA deeper than -








Figure 4. 2 Calculated affinities and ligand efficiency of compounds 140-165 for MGST-1. 
 
The evaluation of the bioactivity of this small set of compounds might be 
helpful for the comprehension of the key features of new mPGES-1 triazole 
based inhibitors. 
For the synthesis of compounds 143, 145-147, 150, 153, 154, 156, 157, 
159-163, and 165, synthetic procedure based on the copper-catalyzed 3 + 2 
Huisgen's reaction (click chemistry) was used, where the triazoles 
intermediates were generated through the condensatio  between the 







Figure 4. 3 Three-dimensional model of interactions of 143 (A) and 159 (B) with the MGST-
1 binding site. The protein is represented by secondary structure, by CPK, and by lines colored 
by atom type (C, gray; polar H, sky blue; N, blue; and O, red). Compound 143 (A) is depicted 
by sticks and balls (by atom type: C, yellow; O, red; and N, blue). Compound 159 (B) is 
depicted by sticks and balls (by atom type: C, blue; O, red; N, dark blue; and S, yellow). 
 
To assess the ability of the selected compounds 143, 145-147, 150, 153, 
154, 156, 157, 159-163, and 165, to interfere with the activity of mPGES-1, a 
cell-free assay using the microsomal fractions of interleukin-1β (IL-1β)-
stimulated A549 cells (as source for mPGES-1) was applied. As shown in 
Table 4.2, compounds 143, 146, 159, and 162 significantly inhibited mPGES-
1 activity, whereas all other derivatives were not significantly active at a 
concentration of 30 µM. Interestingly, these data confirm the results from the 
docking studies favoring 143 and 159 as mPGES-1 inhibitors. As reported 
above, mPGES-1 inhibitors often interact also with o er enzymes within the 
arachidonic acid cascade, such as 5-LO or FLAP and the dual suppression of 
PGE2 and LT formation might reduce side effects.
243 Thus, it was performed a 
further analysis of the test compounds (30 µM, each) for inhibition of 5-LO 






Table 4. 2 Effect of test compounds on the activity of mPGES-1a 
comp. 
mPGES-1 activity 
remaining activity  IC 50 [µM at 30 µM 
143 3.2 12.0% ± 3.7** 
145 > 30 89.0% ± 2.9 
146 > 30 60.1% ± 4.3** 
147 > 30 78.2% ± 12.8 
150 > 30 76.1% ± 7.9 
153 > 30 73.6% ± 8.0 
154 > 30 96.8% ± 0.5 
156 > 30 91.9% ± 8.1 
158 > 30 87.9% ± 8.4 
159 > 30 59.8% ± 7.2** 
160 > 30 85.0% ± 9.3 
161 > 30 90.0% ± 6.8 
162 > 30 72.1% ± 4.2* 
163 > 30 98.2% ± 7.3 
165 > 30 88.7% ± 2.7 
aData are given as mean +/- S.E., n=4-6. *p < 0.05, **p < 0.01 
 
Intriguingly, among the test compounds, 159 was the most active derivative 
with IC50 = 0.8 µM, followed by 160, 143, 156, and 146 (Table 4.2, IC50 = 4.1, 
6.7, 8.8, and 27 µM, respectively), which all inhibited 5-LO activity in a 
concentration-dependent manner. 5-LO inhibition was reversible, as 
demonstrated by wash-out experiments (not shown). Also, 145, 153, 162, and 
165 significantly inhibited 5-LO at a concentration of 30 µM, but the 
magnitude of inhibition did not exceed 50% (Table 4.3), and thus, IC50 values 
could not be determined. Because FLAP inhibitors do not inhibit 5-LO activity 





potential inhibitory effect on FLAP in human neutrophils activated by 
ionophore A23187. Compound 43 (IC50 for FLAP in neutrophils 
approximately 70 nM)51 served as the control, and DMSO (0.3%, v/v) was 
used as the vehicle control. Compounds 143, 145, 146, 150, 159, 160, 163, and 
164 reduced 5-LO product formation at 30 µM by more than 50% in a 
concentration-related manner with IC50 values in the range of 0.4-9.3 µM 
(Table 4.3). For 143 and 159, the IC50 values were determined at 8.8 and 0.6 
µM, respectively, which fits well with the activities in cell-free 5-LO assays, 
and also, 160 was similarly efficient (IC50 = 2.8 µM) as for isolated 5-LO. 
Table 4. 3 Effect of Test Compounds on the Activity of 5-LO in Cell-Free and Cell-Based 
(Intact Neutrophils) Assaysa 
comp
. 
5-LO activity; cell-free 
IC 50 [µM] activity at 30 µM (%) 
5-LO activity; intact neutrophils 
IC 50 [µM] remaining activity at 30 µM (%) 
143 6.7 20.0% ± 0.9** 9.2 20.1% ± 11.0** 
145 > 30 62.3% ± 1.4** 0.9 34.8% ± 7.0** b)
146 27 48.8% ± 0.4** 0.4 1.1% ± 0.3** b) 
147 > 30 82.9% ± 0.9 > 30 85.7% ± 3.5 
150 > 30 80.8% ± 5.3 9.3 14.6% ± 5.2** 
153 > 30 58.4% ± 12.7* > 30 70.2% ± 8.5 
154 > 30 77.4% ± 0.9 > 30 79.9% ± 10.7 
156 8.8 10.1% ± 4.6** > 30 52.7% ± 15.0* 
157 > 30 82.5% ± 4.4 > 30 92.1% ± 8.1 
159 0.8 13.6% ± 2.8** b) 0.6 3.5% ± 2.5** b) 
160 4.1 5.1% ± 0.8** 2.8 21.2% ± 4.3** b)
161 > 30 78.4% ± 10.3 > 30 84.5% ± 3.4 
162 > 30 57.3% ± 1.2** 6.0 17.3% ± 2.5** b) 
163 > 30 60.7% ± 10.0 1.7 22.0% ± 2.6** b) 
165 > 30 59.2% ± 6.4* > 30 70.1% ± 9.0 





All in all, on the basis of the outcomes of the biological activity data, 4 is 
the most efficient inhibitor of mPGES-1, 46 might act as a FLAP inhibitor, 
while 159 might be a potent direct 5-LO inhibitor, besides moderate inhibition 
of mPGES-1. Hence, we aimed to rationalize the results through molecular 
modeling studies. As preliminarily remarked, it should be put in evidence that 
compounds 143 and 146, inhibiting the two MAPEG family members, showed 
quite similar chemical features; on the contrary, the more encumbering ligand 
159 seems to target no structurally related MAPEG enzymes.  
For the reported calculations, it was used the 3D structure of FLAP in 
complex with the inhibitor 166 (MK-591, Scheme 4.2)286 solved by Ferguson 
et al.287 in 2007 [protein data bank (PDB) ID code 2Q7M]. Because of the lack 
of crystal structure information on 5-LO, we used a 15-LO288 (PDB ID code 
1LOX) enzyme, presenting the highest sequence similarity (38% identity with 
human 5-LO) among the dioxygenase family (8-, 9-, 11 and 12-LO). Taking 
into account the considerations reported above for the MGST-1 enzyme, also 
in the case of FLAP, the binding specificity was conferred by the H-bond with 





















In the reported proposed pose, 146 (Figure 4.4) not only interacts with the 
fundamental amino acids but also adopts the equivalent spatial disposition of 
the cocrystallized inhibitor,288 maintaining the same interactions network. 
Moreover, the phenyl group in R1 forms a π-π stacking with Phe25.  
 
 
Figure 4. 4 Three-dimensional model of interactions between 146 and FLAP. The protein is 
represented by secondary structure, by CPK, and by lines colored by atom type (by atom type: 
C, gray; polar H, sky blue; N, blue; O, red; and S, yellow). Compound 7 is depicted by sticks 
and balls (by atom type: C, sky blue; O, red; N, dark blue; S, yellow; and H, white). 
Compound 44 is depicted by sticks and balls (C, O, N, S, and Cl dark pink). The figure 
highlights similar interactions for both 7 and 44with arachidonic acid-binding site. 
 
Three different classes of inhibitors can be generally considered for 5-
LO:289 (1) antioxidant agents interfering with the redox catalytic cycle of the 
enzyme, (2) iron-chelating agents, and (3) nonredox type inhibitors, which 
compete with arachidonic acid for the binding to the enzyme.285 In the 
described docking studies, it was supposed that 159 acts as nonredox type LO 
inhibitor. As described for mPGES-1, the rationaliztion of the 5-LO binding 





of the enzyme as reported by Charlier et al.290 (see Table 4.4), taking into 
consideration the specific polar interaction of the carboxylate moiety of 
arachidonic acid with Lys4095-LO (Arg40315-LO).  
 


























For compound 159, it was obtained two different conformation families, 
accounting for two independent high affinity binding modes (Figure 4.4 A,B). 




Figure 4. 5 Three-dimensional model of interactions of 159 and 15-lipoxygenase enzyme 
active site. The protein is represented by CPK and by lines colored by atom type (by atom 
type: C, gray; polar H, sky blue; N, blue; O, red; and S, yellow). Two different conformations 
(A and B) of the complex are depicted. Compound 159 is depicted by sticks and balls (by 
atom type: C, green; O, red; N, dark blue; and S, yellow). 
 
In particular, in the first conformation (Figure 4.4A), the phenyl group in R1 
shows a cation-π interaction, while in the second conformation (Figure 4.4B), 
the same cation-π interaction with Arg403 was exerted by the naphtyl group in 
R2 present in the alternative conformation. In the latter case, the oxygen atom 
in R2 forms an additional H-bond with the positively charged (Arg403) 
residue. Even if R1 and R2 are located on the opposite sites of the target 
pocket, and the other interactions with the receptor c unterpart remain 
unmodified and are in accordance with the structural requirements indicated 
by Charlier et al.,290 that is, two hydrophobic groups, an aromatic ring, and 





In summary, it was applied a rapid in silico screening on a small set of 
triazole derivates for directing the click chemistry synthesis of the most 
promising mPGES-1 inhibitor 143. In light of the good qualitative accordance 
between the results from the biological assays and the prediction of the 
molecular docking calculations, a satisfactory explanation of the putative 
binding mode for the new triazole based compounds wa  provided. Biological 
assays disclosed three different benchmark compounds 143, 146 and 159 as 
inhibitor of mPGES-1, FLAP and 5-LO, respectively.  
 
4.2.1 Computational Details 
Molecular docking calculations were performed on a two dual-core Intel 
Xeon 3.4 GHz, using Autodock 3.0.5 software.55 For all the docking studies on 
MGST1, FLAP and 15-LO a grid box size of 98 x 98 x 126, 70 x 126 x 78, 
and 68 x 74 x 96, with spacing of 0.375 Å between the grid points, and 
centered at -43.667 (x), 33.493 (y), 2.656 (z), 30.35 (x), 21.836 (y), 55.454 (z), 
and -29.186 (x), 151.802 (y), 51.228 (z) was used respectively. For all the 
docked structures, all bonds were treated as active torsional bonds. In order to 
achieve a representative conformational space during the docking calculations, 
from four to six calculations consisting of 256 runs were performed, obtaining 
1024/1536 structures. The Lamarckian genetic algorithm was used for 
dockings. An initial population of 600 randomly placed individuals, a 
maximum number of 5.0 x 106 energy evaluations, and a maximum number of 
6.0 x 106 generations were taken into account. A mutation rate of 0.02 and a 
crossover rate of 0.8 were used. Results differing by less than 2.5/3.5 Å in 





represented by the result with free energy of binding (Ebinding). All the 3D 






4.3 Design and Synthesis of a Second series of Triazole-based 
compounds as potent dual mPGES-1 and 5-Lipoxygenase 
inhibitors .  
Continuing the studies on small molecules able to block mPGES-1 activity 
described in a previous paragraph, some interesting molecules able to inhibit 
mPGES-1 as well as other key enzymes within the arachidonic acid cascade 
such as 5-lipoxygenase (5-LO) and 5-LO-activating protein (FLAP) were 
identified. The full coherence found between the biological results and the 
predictions of molecular docking calculations provided a satisfactory binding 
mode model of the triazoles reported in a previous paragraph with their 
respective biological targets (i.e., mPGES-1, 5-LO, and FLAP), gaining more 
information to envisage further structural optimizations of the basic template 
in accordance with the catalytic pocket requirements of the enzyme. In more 
detail, the previous investigations disclosed a basic structure 143,269 able to 
efficiently interact with key aminoacid residues in the catalytic site, which 
actually needed to be further optimized especially concerning the substitution 
pattern on the biphenyl moiety in order to provide a better binding affinity 
with the target enzyme.  
In line with these considerations, it was decided to leave the 2-nitro-4-
carboxybenzyl moiety (Scheme 4.3) unchanged and to vari usly decorate the 
right hand portion of the molecule, coming to the id ntification of compound 
11, which retained mPGES-1 inhibition ability, and compound 175, emerging 
as potent dual inhibitor of mPGES-1 and 5-LO enzymes. Building on these 
results, it was decided to further refine the structure of compound 175, leaving 
unmodified the right hand portion of the molecule and performing some minor 





group (compound 179), the full elimination of the ortho-substituent on the 
phenyl ring (compound 180) and finally the insertion of a sulfonamide 
function between the phenyl and the triazole ring (compound 181) by analogy 
with the structural backbone showed by a triazole-based compound previously 
identified by us as potent dual inhibitor of mPGES-1 and 5-LO enzymes.269 
On the basis of the encouraging results regarding the rationalization of the 
inflammation processes related to natural products291,292,293,294,295 and the 
design of new synthetic molecules,269,296 here we report the design and the 
theoretical evaluation of a new significant set of molecules obtained by 
revisiting the lead compound 143 (See Scheme 4.3).297 In particular, the 
scaffold of 143 was substituted with various groups of different size and 
hydrophobicity with the aim to improve potency and to trace a more accurate 
SAR profile of this kind of potential anti-inflammatory drugs.  
As suggested from our previous work,269 the 2-nitro-4-carboxybenzyl 
moiety remarkably influences the activity of the triazole molecules, so this 
moiety was not altered for the molecules 167-178 (Scheme 4.3) combining it 
with small hydrophilic groups (COOH, OH, NH2) at different positions (169, 
171-173, 177-178, Scheme 4.3), or with hydrophobic groups with increasing 
size (168-169, 170, 174-176 Scheme 4.3) to understand their potential 
influence on biological profiles.  
Owing to the lack of the experimental structure of the mPGES-1 open 
active form, for the reported docking calculations by Autodock4.2 software 
the microsomal glutathione transferase 1 (MGST-1)283 was used as model 







The obtained results point out two different docking poses for these 
triazole-based potential mPGES-1 inhibitors: (a) the first one includes 
molecules with ortho- and/or meta-substituted biphenyl groups (168, 171-173, 
and 175, Figure 4.6A), or with a smaller aromatic ring (176) as arms at 
position 4; (b) the second family relates to compounds containing the biphenyl 
portion with at least one substituent in the para position (168, 169-170, 174, 
177-178, Figure 4.6B). However, all the designed molecules accommodate in 
the ligand pocket situated in the region at the intrface of the two mPGES-1 












































































































Figure 4. 6 Two different spatial arrangements of triazole
binding site of MGST-1. (A) Superposition of compounds 
(orange), 173 (purple), 175
(pink), 170 (grey), 174 (light green),
 
On this basis, the substitutions at ortho, meta and para of the biphen
with small hydrophilc groups cause a different pattern of hydrogen bonds with 
MGST-1 among 169
though 171 and 172 
establish a π-cation interaction with Arg129, the ortho COOH of 
hydrogen bond with Arg129 while the meta COOH of 
(Figure 4.7A). On the other hand, the ortho carboxy
interacts with amino acids located at the bottom part of the ligand binding 
pocket establishing a π
nitro-4-carboxybenzyl moiety 
The same hydrogen bond pattern is also observed for the molecules 
mPGES
187 
-1), which guarantees at least in theory the mPGES
-based compounds 
168 (emerald), 
 (blue) and 176 (dark green). (B) Superposition of
 177 (light pink) and 178 (light brown). 
, 171-173, 177-178 (See Figure 4.7A). In particular, even 
have similar docking poses and both molecules are able to 
7 interacts with Arg37 
biphenyl arm of 
-π interaction with the Phe133, and moreover, its 





167-178 in the 
171 yellow, 172 
167 (green), 169 
yl arm 






and 177 (See Figure 4.
para-position of biphenyl arm do not allow the hydrogen bonds with Arg37 
and/or Arg129, but allow the 
whereas for 173, as like for 
interactions with Lys67 and Arg129 are observed.
 
Figure 4. 7 (A) Three dimensional model of the different hydrogen bond
(yellow), 172 (orange) and
dimensional model of the different hydrogen bond pattern of 
(light pink) with MGST
receptor are depicted by stick and balls (by atom type: C, gray; O, red; N, dark blue; and S, 
yellow). 
 
Regarding the molecules with bulky groups (
Scheme 4.3), depicted in Figure 4.
influences the positioning in the ligand binding site. In particular, the 
molecules with para (
(174) substituents at biphenyl portion
Phe134 and establish π
though 176 and compounds with bulkier arms (i.e. 
mPGES
188 
7B), where the OH (177) and/or NH2 (
π-π interaction with Phe133 (See Figure 4.
172, the hydrogen bond with Arg37 and 
 
 178 (light brown) with MGST-1 binding site. (B) Three 
173 (purple), 169
-1 binding site. In both the figures the cruial aminoacids of MGST
168-169, 170, 
8, the different steric hindrance
170) groups, or combined with meta (167
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Figure 4. 8 Three dimensional models of the different hy
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kcal/mol) as the starting point for obtaining preliminary experimental results 
based on the evaluation of the bioactivity of this small set of compounds with 
the aim of a deeper understanding of the key featurs of new mPGES-1 
triazole-based inhibitors. On the basis of the biological results, it was have 
decided to further improve and refine the structure of the most active molecule 
175 that was recognized as new lead compound (see below) for the design of 
triazole based mPGES-1 inhibitors. In particular, with the aim to improve the 
biological activity of new lead compound 175, it was modify its 2-nitro-4-
carboxybenzyl moiety (179-181) taking into account the reported previous 
considerations.269 As be seen from the Figure 4.8, the molecule 180 assumes 
the same docking pose with respect to 175, where the elimination of the NO2 
group only influence the strength of the H-bonding with the Arg113, while the 
π-cation interactions with Arg129 and Arg37, and most f the hydrophobic 
interactions are maintained. On the other hand, the chemical reduction of the 
nitro group to NH2 for 179, and the insertion of a sulfonamide function 
between the phenyl and the triazole ring at 143 yielding 181 causes a different 
positioning of the compounds compared to 175, and a shifting of the bulky 
arm at C-4 of the triazole ring in the MGST-1 ligand pocket. In particular, the 
NH2 group of 179 establishes two additional hydrogen bonds acting as H-bond 
donor with the carbonyl oxygen of Gly223 and Nδ1 of His75, making also 
possible the hydrogen bond between the triazole ring with the hydroxyl of 
Thr33, and hydrophobic interactions of the halogenat d benzene with Gly130, 
Pro127 and Gln126. On the other hand, the sulfonamide function of 181 only 






Figure 4. 9 (A) Three dimensional models of the different hydrogen bond pattern and 
peculiar hydrophobic interactions of 174 (blue), 179 (light blue), 180 (white), and 181 (cyan) 
with MGST-1 binding site. (B) Calculated free energy of binding expressed as kcal/mol of 
compounds 174 and 179-181 for MGST-1. The crucial amino acids of MGST-1 receptor are 
depicted by stick and balls and CPK (colored by atom ype: C, gray; O, red; N, dark blue; and 
S, yellow). 
 
As shown in Figure 4.9B, only 179 and 180 showed an improvement of the 
calculated affinity compared to the lead compound 175, suggesting the critical 
role of the hydrogen bonding and hydrophobic contacts for the potential 
antagonist activity; as a consequence, these compounds were synthesized and 
their biological activity was assessed to prove thediscussed theoretical 
findings.  
Concerning the synthesis of analogues 167-181, the retro-synthetic 
approach suggest to obtain the triazole ring through the copper-catalyzed 3+2 
Huisgen’s cycloaddition between the appropriate terminal alkynes and 
azides,298 while to generate the differently decorated biphenyl systems we 
relied on the Suzuki cross-coupling reaction.299  
In order to assessed the ability of the test compounds to interfere with 
mPGES-1 activity, a well-established cell-free assay257,300 was applied where 





human mPGES-1 enzyme and PGH2 (20 µM) as substrate for mPGES-1. The 
mPGES-1 inhibitor MK-886 (IC50 = 2.4 µM) was used a reference 
compound248 that inhibited the enzymatic reaction by 82±6.4% at a 
concentration of 10 µM (not shown). The results of the assessment of the 
mPGES-1-inhibitory activities of compounds 143, 167-181 are given in Table 
4.5.  
 





(IC50 [µM]; remaining 
activity at 10 µM) 
5-LO 
(IC50 [µM]; remaining activity at 10 µM) 
cell-free cell-based 
143 3.2 6.7 9.2 
167 
> 10 
(87.4 ± 9.1%) 
> 10 
(84.9 ± 11.1%) 
> 10 
(111.1 ± 8.4%) 
168 
> 10 
(88.9 ± 4.2%) 
> 10 
(62.7 ± 12.2%) 
> 10 
(125.0 ± 12.0%) 
169 
> 10 
(65.5 ± 5.1%) 
> 10 
(63.5 ± 11.3%) 
> 10 
(100.1 ± 5.3%) 
170 
> 10 
(72.5 ± 4.3%) 
6.1 
> 10 
(96.5 ± 7.3%) 
171 
> 10 
(94.1 ± 8.5%) 
> 10 
(75.3 ± 13.1%) 
> 10 







(82.1 ± 2.5%) 
> 10 
(74.7 ± 9.6%) 
> 10 
(123.8 ± 5.5%) 
173 
> 10 
(55.6 ± 0.8%) 
> 10 
(80.2 ± 2.7%) 
> 10 
(113.9 ± 10.1%) 
174 
> 10 
(54.3 ± 1.5%) 
> 10 
(64.3 ± 11.8%) 
> 10 
(90.2 ± 9.3%) 
175 1.2 2.0 5.3 
176 5.5 
> 10 
(52.2 ± 9.6%) 
> 10 
(89.7 ± 2.8%) 
177 
> 10 
(74.2 ± 1.8%) 
6.8 
> 10 
(108.3 ± 1.1%) 
178 
> 10 
(93.0 ± 21.2%) 
> 5 
(62.7 ± 12.7%) 
[5 µM] 
> 5 
(90.9 ± 8.6%) 
[5 µM] 
179 0.68 0.9 2.1 
180 1.0 1.47 2.0 
181 
> 10 
(78.6 ± 9.6%) 
1.96 1.2 
 
For compound 143, carrying a biphenyl, an IC50 value of 3.2 µM was 
obtained, which is in agreement with previous reported finding.269 Bioisosteric 





176, was essentially tolerated (IC50 = 5.5 µM). However, substitution of the 4-
phenyl in 167-168, 170-174, 178-177, show clearly detrimental with IC50 
values > 10 µM. In contrast, when the bulky, halogenat d phenylether was 
inserted in 2´-position (compound 175), a significant improvement in the 
potency was obtained, with an IC50 value = 1.2 µM.  
Next, the influence of the 2-nitro group within the 4-carboxybenzyl moiety 
on mPGES-1 inhibition was investigated. Omission of the 2-nitro moiety 
(resulting in compound 170) slightly improved mPGES-1 inhibition (IC50 = 
1.0 µM). Replacement of the 2-nitro function by an amino moiety further 
increased the efficiency and the respective compound 179 exhibited an IC50 
value of 0.68 µM, representing the most potent mPGES-1 inhibitor within this 
study. Exchange of the methylene bridge next to the triazole of 180 by a 
sulfone moiety (compound 181) again abolished the gain of potency in 
agreement with reduced free energy of mPGES-1 binding.  
Therefore, and based on the previous observation that compound 143 also 
efficiently inhibits 5-LO,269 we assessed the potential of the above-mentioned 
compounds for inhibition of human 5-LO in well-established cell-free and a 
cell-based models.269,300,301 Interestingly, inhibition of 5-LO in both the cell-
free and the cell-based test systems essentially correlated with the interference 
of the compounds with mPGES-1. Thus, compounds 167-174, 177 and 178 
that all failed or hardly inhibited mPGES-1 were also modest 5-LO inhibitors 
(IC50 > 10 µM), except the sulfonamide 170 and the 4´-OH biphenyl analogue 
177 of compound 143 that suppressed 5-LO in the cell-free (but not in he
intact cell) assay with IC50 = 6.1 and 6.8 µM, respectively. On the other hand, 
the potent mPGES-1 inhibitors 175, 179 and 180 efficiently inhibited 5-LO 
activity with IC50 values in the range of 0.9 to 2 µM in the cell-free and 2.0 to 





181, which was inactive for mPGES-1 but a potent 5-LO inhibitor with IC50 = 
1.9 and 1.2 µM in cell-free and cell-based systems, respectively. Obviously, 
the sulfone or sulfonamide moieties (in compounds 181 and 170, respectively) 
govern 5-LO inhibition but are detrimental for interference with mPGES-1. 
Taken together, compound 179 turned out to be the most potent dual mPGES-
1/5-LO inhibitor out of these series with 4- and 7-fold lower IC50 values versus  
the parental lead compound 143.  
To rationalize the inhibitory activity of 170, 175, 177 and 179-181 on 5-LO 
by means of molecular docking, it was used the crystal structure of stable 5-
LO recently reported by Newcomer and co-workers.302 It was considered the 
molecules as possible nonredox-type 5-LO inhibitors285,289 since it does not 
show any features of a redox-active agent or properties of an iron-ligand. 
Because the 5-LO was crystallized without ligand,302 the model interactions 
described by Wouters et al.290 was used as reference which was already 
successfully used for rationalize the binding mode f nonredox-type 5-LO 
inhibitors.269,303,304  
In the reported models, in fact, all the molecules interact with a binding site 
formed by Arg411, Ile406, Phe177, Lys409, Tyr181, Leu607, Leu414, 
Leu420, Trp599, Asn425, Gln363, Phe421, and Leu368, however, the 
different size of the second arms influence their binding mode on the protein 
molecular surface. As depicted in Figure 4.10, for all six potential inhibitors, 
the -COOH group and the triazole ring of 2-nitro-4-carboxybenzyl form a 
hydrogen bond with Arg596 and a π-cation interaction with Lys243, 
respectively. On the other hand, the -NH2 group of 179 allows a further 
hydrogen bond with the carbonyl oxygen of Gly419 and the carboxylic group 
in the side chain of Asp422, while the oxygen of the halogenated arms of 175, 
179-181 act as H-bond acceptors with the NHε2 of Gln413, and moreover, they 
 
are able to establish electrostatic interactions with Lys409 and Lys173 by the 
chlorine atom. Furthermore, even though 
compared to the other compounds, it establishes hydrophobic contacts with 
Arg411, Asn148, Cys159, Glu417, Ile415, Lys158, Trp147.
 
Figure 4. 10 Three dimensional model of the
(light blue), 180 (white), 
surface (A) (colored by atom type: C, gray; O, red; N, dark blue; and S, yellow) and purple 
ribbon (B). The crucial aminoacids of 5
(colored by atom type: C, gray; O, red; N, dark blue; and S, yellow).
 
All these interactions provide complexes with an increased predicted 
stability that is fully compatible with the results of the experimental biological
assays, giving a good rationalization of the 5
175, 177, 179-181.  
 
4.3.1    Computational details
The molecular docking calculation were performed using Autodock 4.2 
software56 on 4x AMD 486 Opteron SixCore 2.4 GHz. For all the docking 
studies on MGST1 (pdb code: 2H8A)
mPGES
196 
170 shows a different binding mode 
 
 170 (grey), 175 (blue), 177
and 181 (cyan) with 5-LOX. The 5-LOX is represented by molecular 
-LOX are depicted by stick and balls and CPK 
 
-LO inhibitory activity of 
 











30 x 28 x 28, with spacing of 0.375 Å between the grid points, and centered at 
-43.667 (x), 33.493 (y) and 2.656 (z) was used covering the active site of the 
receptor. For all the docked structures, all bonds were treated as active 
torsional bonds. To achieve a representative conformational space during the 
docking studies and for taking into account the variable number of active 
torsions, 10 calculations consisting of 256 runs were performed, obtaining 
2560 structures for each ligand. The Lamarckian genetic algorithm (LGA) was 
employed for docking calculations, choosing an initial population of 600 
randomly placed individuals. The maximum number of energy evaluations and 
of generations was set up to 5 x 106 and to 6 x 106 respectively. Results 
differing by less than 3.5 Å in positional root-mean-square deviation (RMSD) 
were clustered together and represented by the result with the most favorable 
free energy of binding. On the other hand, for the rationalization of the binding 
mode 170, 175, 177, 179-181 with 5LO (pdb code: 3O8Y)302 we used a 
Autodock Vina software choosing a grid box size of 30 x 28 x 28, with 
spacing of 1.000 Å between the grid points, and center d -11.146 (x), 66.57 
(y) and 0.523 (z) covering the active site of the receptor. For the docking 
studies, we used an exhaustiveness of 8 with maximum energy difference of 
3kcal/mol between the best binding mode and the worst ne displayed. 
Illustrations of the 3D models were generated using the Python software.165
 
  





























5.1. Human Group IIA Phospholipase A2: an Overview  
In this chapter, it will be described the rationaliz t on by molecular docking 
of the marine natural products binding mode and mechanism of action, which 
act as ihibitors of human synovial Phospholipases A2: Bolinaquinone (BLQ, 
Dysidea sp., 182 Scheme 5.1)291 and Cladocoran A (CLD A, Mediterranean 
coral Cladocora cespitosa, 183 Scheme 5.2).292  
Phospholipases A2 (PLA2) belong to the esterase enzymes group and acts in 
the release of the arachidonic acid from the membrane phospholipids305, which 
in turn leads to the synthesis of key signaling molecu es in the inflammation 
responses, such as prostaglandins, leucotrienes and pl telet-activating factors 
through the so-called ‘arachidonic acid cascade’.306 PLA2 enzymes are 
classified as cytosolic PLA2 (cPLA2), intracellular PLA2 (iPLA2) and secretory 
PLA2 (sPLA2) on the basis of their cellular location.
306 The sPLA2s are small 
secreted proteins (14–18 kDa) usually containing 5 to 8 disulfide bonds (Table 
5.1).  
 
Table 5. 1 Secreted phospholipases A2 (sPLA2) 
Group Source 
Molecular mass 
(kDa) Disulfide bonds 
IA Cobras and Kraits 13–15 7 
IB 
Human/porcine 
pancreas 13–15 7 
IIA 
Rattlesnakes; human 
synovial 13–15 7 
IIB Gaboon viper 13–15 6 
IIC 
Rat/murine testis 15 8 
IID Human/murine 14–15 7 







brain/heart/uterus 14–15 7 
IIF 
Human/murine 








heart/lung/macrophage 14 6 
IX 
Snail venom 
(conodipine-M) 14 6 
X 
Human 
spleen/thymus/leukocyte 14 8 
XIA 
Green rice shoots 
(PLA2-I) 12.4 6 
XIB 
Green rice shoots 
(PLA2-II) 12.9 6 
XII Human/murine 19 7 
XIII Parvovirus <10 0 
XIV 
Symbiotic fungus/ 
bacteria 13–19 2 
 
This group of enzymes uses an active site histidine and absolutely requires µM 
levels of Ca2+ for catalysis. In close proximity to the catalytic histidine there is 
a conserved aspartate. The two amino acids form a His/Asp dyad (Figure 5.1), 
not showing a distinct preference for particular fatty acids. The sPLA2s are 
found in plants,307 insects,308 molluscs,309 reptiles310 and mammals.311 
Mammalian sPLA2 enzymes possess a larger molecular mass of around 55 kDa 
due to N-terminal and C-terminal extensions.312  




Among the calcium dependent sPLA2’s, type IIA PLA2 (sPLA2-IIA), an 
isoform isolated from human synovial fluids, is well known to be implicated in 
the pathogenesis of inflammation;313 high levels of this enzyme have been 
recovered in serum tissues affected by a variety of inflammatory pathologies, 
including rheumatoid arthritis, septic shock, psoriasis and asthma.314  
 
 
Figure 5. 1 Schematic rappresentation of catalytic mechenism of sPLA2.  
 
Moreover, the latest findings on the oncogenic action of PLA2 in prostate 
cancer and its association with neurological disease offers further motivation 
for finding new modulators of its function.315,316  
The marine environment is a rich source of molecules endowed with anti-
PLA2 properties, a number of which have shown potent and selective in vitro 
and in vivo anti-sPLA2 activity.
317,318,319 One of the most widespread groups of 
constituents found in sessile organisms with a typical selective profile against 
secretory PLA2 are the sesquiterpenes bearing a γ-hydroxybutenolide ring, 




whose reference compound is manoalide,319,320,321,322 Since then, many other 
related molecules have been isolated, such as seco-man alide,323 
luffariellolides,324 luffariellins,325 luffolide,326 cacospongionolides,327 and 
recently petrosaspongiolides M-R,328 all of which are capable of irreversible 
inhibition of PLA2. Among these compounds, petrosaspongiolide M (PM, 2) 
has been the subject of detailed in vitro and in vivo pharmacological 
investigation, and the results suggested a double interaction of PM with two 
enzyme molecules, one of them covalently modified an the other contacting 
the inhibitor through its active site.329  
Therefore, the discovery of selective sPLA2 inhibitors and the assessment 
of their molecular mechanism of enzyme inactivation may have a relevant 
impact in the fields of chemical biology, medicinal chemistry and 
pharmacology. 




5.2 The molecular mechanism of human group IIA 
phospholipase A2 inactivation by bolinaquinone 
It does not come as a surprise that natural kingdoms, and particularly the 
marine environment, have proven to be a rich source of molecules exhibiting 
anti-PLA2 properties; for instance, a number of sponge metaboli es have 
shown potent activity in vitro and in vivo against sPLA2, as opposed to their 
rather poor effects on cPLA2.
317,319,330 Numerous marine natural products 
(MNPs) featuring a quinone and/or hydroxyquinone nucle s elicited sPLA2 
inactivation with good potency..331,332a Among MNPs,332 Bolinaquinone (BLQ, 
Scheme 5.1),333 one of the most active metabolites of this class, inactivates 
human synovial sPLA2-IIA, bee venom PLA2 and porcine pancreatic group I 
PLA2, with IC50 values in the mM range, demonstrating its higher activity with 
respect to other known PLA2 natural inhibitors, such as manoalide
334,335,336 and 
petrosaspongiolide M.337,321,322,329  
BLQ is a sesquiterpene metabolite isolated from the marine sponge Dysidea 
sp. in 1998 by Ireland and co-workers,333 possessing a hydroxy-p-quinone 
moiety connected to a trans-decalin terpene unit in a rearranged drimane 
skeleton.333,338 Its significant anti-inflammatory properties were cognized 
and thoroughly examined both in vitro and in vivo.338 In particular, BLQ was 
tested as inhibitor of the production of mediators in acute and chronic 
inflammatory processes and as modulator of the oxidative stress parameters in 
2,4,6-trinitrobenzenesulphonicacid (TNBS)-induced colitis in mice. BLQ has 
been shown its ability to significantly reduce nitrotyrosine immunodetection 
and colonic superoxide anion production and, furthermore, to decrease the 
extension of apoptosis, suggesting potential protectiv  actions in intestinal 
inflammatory diseases.339  















Scheme 5. 1 Molecular structure of BLQ. 
 
Following on-going extensive investigation on the PLA2 inactivation 
mechanism by anti-inflammatory marine natural products,321,322,329,340 and 
attracted by the perspective of a rational design of ovel inhibitors as new 
potential lead compounds against inflammation-related diseases,341,342 the 
molecular mechanism of sPLA2-IIA inhibition by BLQ was investigated. The 
opportunity of exploring the reactivity of the p-quinone systems in this 
biological context and the latest findings of an onc genic action of PLA2 in 
prostate cancer343 offered further motivations for this project.  
Herein, the reported results suggest that the inhibition mechanism is mainly 
ruled by a non-covalent event with a key role of the catalytic Ca2+ ion, 
anchoring the BLQ hydroxyl-quinone moiety inside thactive site.  
The reported results on the elucidation of the sPLA2-II  inactivation 
mechanism by BLQ consisted of the following steps: (a) analysis of the 
sPLA2-IIA inhibition profile; (b) structural analysis of the protein-inhibitor 
complex; (c) in silico generation of a 3D model of the protein–inhibitor 
complex. A combination of spectroscopic techniques (UV and Surface 
Plasmon Resonance (SPR)), classical protein chemistry protocols (proteolytic 
digestions, RP-HPLC), mass spectrometry (MS) and molecular modelling was 




employed. The inhibition of sPLA2-IIA activity by BLQ was monitored 
measuring the enzymatic activity of the native protein in the considered 
experimental conditions. sPLA2-IIA enzymes are inactive on isolated 
phospholipid substrates, but undergoes ‘interfacial activation’ after the correct 
arrangement on the phospholipid layers.  
In the attempt to ascertain the mechanism of the inibition, the BLQ-sPLA2-
IIA affinity by SPR biosensor analysis was monitored.344 On the basis of these 
experiments, the experimental dissociation constant (KDexp) of the BLQ-
sPLA2-IIA complex was then calculated through the bioinfrmatics analysis of 
the sensogram traces. In absence of Ca2+ ions, KDexp was estimated at 
1.13±0.75x10-6 M, whereas its value significantly decreased in presence of 
Ca2+ ions (1.87±2.93x10-8 M). Thus, the inactivation mechanism appears to be 
mainly induced by a direct interaction between BLQ and sPLA2-IIA. 
Furthermore, these preliminary results also suggest a key role of the calcium 
ion in the enhancement of BLQ affinity to the enzyme. As already done in 
previous studies, in which the bee venom PLA2 was shown to be affected by 
both covalent and non-covalent interactions when incubated with several 
natural inhibitors,321,322,329,340 it was applied a mass spectrometric approach in 
the analysis of the sPLA2-IIA-BLQ complexes. A selective histidine alkylating 
agent pNBr (MW¼244 Da), well known for being able to specifically modify 
the catalytic His residues of different sPLA2 (DM¼164 Da)
345 was used. 
Comparative pNBr modification experiments in presence and absence of a 
given inhibitor hence provides valuable evidence on the type of inhibition 
mechanism, (if competitive or not). 
From the result analysis, all evidences suggest that BLQ acts as a competitive 
sPLA2-IIA inhibitor, even though a mixed inhibition process cannot be 
excluded. Moreover, in the attempt to establish whether BLQ promoted 
 
enzymatic inactivation in terms of pure non
modification of the enzyme or both, a RP
incubation mixture was performed. 
The detection of a considerable amount of a sPLA
was obtained (Figure 
 
Figure 5. 2 Reaction mechanism for the covalent inactivation of sPLA
reaction site has been pointed on C
 
This evidence suggests the formation of an
the protein and the inhibitor with
of a sPLA2-IIA nucleophilic g
quinone ring of BLQ, followed by a 
methanol, as already reported in a previous study
between BLQ and bee venom PL
of BLQ occurred at pH
was considered irrelevant in the inactivation mechanism of the
Marine natural products as hsPLA
206 
-covalent association, covalent 
-H LC-MS analysis of the 
 
2-II BLQ covalent adduct 
5.2).  
2-IIA by BLQ. BLQ 
-20.340 
 irreversible complex between 
 1:1 stoichiometry, due to a Michael addition 
roup (e.g. an e-amino group of Lys) onto the
b-elimination of one
 regarding the interaction 
A2.
340 However, since the covalent reactivity 





 molecule of 
 enzyme, and 




consequently the identification of the reactive site( ) on the sPLA2-IIA was 
left unresolved.  
As a final step, in order to shed more light on the rel vance of the non-
covalent interaction in the enzyme inhibition process, it was resorted to a 
molecular docking approach by building a 3D model of the sPLA2-IIA-BLQ 
complex. The human sPLA2-IIA belongs to the calcium-dependent class of 
sPLA2
346 in which the Ca2+ ion is anchored into the active site through the 
contacts with the carboxylate oxygen atoms of Asp48, the backbone oxygen of 
His27, Gly 29 and Gly 31 (See Figure 5.1), and the two oxygen of the 
substrate, if present. The crystal structure of inhibited sPLA2-IIA from 
inflammatory exudates solved by Sigler and co-workers in 1991347 (PDB code: 
1POE) was used as molecular target for docking calculations (Figure 5.3). 
 
 
Figure 5. 3 Three-dimensional model of crystal structure solved by Sigler in 1991. 
 




The first step of our studies was the refinement at density functional theory 
(DFT), B3LYP level of the sPLA2-IIA catalytic site. In particular, in order to 
obviate for the lack of appropriate force field parameter to model the 
metal/ligand interactions, the charges of the Ca2+ ion and of the amino acids 
involved in the metal coordination, namely His27, Gly29, Gly30 and Asp48 
(Figure 5.4) were calculated using Gaussian 03 Software Package.160 
 
 
Figure 5. 4 Three-dimensional model of the Ca2+ ion anchored into the active site of sPLA2-
IIA. 
 
Such QM supported procedure highly improved the accuracy of the molecular 
docking results, as already established in the docking studies of other metal 
enzymes.147 The hydroxyl group of the BLQ quinone ring as dissociated at 
physiological pH and, consequently, it was considere  deprotonated348 in the 
molecular docking calculations by Autodock 4.0.1 software. In the three-
dimensional model of the sPLA2-IIA-BLQ complex, BLQ interacts in the 
enzyme active site with the same set of residues observed in the transition-




state analogue reported in literature.347 Such analogy in the binding of sPLA2 
is depicted in Figure 5.5a, and strongly supports the significance of the 
obtained docking results. Mainly, the oxygen atoms of hydroxy–quinone 
system are of primary importance for their interactions network; namely, both 
the C-1 carbonyl group and the deprotonated C-2 hydrox l residue coordinate 
the calcium ion in a bidentate fashion, while only the C-2 hydroxyl establishes 
hydrogen bonds with NH of Gly29 (Figure 5.5b).  
 
 
Figure 5. 5 (a) BLQ and transition-state analogue superimposition n the sPLA2-IIA binding 
site. The green mesh represents the hydrophobic pocket f the protein. The Ca2+ is represented 
in orange. BLQ is depicted by sticks (yellow) and balls (C, yellow; O, red); the transition state 
analogue is shown by sticks (sky blue) and balls (C, sky blue;O, red). The figure highlights the 
similar interactions with the shallow hydrophobic groove on the enzyme surface. (b) The 
flexible protein is represented by CPK and sticks and balls coloured by atom type (by atom 
type: C, gray; polar H, sky blue; N, blue; O, red), the rigid protein is represented by dark blue 
sticks and balls. BLQ is depicted by sticks and balls (by atom type: C yellow, O red). 
 
Moreover, it is important to note that the flexible amino acids Leu2, Phe5, 
His6, Ile9, Tyr21, His47, Phe98 rearrange around the BLQ (see relative 
position of the amino acids in the rigid—coloured in dark blue—and flex 
target-coloured by atom type-) generating multiple Van der Waals interactions 
with the target. Moreover the entire hydroxy–quinone ring interacts with 




Gly22, Gly29, Val30 and the bicyclic sesquiterpene moiety creates a number 
of hydrophobic contacts with Ala17, Ala18, Gly22, Cys28 and Gly29. All the 
above-mentioned contacts contribute to the final theoretical dissociation 
constant (KDcalc) of 6.92x10
-6 M. Indeed, both the non-covalent interactions 
with large hydrophobic surfaces of the active site and the chelation of the 
essential calcium ion by BLQ are responsible of the competitive inhibition 
process.  
Besides, in order to validate and to obtain a term of quantitative comparison 
for the results described above, it was re-investigated by molecular docking 
(Autodock 3.5 software)55 the bee venom PLA2 inhibition by BLQ whose 
main features had been previously investigated by molecular docking.340  
Also for the bvPLA2, its binding site was refined at Quantum Mechanical 
(QM) level. The charges of Ca2+ ion 501 and of Trp8, Gly10, Gly12, Asp35 
were calculated at the DFT B3LYP level using the 6-31+G(d) basis set and 




Figure 5. 6 3D model of the Ca2+ ion anchored into the active site of bvPLA2. 




This refined structure of target with the BLQ optimized, as described 
above, were used as input for docking calculations. The analysis of the 
complex between bvPLA2 and BLQ (Figure 5.7) revealed that the oxygen 
atoms of hydroxy-quinone system bind to the calcium ion in a bidentate 
fashion and establish hydrogen bonds with the amino acids of the catalytic 
center, in particular, C-4 carbonyl group with NH of Gly12, C-5 methoxyl 
group with NH of Gly10, and C-1 carbonyl group with NH of Thr57. 
Moreover, the hydroxy-quinone system interacts with the hydrophobic 
aminoacids of the catalytic site: Gly10, His11, Gly32, His56, Thr57.  
 
 
Figure 5. 7 3D model of the interaction between BLQ and the bvPLA2 binding site. 
 
The bicyclic sesquiterpene moiety establishes appropriate hydrophobic 
contacts with the Tyr3, Cys9, Gly10, Val83, Met86, Tyr87 playing an 
essential role in the inhibition mechanism. In summary, the docking 
calculations show a slight different arrangement of the BLQ in the bee venom 




PLA2 catalytic centre with respect to the complex with the sPLA2-IIA. (K Dcalc 
of the BLQ-bee venom PLA2=
 41.13x10-6 M). Such results are in good 
qualitative agreement with the biological assays,349 where BLQ inhibits 
sPLA2-IIA, and bee venom PLA2 with IC50 values of 0.2 and 0.1 µM, 
respectively. 
Moreover, on the basis of the mechanism of histidine alkylanting agent 
Para-Nitrophenacyl-Bromide (pNBr) the three dimensio al model of the 
hsPLA2 with the modified His47 was built. The modified active site was 
refined at the quantum mechanical (QM) level calculting the partial charges 
of the Ca2+ ion and of the amino acids involved in the metal coordination 
(His27, Gly29, Gly30, Asp48), and of the His47 covalent linked to pNBr 
(Figure 5.8) at the DFT B3LYP level using the 6-31+G(d) basis set and 
ChelpG148 method for population analysis using Gaussian 03 Software 
Package.160  
 
Figure 5. 8 3D model of the Ca2+ ion anchored into the modified active site of sPLA2-II .  
 
Docking calculation by Autodock 3.0.555 were performed on the mutated 
sPLA2-IIA and the refined BLQ structure. From the analysis of the 
calculations it emerged that, in the modified complex the pNBr fills equivalent 




space of the BLQ complexed with the sPLA2, as described in the main text 
(Figure 5.5), on consequence in the three dimensional model the 
hydroxyquinone marine terpenoid is obliged to arrange at the opposite side of 
the pNBr (Figure 5.9).  
 
 
Figure 5. 9 3D model of the BLQ and the pNBr into the active sit  of hsPLA2. The protein is 
represented by secondary structure. BLQ is depicted by sticks and balls (colored by atom type: 
C yellow, O red). The pNBr is depicted by sticks colored by atom type: C grey, O red, N dark 
blue. 
 
The BLQ coordinates the calcium ion in the bidentate f shion, and the C-4 
carbonyl group establishes hydrogen bonds with NH of Gly31 (not displayed), 
and it interacts with the Gly31, Val30, Asp48, Gly125, Lys52, Gly125, Tyr51, 
Tyr126. All the above-mentioned contacts contribute to the final theoretical 
dissociation constant (KDcalc) of 2.3x10
-5 M. This result suggests that 
alkylation of His47 with pNBr do not completely block, but undoubtedly 
obstruct the BLQ binding suggesting that the suboptimal hydrophobic 
interactions are responsible for a predicted decrease in the binding affinity to 
the receptor of about 1000-fold (KDcalcr of BLQ 1.55x10
-8 vs KDcalc of BLQ in 




presence of pNBr 2.3x10-5), confirming that the non-covalent interactions with 
large hydrophobic surfaces of the active site are the driving force in the 
inhibition processes.  
On summary, it is possible to affirm confident that the inactivation 
mechanism is completely due to a non-covalent event at physiologically 
relevant conditions. Thus, the covalent reactivity of BLQ detected in more 
drastic experimental setting, at high pH values, must be considered irrelevant 
in terms of enzyme inhibition. The comprehension of the molecular 
mechanism of the sPLA2-IIA inactivation by BLQ could be helpful for the 
design and synthesis of a new chemical class of PLA2 inhibitors, able to 
specifically target the enzyme active site without being endowed with covalent 
reactivity. 
 
5.1.2 Computational details  
All the QM and molecular docking calculations were p rformed on a two 
dual-core Intel Xeon 3.4 GHz. The charges of the sPLA2-IIA chain A (Ca
2+ ion 
801 and of Gly29, Gly31, His27, Asp48) catalytic centr  were calculated at the 
DFT B3LYP level using the 6–31+G(d) basis set and ChelpG148 method for 
population analysis. The standard AutoDock 4 force field parameters were 
used for the docking calculations of the metallo-prtein sPLA2-IIA: calcium 
radius=1.98Å and well depth=0.55 kcal/mol. A flexible docking involving the 
amino acids of the shallow groove on the enzyme surface, namely Leu2, Phe5, 
His6, Ile9, Tyr21, His47, Phe98 was performed. A grid box size of 50 x 50 x 
50 with spacing of 0.375 Å between the grid points, and centered at 23.0 (x), 
5.5 (y) and 64.0 (z), covering the active site on the sPLA2-IIA surface was 
used. The implicit salvation method of Autodock 4.0.1 was used in the 




calculation. In particular, the water was considere as a continuous medium, 
and the desolvation term was evaluated considering: (a) an atomic solvation 
parameter for each atom type, corresponding to an estimate of the energy 
needed to transfer the atom between a fully hydrate s ate and a fully buried 
state, and (b) an estimate of the amount of desolvati n when the ligand is 
docked. The Lamarckian genetic algorithm with an initial population of 150 
randomly placed individuals, a maximum number of 2.5x105 energy 
evaluations, and a maximum number of 2.7x104 generations were taken into 
account was used for dockings by Autodock 4.0.1 software.56 A mutation rate 
of 0.02 and a crossover rate of 0.8 were used. Results differing by less than 2.0 
Å in positional root-mean-square deviation (RMSD) were clustered together 
and represented by the result with the most favorable free energy of binding.  
For what concern bvPLA2 (PDB code 1POC),
350 it being a metal enzymes 
and so a non-bonded model for metal center (Calcium Radius=1.98 Å, well 
depth=0.55 kcal/mol) was used. For all the docking calculations a grid box 
size of 100 x 96 x 115 with spacing of 0.375 Å between the grid points, and 
centered at 46.6 (x), 30.6 (y) and 26.0 (z), covering the active site on the 
bvPLA2 surface was used. In order to achieve a representative conformational 
space during the docking calculations, six calculations consisting of 256 runs 
were performed, obtaining 1536 structures (256 x 6). The Lamarckian genetic 
algorithm was used for dockings. An initial population of 150 randomly 
placed individuals, a maximum number of 2.5 x 105 energy evaluations, and a 
maximum number of 2.7 x 104 generations were taken into account. A 
mutation rate of 0.02 and a crossover rate of 0.8 were used. Results differing 
by less than 2.0 Å in positional root-mean-square deviation (RMSD) were 
clustered together and represented by the result with the most favorable free 
energy of binding.  




For what concern a modified model sPLA2-IIA with pNBr, as described 
above, a grid box of 48 x 60 x 66 with spacing of 0.375 Å between the grid 
points, and centered at 23.0 (x), 6.6 (y) and 65.0 (z), covering the active site on 
the sPLA2-IIA  surface was used. In order to achieve a representative 
conformational space during the docking calculations, six calculations 
consisting of 256 runs were performed, obtaining 1536 structures (256 x 6). 
The Lamarckian genetic algorithm was used for dockings. An initial 
population of 150 randomly placed individuals, a maxi um number of 2.5 x 
105 energy evaluations, and a maximum number of 2.7 x 104 generations were 
taken into account. Results differing by less than 3 Å in positional root-mean-
square deviation (RMSD) were clustered together andrepresented by the 
result with the most favourable free energy of binding.  
All the 3D models were depicted using the Python165 software, molecular 
surfaces are rendered using maximal speed molecular s rface (MSMS).166




5.3 The Binding Mode of Cladocoran A to the Human Group 
IIA Phospholipase A2 
Cladocoran A (CLD A, Scheme 5.2) is a member of the sesterterpenoid 
ghydroxybutenolides with a unique carbon skeleton, isolated from the 
Mediterranean coral Cladocora cespitosa by Fontana et al., together with its C-
18 deacetylated congener (CLD B).351,352,353 CLD A is endowed with a high 
sPLA2 inhibitory effect, comparable to that of manoalide, with an IC50 of 
0.78(±0.06) µm.351 On this basis, it would be interesting to disclose the CLD A 
mechanism of action on sPLA2-IIA enzyme.  
The elucidation of the sPLA2-IIA interaction mechanism by CLD A was 
performed by a detailed structural analysis of the covalent and noncovalent 
contributions to the protein–ligand complex, through a combination of 
classical protein chemistry protocols (proteolytic d gestion, RP-HPLC), nano-
ESI and MALDI mass spectrometry (MS). Furthermore, an in silico 3D model 
was generated by molecular docking calculations to provide a more detailed 
picture of the protein–ligand adduct. The results de cribed in this paragraph 
prove that the interaction mechanism is mainly ruled by a no covalent 
competitive occupancy of sPLA2-IIA active site by CLD A, together with a 
selective covalent modification of the enzyme. 
As already carried out in previous studies on sPLA2,
319-322,329,340,291,354 the 
first step is represented by the analysis of sPLA2 potential covalent 
modification by CLD A through liquid chromatography-nano-ESI MS (LC-
nano-ESI-MS).  
 












Scheme 5. 2 Molecular structure of CLD A. 
 
In the first pathway, two reaction steps can be postulated. In the first 
pathway (Figure 5.10A), in which an aspecific esteras  activity of the enzyme 
gives rise, after hydrolysis at the C-18 acetate function, to a secondary alcohol 
and a Schiff base formation between a nucleophilic amine residue on the 
sPLA2-IIA and the masked aldehyde of the γ-hydroxybutenolide ring (total 
mass increment of 384.2 Da) occurs. In a second hypot esis (Figure 5.10B) 
nucleophilic attack of a sPLA2-IIA residue on CLD A C-18 causes the loss of 
acetic acid (total mass increment of 384.35 Da).  
 
Figure 5. 10 Covalent interaction pathways between sPLA
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towards pNBr result of specific accommodation of CLD A into the enzyme 
active site. 
In order to rationalize the binding mode of CLD A on sPLA2-IIA enzyme 
(PDB ID: 1POE)347 molecular docking calculations using Autodock 4.2 
software356 were performed. As reported in the paragraph 4.2,291 sPLA2-IIA 
structure refined at quantum mechanical level, in which the charge of the 
amino acids of the catalytic site (namely His27, Gly29, Gly30 and Asp48 and 
calcium ion) were calculated at density functional theory (DFT) B3LYP level, 
was used as model receptor. On the other hand, the CLD A γ-
hydroxybutenolide ring was considered whether opened and deprotonated at 
physiological pH. Prior to the docking calculations, CLD A conformational 
search by means of molecular dynamics at different temperatures (300 and 750 
K) with a Monte Carlo conformational search using the MMFFs force field 
included in the MacroModel159 software package were performed.  
As shown in Figure 5.11, CLD A fits into the sPLA2-IIA active-site pocket, 
establishing extensive van der Waals and hydrophobic interactions with 
protein side-chains and chelating the essential calcium ion with its carboxylate 
moiety. Mainly, it is able to interact with Leu2, Phe5, Ile9, Ala17, Gly22, 
Cys28, Val30, Phe98, and it forms hydrogen bonds with Lys62 and Gly29 
(Figure 5.11 B). All the above-mentioned contacts contribute to the final 
theoretical dissociation constant (KDcalc) of 0.38 µm.  
Thus, the results of docking calculations support the view that CLD A 
preferentially interacts with the enzyme active sit, as previously disclosed by 
MS analysis. 





Figure 5. 11: a) Three dimensional model of the complex between CLD A and sPLA2-IIA; b) 
detailed interactions of CLD A with the sPLA2-IIA active site.  
 
Moreover, since MS data clearly show also the existnce of covalent binding 
of CLD A on sPLA2-IIA surface, a second molecule of CLD A on sPLA2-
IIA–CLD A noncovalent complex was docked, in order to establish if the 
Ser82 environment can be recognized by the marine bioactive sesterterpenoid. 
The reported docking calculations showed that CLD A is able to interact with 
external part of the enzyme presenting amino acid Ser82 (Figure 5.12). In 
particular, the ligand is able to form a hydrogen bond with Ser82 NH by the 
CLD A carbonyl at C-18, and with Arg57 and Cys83 side-chains by CLD A 
carboxyl and carbonyl groups on the g-hydroxybutenolide ring. Moreover, 
CLD A is in close contact with Gly58, Cys59, and Asp91 on the protein 
surface.  
 





Figure 5. 12: a) Three dimensional model of the complex between two molecules of CLD A 
and sPLA2-IIA. b) Detailed interactions of the second molecul  of CLD A with the external 
part of sPLA2-IIA. 
 
This pattern of hydrophilic and hydrophobic interactions of CLD A with 
sPLA2-IIA causes the projection of the reactive center C-18 bearing an acetyl 
function towards the hydroxyl group of sPLA2-IIA Ser82. However, the minor 
efficiency of such interactions is responsible for a low calculated binding 
affinity to the target (KDcalc of 194.32 µm). 
The reported results, collected by a combination of biochemical 
approaches, advanced mass spectrometry and molecular modeling, suggest a 
competitive inhibition mechanism guided by a noncovalent molecular 
recognition event, and disclose the key role of the CLD A γ-
hydroxybutenolide ring in the chelation of the catalytic calcium ion inside the 
enzyme active site. Moreover, CLD A is able to react selectively with Ser82, 
although this covalent event seems to play a secondary role in terms of 
enzyme inhibition. 
 




5.3.1 Computational details  
The sPLA2-IIA model optimzed at QM level as described in thesection 4.2.1 
was used for molecular docking calculations using Autodock 4.2 software356 
on a two dual-core Intel Xeon 3.4 GHz. For the docking studies, a grid box 
size of 126 x 126 x 126 and centered at 23.912 (x), 1.212 (y), 67.788 (z) in the 
first calculation (1:1, sPLA2-IIA/CLD A), and of 50 x 72 x 46 and centered at 
41.225 (x), 2.823 (y), 59.81 (z) in the second case (1:2, sPLA2-IIA–CLD 
A/CLD A) was used. The spacing between the grid points was 0.375 Å, and 
the active site and the external part of sPLA2-II  were covered in both 
calculations. To achieve a representative conformation l space during the 
docking studies and to take into account the variable number of active 
torsions, ten calculations, in both cases consisting of 256 runs, were 
performed, and 2560 structures were obtained for CLD A. The Lamarckian 
genetic algorithm (LGA) was employed for docking calculations, choosing an 
initial population of 600 randomly placed individuals. The maximum number 
of energy evaluations and of generations was set to 5x106 and to 6x106. 
Results differing by less than 3.5 Å in positional root-mean-square deviation 
(RMSD) were clustered together and represented by the most favorable free 
energy of binding. Illustrations of the 3D models were generated the Python 
software.165
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6.1. The Farnesoid X Receptor (FXR) and Human Pregnane-
X-Receptor (PXR) as Modulator of Bile Acid Metabolism 
In this chapter it will be described, by mean of molecular docking, the 
binding modes of the marine natural products extract from Theonella 
swinhoei, acting as ligands of two foundamental bile acid receptors: human 
farnesoid-X-receptor (FXR) and human pregnane-X-receptor (PXR). In 
particular it will be rationalize at atomic level the antagonist and/or modulator 
activity of Conicasterols (B-D, G-K), Theonellasterols (B-H, J), and 
Swinosterol B on FXR, and their agonist activity on PXR.294,357,358,359 
Nuclear receptors (NRs) are ligand-dependent transciption factors that 
control many biological functions, such as cell growth, differentiation, 
embryonic development, and metabolism. Upon activation by binding of small 
lipophilic molecules, such as steroids and thyroid hormones, retinoids, vitamin 
D, and dietary and endogenous lipids, NRs interact with coactivators to 
modulate directly the expression of responsive genes i volved in development, 
reproduction, and metabolism.360 Pharmaceutical control of the activity of NRs 
with synthetic ligands having agonistic or antagonistic activity is a powerful 
tool for the management of various clinical conditions, including several forms 
of cancer, type 2 diabetes, and metabolic syndrome.361 
Hepatobiliary transport of bile acids is mediated by specific transporters 
expressed at the canalicular membrane of the hepatocyte. Impaired function of 
these transporters leads to reduced bile formation or cholestasis and mutations 
in these genes are associated with a variety of heredita y cholestatic 
syndromes.362,,364 At the transcriptional level, these transporters and the phases 
I and II metabolizing enzymes involved in processing of their substrates are 
coordinately regulated by members of the nuclear receptor family of ligand-




modulated transcription factors.365 In the last decade, two nuclear receptor, the 
farnesoid-X-receptor (FXR) and the pregnane-X-receptor (PXR), with both 
receptors functioning as bile acid activated receptors, have emerged as the 
main receptors involved in regulating bile acid synthesis, detoxification and 
excretion in the liver and gastro-intestinal tract.366,367,368369 However, since 
FXR agonists inhibit MRP-4, a basolateral transporter that regulate bile acids 
excretion from basolateral membrane of hepatocytes,370 and FXR gene 
ablation protects against liver injury caused by bile duct ligation,371 it has been 
suggested that FXR antagonists, rather than FXR agonists, might hold promise 
in the treatment of cholestatic disorders.372,293 In addition to FXR, PXR is a 
recognized target for treatment of cholestasis.373  
The pregnane X receptor (PXR; also known as NR1I2), a member of the 
nuclear receptor family of ligand-activated transcription factors, is a key 
regulator of cytochrome P450-3A (CYP3A) gene expression in mammalian 
liver and small intestine,374 CYP2B6,375 and CYP2C9 as well as many other 
enzymes and transporters, such as P-glycoprotein (ABCB1),376 and proteins 
involved in the transport, metabolism, and biosynthesis of bile acids.377 These 
discoveries have shown how drugs may regulate not only their own 
metabolism but potentially also their own efflux, as demonstrated for 
paclitaxel.378 Overall, there is an incredibly broad structural diversity in the 
molecules that bind to human PXR in vitro. In particular, PXR is activated by 
a broad range of compounds as e.g. bile salts,378,379 cholesterol and its 
metabolites,380 statins,381 endocrine disruptors,382 imidazoles,383 biphenyles,384 
azoles,385 synthetic peptide bond mimetics,386 anticancer compounds,387 herbal 
components and plant extracts,388,389,390 carotenoids,391 vitamins,392 HIV 
protease inhibitors,393 calcium channel modulators,394 steroids,395 
plasticizers,396 pesticides,397 peroxisome proliferator-activated receptor-γ 




antagonists,398 as well as other diverse xenobiotics and 
endobiotics,399,400,401,402,403,404 including agonists for additional nuclear 
receptors405 (See Figure 6.1 for some examples). 
 
 
Figure 6. 1 Structures of selected PXR agonists and antagonists.  
 
Although these diverse interactions imply promiscuity, PXR also exhibits 
specificity, as evidenced by the differences in the p armacologic activation 
profile of PXR across species. For instance, human PXR is activated by 
rifampicin and the cholesterol-lowering drug SR12813,406 whereas mouse 
PXR is not;412 mouse PXR is activated by the synthetic steroid 5-pregnen-3b-
ol-20-one-16a-carbonitrile (PCN), whereas the human receptor is not. Thus, 




by binding diverse but precise arrays of compounds, PXR exhibits directed 
promiscuity. 
PXR acts as a transcription factor.407 Once activated, PXR heterodimerizes 
with the retinoid-X-receptor (RXR) (Figure 6.2), binds to regulatory DNA 
sequences in the nucleus, and modulates transcription of genes involved in the 
oxidation, conjugation, and export of compounds from cells. PXR mediates 
the detoxification of endogenous and exogenous compounds and prevents 
toxic accumulation of metabolites within cells. While PXR is primarily 
expressed in the gastrointestinal tract and liver, r cent reports showed that 
PXR is expressed in immune cells, including CD4+, CD8+ T lymphocytes, 
CD19+ B lymphocytes, and CD14+ monocytes in humans.408,410  
 
 
Figure 6. 2 Drug–drug interactions. The molecular basis of a drug–drug interaction. The 
orphan nuclear receptor PXR is a transcription factor that regulates the expression of the 
CYP3A gene (yellow) in the liver and intestine. It functions as a heterodimer with the nuclear 
receptor RXR. Drug A binds to PXR and induces expression of the CYP3A enzyme (pink), 
accelerating the metabolism of drug B, which is a substrate for CYP3A. CYP, cytochrome 
P450; OH, hydroxyl group; PXR, pregnane X receptor; RXR, retinoid X receptor. 
 
Several studies have shown that rifampicin, an human PXR activator,408,409 
used for treating pruritus in cholestasis, suppresses both humoral and cellular 




immunity and identified rifampicin as a powerful immunosuppressive drug. 
Moreover, reciprocal repression between PXR and NF-κB was shown. In the 
colon, PXR-mediated repression of NF-κB target genes appears to be a critical 
mechanism by which PXR activation decreases inflammtion408,409 The 
CYP3A gene products are heme-containing proteins that metabolize a wide 
variety of chemicals, including >50% of all prescription drugs.411 PXR is 
activated by most of the xenobiotics (exogenous chemicals) that are known to 
induce CYP3A gene expression, including the commonly used antibiotic 
rifampicin, the glucocorticoid dexamethasone, and the herbal antidepressant 
St. John’s wort.374,412 Like other nuclear receptors, PXR contains both a DNA-
binding domain and a ligand-binding domain. PXR binds to the xenobiotic 
DNA response elements in the regulatory regions of CYP3A genes as a 
heterodimer with the 9-cis retinoic acid receptor, also known as the retinoid X 
receptor (RXR).374 PXR can mediate dangerous drug-drug interactions. For 
example, hyperforin,413 a constituent of St. John’s wort, activates PXR and
upregulates CYP3A expression, which leads to the metabolism of vital drugs 
including the antiretroviral drug indinavir and the immunosuppressant 
compound cyclosporin..414,415,416 Cholestasis is a severe hepatic disorder that is 
characterized by the accumulation of toxic bile acids in the liver.417 It is a 
chronic incurable disease that ultimately leads to fa al hepatic failure. Pxr –/– 
mice show defective bile-acid excretion418,419 and the herb St John’s wort — a 
PXR activator420,421— has been used as a folk remedy for cholestasis.422 So, 
the use of PXR agonists as therapeutic agents might be warranted in these 
patients, despite the likelihood of inducing deleterious metabolism of other 
drugs. 
Among nuclear receptors, farnesoid X receptor (FXR; also known as 
NR1H4) has emerged as a valuable pharmacological target423 because of its 




role in regulating bile acids (BAs), lipid, and glucose homeostasis. Activation 
of FXR, highly expressed in the liver, intestine, kidney, and adrenals, leads to 
complex responses, the most relevant of which is the in ibition of bile acids 
synthesis through the indirect repression of the expression of cytochrome 7A1 
(CYP7A1), the rate limiting enzyme of this pathway.  
FXR is activated by cholesterol metabolism end-products, bile acid 
derivatives, such as primary bile acids and secondary bile acids, and synthetic 
ligands.424 Primary bile acids include chenodeoxycholic acid (CDCA) and 
cholic acid (CA), while secondary bile acids include eoxycholic acid (DC) 
and lithocholic acid (LCA). FXR heterodimerizes with another nuclear 
receptor, retinoid X receptor (RXR) (Figure 6.3), and the heterodimer 
regulates gene expression by binding to a specific onsensus DNA sequence, 
termed farnesoid X responsive element (FXRE), which is an inverted repeat of 
the hexameric AGGTCA recognition motif separated by single nucleotide (IR-
1), located in the promoter region of FXR target genes.425 
FXR regulates the expression of genes encoding proteins involved in 
cholesterol homeostasis, in bile acid biosynthesis (CYP7A1426 and 
CYP8B1427) transport and disposition (BSEP,428 IBABP,428 and NTCP429) 
FXR regulates the expression of small heterodimer partner (SHP).430 SHP 
attenuates the expression of CYP7A1 by inhibiting the activity of liver 
receptor homologue 1 (LRH-1), which is known to augment CYP7A1 
expression.430 FXR also decreases the expression of CYP8B1, which is t e 
enzyme catalyzing hydroxylation of CDCA at the 12a position to produce CA. 
FXR induces bile salt export pump (BSEP), which transports bile acids from 
hepatocytes to bile canaliculi, and induces the expression of the intestinal bile 
acid binding protein (IBABP), which shuttles bile acids from the apical to the 
basolateral side of the enterocytes during their absorption. 
 
Figure 6. 3 Schematic representation of FXR structure (top) andFXR/RXR
formation upon activation by their respective ligands
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addition to PSC and PBC, an obstructive form of cholestasis occurs in patients 
suffering from biliary stones or biliary and pancreatic tumors.431 Theoretically, 
because PBC and PSC are characterized by bile duct destruction, therapy 
should be aimed at activating bile acid secretion from the basolateral 
membrane of hepatocytes, while stimulation of bile acid secretion from the 
apical membrane is likely to worsens liver injury due to the obstruction of bile 
flow.433 FXR is a bile acid sensor that regulates bile acid synthesis and 
excretion. While activation of FXR favours bile acid detoxification by 
hepatocytes and FXR ligands have been proposed in the treatment of PBC 
patients,431 results from models of obstructive cholestasis in FXR-/- mice have 
shown that FXR gene ablation protects against liverinjury caused by ligation 
of common bile duct (BDL).433 Molecular decoding of  BDL model has lead to 
the demonstration that FXR functions as a negative regulator of multidrug 
resistance-associated protein (MRP)-4, a gene mediating basolateral secretion 
of bile acids. Thus, while FXR-/- mice adapt to bile duct obstruction by an ≈20 
fold induction in the expression of MRP-4 mRNA, these changes are not 
reproduced in wild type mice. Because, the induction of MRP-4 represents an 
adaptive response to bile duct obstruction and protects the liver from 
accumulation of toxic bile acids during cholestasis by facilitating their efflux 
into blood for ultimate renal excretion, and MRP-4-knockout mice are 
sensitised to liver injury induced by BDL,434 regulation of this basolateral 
transporter exerts an essential role in orchestrating the adaptive changes under 
conditions of impaired canalicular bile salt excretion.432,435a,357  
After its deorphanization436,437,438 a number of nonsteroidal439 and steroidal 
compounds,440 have been shown to interact with the ligand binding domain 
(LBD) of the receptor and to promote FXR mediated gene transcription 
(Figure 6.4 ).441  





Figure 6. 4 Structures of FXR agonists CDCA (191), 6-ECDCA (192), GW-4064 (193), 
fexeramine (194), and AGN-31 (195): and of FXR antagonists guggulsterone (196) and AGN-
34 (197). 
 
Among these, 6-ECDCA (192) has emerged as a potent, orally bioavailable 
FXR agonist,442 and ongoing clinical trials have shown its utility in the 
treatment of type 2 diabetes.443 In this scenario the discovery of FXR 
modulators represents an important answer to the urg nt demand of new drugs 
for the treatment of relevant human diseases including dyslipidemia, 
cholestasis, nonalcoholic steatohepatitis (NASH), and type 2 diabetes.  
Nevertheless the use of potent FXR ligands holds some potential risk. 
Indeed, it has been shown that FXR activation in mam lian cells and tissues 
inhibits biosynthesis of endogenous bile acids by indirect transrepression of 
cholesterol 7α-hydroxylase (CYP7A1), a gene encoding for the first and rate 
limiting enzyme involved in their biosynthesis. This effect is indirect and 
mediated by activation of SHP, small heterodimer partner, an atypical nuclear 
receptor that lacks the DNA binding domain and thatbinds to liver X receptor 
(LXR), causing its displacement from a positive regulatory element in the 
CYP7A1 promoter.423 Despite the effect of SHP, which has been shown to be 
dispensable in some settings, it is well recognized that SHP activation 




amplifies the effects of FXR on bile acids uptake and biosynthesis, strongly 
suggesting that identification of SHP-sparing FXR modulators might have the 
potential to promote bile acid detoxification without interfering with the 
biosynthesis (Figure 6.5).  
 
 
Figure 6. 5 Schematic representation of the activity of FXR and PXR on target genes.  
 
As the results of enzymatic reactions, natural products have an intrinsic 
capacity to recognize and bind macromolecules, perturb heir activity, and 
modulate biological processes. Besides their potential use as pharmaceutical 
drugs, natural products have and will continue to play critical roles as 
biological probes, essential component of today’s research arsenal and useful 
to dissect complex biological processes and ultimately, to identify novel 
therapeutic targets. The observation that ≈40% of modern pharmaceuticals are 
derived from biological sources444 highlights the incredible biomedical 
potential represented by the chemical analysis of the biodiversity of natural 
organisms.444 
Besides, in fact, the significant contribution deriv d from highthroughput 
screenings of chemical libraries and chemical strategy based on extensive 




modifications of the BAs body and side chain, only few natural FXR 
modulators have been described. Guggulsterone (196 Figure 6.4) the active 
component of the resin extract of the tree Commiphora mukul,445and 
xanthohumol,446 the principal prenylated chalcone from beer hops, are two 
well characterized examples of FXR modulators isolated from the vegetal 
realm. Recently the marine environment has also emerged as a source of 
human nuclear receptor ligands, and several molecules, including scalarane 
sesterterpenes,447 isoprenoids,448 and polyhydroxylated sulfated steroids,293 
have been shown to act as FXR antagonists, whereas to the best of the 
knowledge, no examples of marine derived FXR agonists are known.  
Among natural sources, marine environment, with its va t pool of plants, 
animal and micro-organisms, represents a greater promise to provide original 
molecules for treatment of human diseases. Sponges of the genus Theonella 
have attracted the interest from the scientific community for the impressive 
variety of bioactive secondary metabolites with unusual structures and 
powerful biological effects. Representative compounds include non-ribosomal 
peptides exemplified by the antifungal theonellamides, a new class of sterol-
binding molecules that induce membrane damage and activate Rho1-mediated 
1,3βD-glucan synthesis449 and complex polyketides such as the actin-bounding 
macrolide swinholide A.450 In addition, sponges of Theonella genus are 
distinctive in producing biosynthetically unique sterols. Decodification of 
these non conventional steroids has allowed the identification of 24-
ethylsterols endowed with potent activity towards mammalian nuclear 
receptors including the FXR and pregnane-X-receptor (PXR).294  
Steroids bearing a 4-methylene group are relatively rare metabolites. They 
were exclusively isolated from sponges of the genus Theonella, mainly from 
T. swinhoei, and were unaccompanied by conventional steroids and re 




proposed as ideal taxonomic markers for sponges of the genus Theonella.451 
Since the isolation, by Djerassi et al., of conicasterol and theonellasterol 
(Figure 6.6) from T. conica and T. swinhoei,452 respectively, about 20 new 4-
methylene-steroids were isolated from Theonella sponges.451,453,454,455,456 
Common structural features are a 24-methyl and/or 24-ethyl side chain, the 
presence of oxygenated functions at C(3), C(7), or C(15), and of a ∆8,14 double 
bond rarely replaced by a 8(14)- seco-skeleton. 
 
 
Figure 6. 6 Theonellasterol and conicasterol previously isolated from Theonella 
species. 
 
As a part of a systematic study on the chemical divers ty and bioactivity of 
secondary metabolites from marine organisms collected a  Solomon Islands,457 
it was found a single specimen of the sponge Theonella swinhoei as an 
extraordinary source of new metabolites. Analysis of the polar extracts 
afforded anti-inflammatory perthamides C-D,458,459 solomonamides A-B,460 
and solomonsterols A-B.295 Theonellasterol and Conicasterol contains a 
relatively rare 8(14) double bond and a biosynthetically unusual 4-methylene 
functionality. This unusual functional group has been proposed to 
biogenetically arise from a shunt in the oxidative d methylation of the 4-
methyl series, through the dehydration of the primay alcohol formed in the 




first oxidation of the methyl group.452 The biological function of these 4-
methylenesteroids is unknown. However, the relative abundance of these 
steroids in the apolar extract of Theonella swinhoei as well as their ability to 
fit in the ligand binding domain of FXR and PXR, emphasize a plausible role 
as putative ligands for ancestral sponge nuclear receptor(s). 




6.2 Theonellasterols and Conicasterols from Theonella 
swinhoei. Novel Marine Natural Ligands for Human 
Nuclear Receptors 
In this paragraph, it will be report the results of the chemical analysis of the 
less polar extracts, which resulted in the isolation and identification of 
theonellasterol452 together with 10 new polyoxygenated steroids, which were 
named theonellasterols B-H (200-206) and conicasterols B-D (207-209) 
(Figures 6.7 and 6.8). These marine steroids are endowed with potent agonistic 
activity on the human pregnane-X-receptor (PXR) while antagonize the effect 
of natural ligands for the human farnesoid-X-receptor (FXR). Exploiting these 
properties, the theonellasterol G (205) was identified as the first example of 
PXR agonist and FXR modulator from marine origin that might have utility in 
treating liver disorders. 
 
 
Figure 6. 7 Theonellasterols from Theonella swinhoei. 
 
 
Figure 6. 8 Conicasterols from 
The structures of compounds 
extensive spectroscopic data (MS, 
and ROESY) analysis (See Figure 6.9).
 
Figure 6. 9 Key HMBC (blue arrows) and ROESY (red arrows) correlations for 
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Theonella swinohei produces steroids that act as NRligands. Solomonsterols 
A and B,295 isolated from its polar extracts, are potent PXR agonists and new 
pharmacological anti-inflammatory leads. With this background in mind, it 
was investigated whether this family of hydroxylated sterols might act as 
modulators of two well characterized nuclear receptors, the farnesoid-X-
receptor (FXR) and pregnane-X-receptor (PXR), highly expressed in the 
mammalian livers. For this purpose, compounds 200-207461 and compound 
209 were challenged in a reporter gene assay using HepG2 cells, a human 
hepatoma cell line. As illustrated in Figure 6-10A, all compounds, except 
theonellasterol G (205), that partially activated FXR, failed to activate FXR at 
the concentrations of 10 µM. By contrast, all compounds, with the exception 
of theonellasterols D (202) and H (207), effectively antagonized FXR 
transactivation induced by CDCA (191, Figure 6.4) (Figure 6-10B).  
 
 
Figure 6. 10 Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-
FXR, pSG5-RXR, pCMV-bgal, and p(hsp27)TKLUC vectors and stimulated 18 h with (A) 
CDCA, 10 µM, and compounds 1-8 and compound 10, 10 µM. (B) CDCA, 10 µM, alone or in 
combination with compounds 200-207 and compound 209, 50 µM. *P < 0.05 versus not 
treated (NT). #P < 0.05 versus CDCA (n = 4). 














































































It is noteworthy that theonellasterol G (205) behaves as an antagonist in the 
presence of CDCA but is able to partially transactivate FXR, indicating that 
this agent is an FXR modulator. As shown in Figure 6.11A, at the 
concentration of 10 µM, all these compounds were PXR agonists.  
 
 
Figure 6. 11 Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-
PXR, pSG5-RXR, pCMV-bgal, and p(cyp3a4)TKLUC vectors and stimulated 18 h with (A) 
rifaximin, 10 µM, and of compounds 200-207 and compound 209, 10 µM. (B) Rifaximin, 10 
µM, alone or in combination with compounds 1-8 and compound 10, 50 µM. *P < 0.05 versus 
not treated (NT). #P < 0.05 versus rifaximin (n = 4). 
 
Interestingly, also theonellasterol G (205) acted as a PXR ligand, suggesting 
that this compound might be considered the first FXR modulator and PXR 
ligand so far identified.  
On the basis of the above-mentioned results, it wasthen analyzed, by 
means of molecular docking calculations, the interactions of polyhydroxylated 
steroids 200-207 and 209 with human FXR and PXR, in order to generate a 
structure-activity relationship and obtain information on their binding mode at 
atomic level. All the calculations were run by Autodock4.2 software.56 As 












































































shown in the Figure 6.12, compounds 200-207 and 209 adopt the same 
positioning in the FXR binding site when compared to 6-ECDCA (192 Figure 
6.4). Even if the junction between A/B rings is trans and the OH group at 
position 3 is in the β position with respect to the cocrystallized molecu, for 
all the complex models relative to compounds 200-207 and 209, the 
fundamental hydrogen bond contacts with the two amino acids of the catalytic 
triad462 (namely Tyr358 in helix 7, His444 in helix 10/11) are maintained.  
 
 
Figure 6. 12 Two different spatial arrangements of polyhydroxylated steroids 200-207 and 
209 in the binding site of FXR (chain A of crystal structure 1OSV). (A) Superposition of 6-
ECDCA (192, light blue) with compounds 200 (pink), 201 (red), 205 (yellow), 206 (green), 
and 207 (white). (B) Superposition of 6-ECDCA (192, light blue) with compounds 202 (blue), 
203 (purple), 204 (dark red), and 209 (orange). 
 
Consequently, it is possible to single out two different docking poses for 
these molecules: (a) the first one regards compounds containing the OH group 
at position 3 and/or the OH group at position 15 in a trans relationship (200, 
201, 205-207, Figure 6.12A), (b) the second family includes comp unds 
having the 3- and 15- OHs in a relative cis arrangement (202-205, and 209, 
Figure 6.12B). These results are also in agreement with the biological activity 
of our polyhydroxylated steroids (see above). Nevertheless, for all compounds 
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Figure 6. 13 Three dimensional models of docking pose of 
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As previously reported,463,464,465,466 the activation of FXR receptor by bile 
acids and bile acid analogues is affected by simultaneous presence of two R-
OH at position 3 and 7 and by a good balance between hydrophobic and 
hydrophilic substituents at the R and β face of the nucleus. Moreover, Fujino 
et al.463 have demonstrated that the introduction of β-alkyl and/or β-hydroxyl 
groups at 3 and/or 7 positions decreases the ligand potency. This kind of 
interactions are missing for the described compounds, and in fact all 
compounds, except theonellasterol G (205), failed in the activation of FXR at 
the concentration of 50 µM (see above). In particular, as depicted in Figure 
6.13A, the β-OH group at position 11 of compound 205 is involved in an 
additional hydrogen bond with Leu284 (Helix 3) with respect to its epimer 206 
(Figure 6.13C), where this interaction is lost. Moreover, even if also 203 and 
209 are able to interact with Ser329 (Helix 5) and Leu284 (Helix 3), they 
present a different spatial arrangement (Figures 6.12 and 6.13C) with respect 
to theonellasterol G (205), lacking some hydrophobic interactions with the 
amino acids of FXR ligand binding pocket (e.g., Trp466, Ile270, Thr267, 
Leu345, Figure 6.13). So, the described docking calcul tions point out that the 
simultaneous interactions467 of 6 with Helix 7 (Tyr358) and Helix 3 (Leu284) 
and its optimal hydrophobic contacts with the ligand binding domain 
compared to compounds 206 (only interacting with Helix 7) and 203 and 209, 
respectively (Figures 6.12 and 6.13), cause a great difference in activity 
between these sterols, suggesting that a correct orientation of the OH group at 
position 11 and the hydrophobic contacts with the receptor are critical for the 
FXR modulator activity. 
For what concerns the PXR468 agonist activity, the first observation 
suggested by molecular docking analysis regards the positioning of 
compounds 200-207 and 209 in occupying in the region of PXR’s expansive 
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Figure 6. 14 Three-dimensional model of the most representative polyhydroxylated steroids 
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Finally, compounds 207 and 209, featuring a methyl group at position 24, are 
endowed with a weaker agonist activity with respect to 200 and 203, bearing 
an ethyl group with different configuration. Even though compounds 207 and 
209 are able to interact by their side chain with Leu209, the obtained models 
suggest that their decreased activity is due to lacking interactions with Phe420, 
Leu411, and Phe429 (Figure 6.14). 
In summary, here it was described a novel class of FXR/PXR modulators of 
marine origin, and the above results pave the way to design new selective and 
potent modulators for human nuclear receptors. In particular, this series of 
marine sterols are endowed with potent PXR agonist activity and further 
studies are ongoing to define their potential applications in biomedical 
settings, such as liver toxicity induced by hepatotoxic drugs or sepsis. Of 
relevance, because both FXR and PXR exert antiinflamm tory effects in the 
intestine, a dual ligand holds potential in the treatment of inflammatory bowel 
diseases. Moreover, docking analysis validated the experimental biological 
results and allowed rationalization of the peculiarity activity of theonellasterol 
G (205).  
All together, these results suggested that 4-methylne sterols, proposed as 
ideal taxonomic markers for Theonella sponges, are FXR antagonists and PXR 
agonists. 
 
6.2.1 Computational Details 
Molecular docking calculations were performed by Autodock4.2 software56 
on quad-core Intel Xeon 3.4 GHz. A grid box size of 94 x 96 x 68 for FXR 
receptor, and of 90 x 106 x 92 for PXR rceptor with spacing of 0.375 Å 
between the grid points and centered for FXR at 20.689 (x), 39.478 (y), and 
10.921 (z), and for PXR at 14.282 (x), 74.983 (y), and 0.974 (z) covering the 




active site on the two targets surface was used. The Lamarckian genetic 
algorithm with an initial population of 600 randomly placed individuals, a 
maximum number of 5.0 x106 energy evaluations, and a maximum number of 
6.0x 106 generations were taken into account for dockings by Autodock4.2 
software. A mutation rate of 0.02 and a crossover rate of 0.8 were used. 
Results differing by less than 3.5 Å in positional rootmean-square deviation 
(rmsd) were clustered together and represented by the result with the most 
favorable free energy of binding. Illustrations of the 3D models were 
generated using the Chimera174 and the Python software.165 




6.3 Conicasterol E, a Small Heterodimer Partner Sparing 
Farnesoid X Receptor Modulator Endowed with a 
Pregnane X Receptor Agonistic Activity, from the Marine 
Sponge Theonella swinhoei 
Secondary metabolites from marine organisms collected at Solomon 
Islands,457 were found a single specimen of the sponge Th onella swinhoei as 
an extraordinary source of NRs steroidal ligands (Figure 6.15). Analysis of the 
polar extracts afforded solomonsterols A and B,295 two potent PXR agonists 
and new leads in the treatment of immune-driven inflammatory bowel 
diseases,473 whereas analysis of the apolar extracts allowed th isolation of a 
small library of 4-methylene steroids.294,474  
 
 
Figure 6. 15 Nuclear receptors ligands previously isolated from the marine sponge 
Theonella swinhoei. 




Importantly, even if the junction between A/B rings is trans and the OH 
group at position 3 is in the β position with respect to the natural ligand 
CDCA, the described docking studies demonstrated that all these compounds 
could be accommodated in the ligand binding domain of FXR, establishing 
hydrophobic and hydrogen bond contacts with the catalytic triad.462 
Furthermore, within this series, it was have demonstrated that a methyl group 
at position 24 (conicasterols B−D in Figure 6.15) allows stronger interactions 
with a shallow groove on the FXR molecular surface with respect to the ethyl 
group in theonellasterol-like compounds (theonellasterols B−H in Figure 
6.15).  
Here it will be described the rationalization at atomic level of the putative 
binding mode of conicasterol E (213),357 a 7α,15β-dihydroxyconicasterol 
analogue (Figure 6.16), as the first example of an SHP sparing FXR modulator 




Figure 6. 16 Conicasterol E (213), the first example of SHP-sparing marine FXR modulator. 
 
The structural characterization of conicasterol E was obtained from a 
detailde analysis of the COSY, TOCSY, ROESY, HSQC, and HMBC 
experiments. The configuration at C-24 was determined by comparison of 13C 
 
NMR data with literature data for epimeric
Retrospective analysis of NMR data of theonellasterol F (Figure 
previously isolated from the same sponge,
with conicasterol E (Figure 6.17).
 
Figure 6. 17 COSY connectivities (bold bonds) and HMBC (blue arrows) and ROESY 
correlations (red arrows) for conicasterol E (
 
Conicasterol E (213
(HepG2 cells) transfected with FXR, RXR, 
(pSG5FXR, pSG5RXR, and
vector that contains the promoter of the FXR target gene heat shock
(hsp27) cloned upstream the luciferase gene. As shown in Figure 
conicasterol E (213
contrast to CDCA (
conicasterol E (1) activates FXR with a bell shaped concentration
curve, the agonistic activity being part
as effective as CDCA (
potent than the synthetic FXR ligand 6
shown, 193, Figure 6.4
Human Nuclear Receptors Ligands
250 
 steroidal side chains.




) was tested in vitro using an hepatocarcinoma
β-galactosidase expression vectors 
 pCMV-βgal) and with p(hsp27)TKLUC reporter 
) activates FXR in transactivation assay. However, in 
191), the results of these experiments demonstrate that 
i lly reduced at 50 µM. At
191) in transactivation assay but significantly less 






 cell line 
 protein 27 
6.18, 
−response 
 10 µM, 1 was 




It was then tested whether conicasterol E (213) exerted any antagonistic 
activity against FXR. Because the above-mentioned results revealed a bell-
shaped curve in the concentration−response effect of compound 1 in 
transactivating FXR, the effects was tested of thisagent at 10 µM (data not 
shown) and 50 µM and found that compound 1 was devoid of any antagonistic 
activity when coadministered with CDCA (191) (Figure 5B) and 6-ECDCA 
(data not shown) to HepG2 cells. 
 
 
Figure 6. 18 (A) Relative potency of FXR activation by CDCA (191), 10 µM, conicasterol E 
(1), 10 µM, and 6-ECDCA (2), 1 µM, as measured by transactivation assay in HepG2 cells. 
(B) Conicasterol E (1), 50 µM, does not revert the effect of CDCA (191), 10 µM, on FXR 
transactivation in HepG2 cells. (C) Relative potency of PXR activation by rifaximin, 10 µM, 
and conicasterol E (1) alone, 10 µM, or in combination, 50 µM. Data are the mean ± SE of 
four experiments: (∗) P < 0.05 versus untreated cells (NT). 
 
In addition to an FXR agonistic activity, conicasterol E (213) effectively 
induced PXR expression, being as effective as rifaximin in inducing PXR 
transactivation (Figure 6.18C). Thus, conicasterol E (213) is a dual FXR and 
PXR agonist. To further characterize the biological activity of the conicasterol 
E (213), the effect of this agent on the expression of canonical FXR and PXR 
target genes in hepatocytes was examined, and as shown in Figure 6.19, it was 
found that exposure to conicasterol E slightly increased the expression of 




OSTα and BSEP mRNAs (two FXR regulated genes) and the expression of 
CYP3A4 mRNA (a PXR-regulated gene), while no effect was observed on 
SHP mRNA expression. In addition, in contrast to CDCA, 213 failed to 
repress CYP7A1. Thus, while the expression of this gene was reduced by 30% 
by CDCA, exposure to conicasterol E (213) increased CYP7A1 mRNA by 2- 
to 3-fold. These data are further evidence that in HepG2 cells repression of 
CYP7A1 by FXR is indirect and requires induction of SHP. 
 
 
Figure 6. 19 RT-PCR analysis of effects of CDCA (191), 10 µM, and conicasterol E (213), 10 
µM, on expression of FXR and PXR-regulated genes in HepG2 cells. Conicasterol E (213) 
does not induce SHP, whereas it induces the expression of CYP7A1. Data are the mean ± SE 
of four experiments: (∗) P < 0.05 versus untreated cells (NT); (∗∗) P < 0.05 versus CDCA 
alone. 
 
Further on, when administered in combination with a concentration of CDCA 
of 10 µM, conicasterol E exerted an additive effect with CDCA on the 
expression of OSTα and BSEP while no further changes were observed in the 
expression of SHP (Figure 6.20).  





Figure 6. 20 RT-PCR analysis of effects of CDCA (191), 10 µM, alone or in combination 
with conicasterol E (213), 10 µM, on expression of FXR-regulated genes in HepG2 cells. 
Conicasterol E (213) does not induce SHP even when cells were co-incubated with 3, while 
the association of the two agents partially attenuated the expression of OSTα but increased the 
expression of BSEP. Data are the mean ± SE of four experiments: (∗) P < 0.05 versus 
untreated (NT). 
 
Taken together, these data highlight that conicasterol E (213) is a FXR 
modulator whose potency on selective target genes is very close to that of the 
endogenous mammalian ligand CDCA (191) and lower than that of the 
synthetic agonist 6-ECDCA (192). Interestingly, conicasterol E (213) failed to 
stimulate SHP even when coadministered in combinatio  with CDCA (191). 
Finally, analysis of CYP3A4 expression, shown in Figure 6.21, demonstrated 
that conicasterol E (213) has no antagonistic effects on expression of CYP3A4 
mRNA induced by rifaximin, a potent PXR agonist. 
 
 
Figure 6. 21 Activation of CYP3A4 by the PXR agonist rifaximin, 10 µM, is not modulated 
by conicasterol E (213), 50 µM. Data are the mean ± SE of four experiments: (∗) P < 0.05 
versus untreated (NT). 




As reported in the previous paragraph,294 4-methylene sterols isolated from 
Theonella swinhoei are able to modulate in different ways the FXR activity 
depending on the steroid skeleton substitutions. On this basis and in order to 
describe at atomic level the interactions of 213 with FXR macromolecule, 
molecular docking calculations were performed using Autodock 4.2 
software.56 As shown in Figure 6.22A, the FXR binding site, located between 
helixes 2, 3, 5−7, and 10/11, is occupied by 213, and as previously reported,462 
the β-OH groups at positions 3 and 15 and the trans junctio  between A/B 
rings cause a different positioning with respect to he cocrystallized molecule 
6-ECDCA (192). In particular (Figure 6.22B) conicasterol E (213), compared 
to the synthetic agonist 6-ECDCA (192), is able to interact with two amino 
acids of the catalytic triad formed by Tyr358 in helix 7, His444 in helix 10/11, 
Trp466 helix 12, responsible for the activation of FXR.33  
 
 
Figure 6. 22 (A) Superimposition of 213 (yellow) with 6-ECDCA (192) (red) in the binding 
pocket of FXR (PDB code 1OSV). (B) Amino acids interacting with 6-ECDCA (red) are 
depicted in purple. Amino acids interacting with 213 (yellow) are depicted in green, and 
amino acids interacting with both molecules are depict d in light blue. 
 




Specifically, the 3-OH group at β position forms a hydrogen bond with Tyr358 
in helix 7, while the trans junction between the A/B ring allows a hydrophobic 
interaction with His444 (helix 10/11). The influence of the side chain on the 
FXR binding, it was already described,294 and in fact, the methyl at position 24 
of conicasterol E (213) (yellow, Figure 6.22B) relating to 6-ECDCA (192) 
(red, Figure 6.22B) is able to simultaneously interact with the Met262 (coil 2), 
His291 (helix 3), and Met287 (helix 3) present on the shallow groove of the 
FXR molecular surface protruding toward the solvent. Moreover, the OH at 
position 15β in 213 forms an additional hydrogen bond with the CO of Leu284 
(helix 3), and the steroid skeleton is in close contact with Leu345, Ala288, 
Met447, Phe326, and Trp451 relating to the 6-ECDCA (192). On the other 
hand, the OH at 7α position does not seem to exert further polar interactions 
with the FXR binding site. In summary, conicasterol E (213) presents a 
different spatial arrangement relating to the cocrystallized molecule 6-
ECDCA; however, the reoprted docking calculations point out that its 
simultaneous and efficient hydrophobic and hydrophilic additional interactions 
with the receptor binding site might be responsible for its agonist activity on 
FXR. Further on, the exclusive amino acid interactions exerted by conicasterol 
E (213) might support the notion that the compound is an FXR modulator 
endowed with the ability to activate OSTα and BSEP without effect on SHP 
expression.  
 
6.3.1 Computational Details 
Molecular docking calculations were performed by Autodock 4.2 
software56 on quad-core Intel Xeon 3.4 GHz, using a grid box size of 94 × 96 
× 68, with spacing of 0.375 Å between the grid points and centered at 20.689 
(x), 39.478 (y), 10.921 (z), covering the active site of the FXR.462 To achieve a 




representative conformational space during the docking studies and for taking 
into account the variable number of active torsions, 10 calculations the ligand. 
The Lamarckian genetic algorithm (LGA) was employed for docking 
calculations, choosing an initial population of 600 randomly placed 
individuals. The maximum number of energy evaluations and of generations 
was set up to 5 × 106 and to 6 ×106, respectively. Results differing by less than 
3.5 Å in positional rootmean-square deviation (rmsd) were clustered together 
and represented by the result with the most favorable free energy of binding. 
Illustrations of the 3D models were generated using the Chimera174 and the 
Python software.165 




6.4 4-Methylenesterols from Theonella swinhoei Sponge are 
Natural Pregnane-X-Receptor Agonists and Farnesoid-X-
Receptor Antagonists that Modulate Innate Immunity 
Marine sponges of the genus Theonella have attracted a great interest from 
the scientific community for the impressive variety of bioactive secondary 
metabolites with unusual structures and powerful biological activity. In a 
recent report Crews et al.476 pointed on the existence of at least three 
phenotypes of Theonella swinhoei,477 and observed that the morphology of the 
sponge has some influence on the chemical composition.  
Studying the biodiversity associated to the marine organisms collected at 
Solomon Islands, three Theonella swinhoei specimens was analyzed, two of 
them, whose macroscopic morphology could be ascribed to phenotype I, have 
been subjected by extensive chemical investigation hat disclosed those 
specimens as invaluable sources of new secondary metabolites. These two 
sponges were found to contain swinholides,478 theonellamide A, 
antiinflammatory new perthamide derivatives,458,459 a new class of cyclic 
peptides, solomonamides,460 and new truncated-chain sulfated steroids, 
solomonsterols.295,473 
With surprise, none of the above metabolites was found in the third taxonomic 
voucher, ascribable to phenotype III, even if field collection data (date, site, 
depth) were very similar. On the other hand, when the apolar extracts was 
investigated, in all three specimens, a great variety of polyhydroxysteroids all 
characterized by a 4-methylene functionality was found.  
The isolation of several polyoxygenated 4-methylenesteroids293,294 from the 
two “PKS and NRPS producing” specimens (phenotype I) was recently 
reported, mainly possessing a 24-ethyl side chain (F gure 6.23) and their 




pharmacological evaluation as modulators of two well known nuclear 
receptors, FXR and PXR.  
 
 
Figure 6. 23 Theonellasterols and conicasterols previously isolated from Theonella swinhoei. 
 
The analysis of the apolar extract of the third specim n evidenced again the 
presence of a family of polyhydroxy steroids but in this case most of them 
featuring a 24-methyl side chain (Figure 6.24, coniasterols G-K, 214-218), 
including known conicasterol (199)479 with its 7- and 15-hydroxy derivatives 
(221 and 222),480 dehydroconicasterol (220),481 and the 8-14-seco, 
swinhosterol B (223)482 (Figure 6.25). Trace of a new theonellasterol-like 
derivative, theonellasterol J (219), was also isolated.  
The structural characterizations of compounds were d t rmined by detailde 
analysis of the COSY, TOCSY, ROESY, HSQC, and HMBC experiments 
(See Figure 6.26). The 24R stereochemistry of the side chains of conicasterols 
G-K (214-219) and 24S of theonellasterol J (219) were determined by 
comparison of 1H 483 and 13C chemical shifts.484 






Figure 6. 24 New 4-methylene-sterols isolated from Theonella swinhoei, phenotype III. 
 
 
Figure 6. 25 Known 4-methylene-sterols isolated from Theonella swinhoei, phenotype III. 
 
The structures of compounds 199, 220-223 as conicasterol, 
dehydroconicasterol, 7α-hydroxyconicasterol, 15β-hydroxyconicasterol, and 
swinhosterol B, respectively, were deduced by NMR and mass analysis and by 
direct comparison of their chemical shift data with existing literature 
values.479-482 






Figure 6. 26 Key HMBC correlations for conicasterols G (214), H (215), J (216) and K (218). 
 
As mentioned before, a deep investigation of steroidal composition of 
Theonella swinhoei phenotype I has demonstrated that these specimens 
produce almost exclusively 24-ethylsterols (Figure 6.23), which were already 
reported, and most of them endowed with potent activity towards to well know 
nuclear receptors, FXR and PXR.294,474 Within this library of compounds 
(Figure 6.23), it was also established that the presence of a methyl group at 
position 24 (conicasterols B-D) allows stronger interactions in the external 
part of FXR molecular surface, with respect to compunds bearing an ethyl 
group (theonellasterols B-H).  
Therefore, following this recent acquisition, all compounds isolated from 
Theonella swinhoei phenotype III (Figures 6.24-25) were tested in vitro, using 
an hepatocarcinoma cell line (HepG2 cells) transfected with FXR, RXR, β-
galactosidase expression vectors (pSG5FXR, pSG5RXR and pCMV-βgal), 




and with p(hsp27)TKLUC reporter vector that contains the promoter of the 
FXR target gene heat shock protein 27 (hsp27) cloned upstream the Luciferase 
gene (Figure 6.27). HepG2 cells were stimulated with 10 µM of compounds 1-
11 with or without 10 µM CDCA. As shown in Figure 6.27, even if none of 
these compounds appears to be an FXR agonist in the transactivation assay, 
several compounds, tested at the concentration of 50 µM, showed a slight 
inhibitory activity against FXR transactivation induced by 10 µM of CDCA 
with conicasterol H (215), conicasterol J (214), swinhosterol B (223) and the 
parent conicasterol (199) the most potent of this series.  
 
 
Figure 6. 27 Luciferase reporter assay performed in HepG2 transiently transfected with 
pSG5-FXR, pSG5-RXR, pCMV-βgalactosidase, and p(HSP27)-TK-Luc vectors and 
stimulated 18 h with (A) CDCA (10 µM) and compounds 214-223 (10 µM). (B) CDCA (10 
µM) alone or in combination with compounds 1-11 (50 µM). *P < 0.05 versus not treated 
(NT). **P < 0.05 versus CDCA (n = 4). 
 
In addition to an FXR antagonistic activity, many of these steroids effectively 
induced PXR expression with compounds 199 and 218-219 and compounds 
221-223 being as effective as rifaximin in inducing PXR transactivation 





























































































Because these data indicated that 4-methylenesterol from Theonella hold the 
potential to act as PXR agonists and FXR antagonists, and they hold potential 
in treating human disorders, the activity was furthe  characterized of a select 
sample against expression of a whole family of nuclear receptors. Among all 
molecules showing this dual behavior, swinhosterol B (223) was selected 
because it is a potent PXR agonist endowed with a robust FXR antagonism 




Figure 6. 28 Luciferase reporter assay performed in HepG2 transiently transfected with 
pSG5-PXR, pSG5-RXR, pCMV-βgalactosidase, and p(CYP3A4)-TK-Luc vectors and 
stimulated 18 h with (A) rifaximin (10 µM) and with 1-11 (10 µM). (B) Rifaximin (10 µM) 
alone or in combination with 1-11 (50 µM). *P < 0.05 versus not treated (NT).**P< 0.05 
versus rifaximin (n = 4). 
 
By profiling the expression of 86 genes using a microarray system (Figure 
6.29), it was found that exposure of human HepG2 cells to 10 µM of 
swinhosterol B (223) had no effect on the expression of the waste majority f 



























































































































Figure 6. 29 RT2 profile PCR array analysis showing the relative mRNA expression of (A) 
various nuclear receptors, (B) histone deacetylases nd (C) transcriptional co-regulators (co-
activators and co-repressors) following stimulation of HepG2 cells with 10 µM swinhosterol B 
(11). Data are the mean ± S.E. of three experiments. 
 
However, 223 induced the expression of ESR1, NC0A6, NR1D2, NR2C1, 
PPARGC1A, PSMC3, PSMC5, RARG, RORA and RXRA. None of these 
genes were known target for FXR or PXR. Because the above mentioned data 
suggested that swinhosterol B (223) is a PXR agonist and FXR antagonist, it 
was then investigated whether this agent modulate immune response of 
macrophages. Both PXR and FXR have been shown to exert 
immunomodulatory effects on macrophages. Results of these experiments 
demonstrate that swinhosterol B (223) effectively counteracts stimulation of 
hPXR-macrophages caused by LPS. Indeed, at the concentration of 10 µM, 
swinhosterol B (223) causes a robust attenuation of TNFα, IL-1β and IL-6 
generation induced by LPS.  
To further investigate if the FXR antagonistic profile was maintained in 
macrophages expressing the murine PXR, we have challenged spleen-derived 
monocytes with swinhosterol B (223) in the presence of LPS. In this context 
swinhosterol B (223) fails to inhibit cytokine generation caused by LPS 















































































































































































































































































































































































































recognize the murine PXR. It was investigated whether ese immunological 
effects extended to cells of adaptive immunity. Forthese purposes CD4+ T 
cells were prepared from the spleen on transgenic mice expressing the hPXR 
and wild type mice expressing the murine PXR. Data shown similarly to 
solomonsterol A, a sponge steroid endowed with potent PXR agonistic 
activity, swinhosterol B (223) had no effect on generation of IFNγ, but 
potently stimulated the production of IL-10, an anti-i flammatory cytokine 
from cells isolated from hPXR transgenic mice. The relative potency of the 
effect of swinhosterol B (223) at the concentration of 10 µM was comparable 
to that of solomonsterol A, 10 µM, and to that of T cell activator and mitogen 
concanavallin A, 2 µg/ml.  
Of interest, the ability to induce IL-10 mRNA was lost in CD4+ T cells 
prepared from wild type mice, i.e. mice expressing the murine PXR. Thus 
swinhosterol B (223) induces generation of anti-inflammatory IL-10 via 
induction of PXR.  
The FXR antagonistic effect of swinhosterol B (223) was finally assayed in 
HepG2 cells stimulated with the FXR agonist CDCA. Stimulation of HepG2 
with 223 was itself sufficient to inhibit FXR target genes such as OSTα, BSEP 
and SHP. In addition, when 223 was combined with CDCA, a robust down-
regulation of FXR target genes mediated by CDCA was reported. The 
antagonistic activity of 223 was maintained also for CYP7A1. Indeed, this 
gene was down-regulated by CDCA and this inhibition was significantly 
reversed by 223 co-treatment. 
In order to rationalize the binding mode of the 4-methylenesterols isolated 
from Theonella swinhoei sponge on FXR receptor, molecular docking 
experiments were performed using Autodock 4.2 software.56 In particular, here 
it was report the detailed binding mode analysis of sterols with new 




substitution patterns (214 and 217) and/or with different or original nuclei 
(199-223) to obtain useful information for tracing a detailed and accurate 
profile of new potential steroid-based FXR antagonists. 
Considering the possible hydrophilic interactions with the FXR ligand binding 
domain, the attention on 214, 217 and 223 was focused presenting both 
carbonyl and hydroxyl groups in different position f tetracyclic nucleus. In 
this way, comparing docking results, it is possible to rationalize the influence 
of the different H-bond donor and acceptor pattern on steroids biological 
activity. For these reasons, it was excluded from the reported discussion the 
detailed analysis of compounds with only one OH group at C-7 as in 
compound 9 or at C-15 as in compound 222 or, as the case of conicasterol I 
(216), presenting the same nucleus of theonellasterol G, a ready described.294  
For what concern the other compounds, comparing the div rse rigidity of 
the nucleus of conicasterol (199) vs conicasterol K (218), and swinhosterol B 
(223) combined with the different substitution at the C-24 (219, 199 and 220), 
it was tried to rationalize the influence of the hydrophobic interactions on FXR 
antagonist behavior of marine steroids. On this basis, the compounds of the 
series (214, 199, 217-220, and 223) are able to interact by the OH at C-3 with 
FXR catalytic triad (namely Tyr358 in Helix 7, His44  in Helix 10/11, Trp466 
Helix12)462 (Figure 6.30A), that, as reported in previous studies293,294,474 
represents one of the principal factor responsible of activity on the nuclear 
receptor. In particular conicasterol (199) and swinhosterol B (223), both able 
to antagonize CDCA, form hydrogen bonds with Tyr358 (Helix 7) and His444 
(Helix 10/11); on the other hand conicasterol G (214), conicasterol J (217), 
theonellasterol J (219), and dehydroconicasterol (220) interact only with the 
hydroxyl group of Tyr358 (Helix 7). Comparing the docking pose of the series 
(Figure 6.30A) with respect to the co-crystallized agonist 6-ECDCA and the 
 
isomers E and Z of gugglusterone (
molecules bind the FXR binding pocket formed between the Helix 2, 3, 5
and 10/11.  
 
Figure 6. 30 (A) Superimposition of 6
gugglusterone (196) with 
(red), 220 (brown), and 
FXR molecule is depicted by purple ribbon and the crucial amino acids by sticks
type: C, purple; O, red; N, dark blue, H, white). (B) Amino acids interacting with 6
(sky blue) and Z (yellow)/
interacting with 199 (red) are depicted in green.
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positioning, causes a different spatial arrangement with respect the well known 
ligands missing some hydrophobic interactions with the amino acids of the 
FXR binding site (Phe326, Phe333, Met362). 
reported in our previous study
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receptor with respect to theonellasterol J (219), bearing an ethyl group with 
different configuration at the same position (Figure 6.31A).  
On the other hand, the major rigidity of the side chain of 
dehydroconicasterol (220) in comparison with the parent conicasterol (199) 
(red) does not allow further hydrophobic interactions with Met262 (Coil 2) 
and His291 (Helix 3). Moreover, the different positioning of the unsaturations 
of conicasterol K (218) and theonellasterol J (219) with respect to conicasterol 
(199) (red) and dehydroconicasterol (220) causes a further loss of hydrophobic 
interactions with the amino acids Leu284, Ile349, and Ile354 (Figure 6.31A). 
On the other hand, the unusual open nucleus of swinhosterol B (223) 
maintains the same hydrophobic interactions with respect to 199 with the 
exception of Leu284 and Met262 (Figure 6.31A).  
Considering the other nucleus substitutions, the inv rted positions of CO 
and OH groups at C-7 and C-15 of conicasterols G (214) and J (217) cause a 
different pattern of hydrogen bonds; in fact conicasterol G (214) is in close 
contact only with Ser329, while the α-OH at C-7 of conicasterols J (217) 
forms two hydrogen bonds with FXR binding pocket, as H-bond acceptor with 
OH of Ser329 and as H-bond donor with the OH group f Tyr366. Moreover 
its CO at C-15, as well as the carbonyl group at C-14 of 11, establishes a 
further weak interaction with Ser329 (Figure 6.31B). 
In summary, the different substitutions on the steroid skeleton cause a great 
discrepancy in the pharmacological activity among this class of sterols; in 
particular only swinhosterol B (223), conicasterol (199) and conicasterol J 
(217) exhibit antagonist activity. 
 
Figure 6. 31 (A) Superimposition between 
(brown), and 223 (eme
different hydrogen bond pattern of 
both figures the crucial amino acids of FXR receptor are depicted by purple sticks.
 
The lack, in fact, of simultaneous and efficient hydrophobic additional 
interactions of 218, 
pattern of hydrogen bond of 
these contacts are critical for the competition
FXR binding site, but they are not sufficient for the receptor activation.
Moreover, on the basis of the above biological results, among the whole 
library (Figures 6.24
new potential therapeutic agent with double opposite activity on FXR and 
PXR. For this reason, 
modeling studies, the bases of its PXR agonist behavior. As reported above, 
the Autodock4.2 software
human nuclear pregnane
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PXR470,471,472 presents a large ligand binding cavity
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 with 6-ECDCA in occupying 
-25), swinhosterol B (223) was also disclosed as unique 
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56 was utilized for the docking experiments using the 
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three different docking poses for the marine swinhosterol B (
in Figure 6.32, the OH at C
of Ser247, and with CO of His407 for the docking poses A, B, C, respectively. 
 
Figure 6. 32 Three dimensional models of the possible docki
B (223) with hPXR. 
 
The CO at C-8 establishes further hydrogen bonds with OH of Ser 247 for 
pose A, while the CO at C
Besides the different pattern of hydrogen bonds, all the 
establish different Van der Waal interaction with PXR large ligand binding 
pocket (Figure 6.32
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function strongly supports the exploitation of this compound in rodent model 
of liver inflammation and cholestasis.  
 
6.4.1. Computational Details.  
Molecular docking calculations were performed by Autodock 4.2 software56 
on 4 x AMD Opteron SixCore 2.4Ghz. A grid box size of 94 x 96 x 68 for 
chain A of FXR (pdb code:1OSV),462 and 90 x 106 x 92 for PXR (pdb code: 
1M13)468 was used with spacing of 0.375 Å between the grid points, and 
centered at 20.689 (x), 39.478 (y), 10.921 (z) betwe n the SCH3 of Met262 
and the OH group of Thr267 for FXR, and at 14.282 (x), 74.983 (y), 0.974 (z) 
between the ring of His407 and the side chain of Leu209 for PXR, covering 
the active site of both the receptors. To achieve a representative 
conformational space during the docking studies and for taking into account 
the variable number of active torsions, 10 calculations consisting of 256 runs 
were performed, obtaining 2560 structures for each ligand. The Lamarckian 
genetic algorithm (LGA) was employed for docking exp riments, choosing an 
initial population of 600 randomly placed individuals. The maximum number 
of energy evaluations and of generations was set up to 5 x 106 and to 6 x 106 
respectively. For all the docked structures, all bonds were treated as active 
torsional bonds except the bonds in cycles, which are considered fixed 
together with the receptors. Results differing by less than 3.5 Å in positional 
root-mean-square deviation (RMSD) were clustered together and represented 
by the result with the most favorable free energy of binding. Illustrations of 
the 3D models were generated using the Python165 a d Chimera174 software. 
 




6.5 Discovery of theonellasterol a marine sponge sterol as a 
highly selective FXR antagonist that protects against liver 
injury in cholestasis 
In this paragraph, it will be described is a highly selective FXR antagonist 
4-methylenesteroid isolated from the Theonella swinhoei sponge (Figure 
6.33).359 
 
Figure 6. 33 Chemical structure of theonellasterol isolated from Theonella swinhoei. 
 
The initial processing of the Theonella swinhoei was conducted according 
to procedures described previously.294 The identity of theonellasterol was 
secured by comparison of its NMR and MS spectrum with those previously 
reported.479 
By transactivation and microarray analyses carried out in HepG2 cells, a 
human hepatocyte cell line, it was found that theonellasterol is a selective FXR 
antagonist, devoid of any agonistic or antagonistic activity on a number of 
human nuclear receptors including the vitamin D receptor, PPARs, PXR, LXR 
and progesterone, estrogen, glucorticoid and thyroid receptors, among others. 
Exposure of HepG2 cells to theonellasterol antagonizes the effect of natural 
and synthetic FXR agonist on a number of FXR target genes, including SHP, 
OSTα, BSEP and MRP4. Using this agent a proof-of-concept study was have 




carried out to investigate whether FXR antagonism rescues mice from liver 
injury induced by the ligation of the common bile duct, a model of cholestasis. 
Results from this experiment demonstrates that theonellasterol rescues mice 
from liver injury caused by bile duct ligation as measure by assessing serum 
alanine aminostrasferase levels and extent of livernec osis at histopathology. 
Analysis of genes involved in bile acid uptake and excretion by hepatocytes 
reveals that theonellasterol increases the liver expression of MRP4. 
Administering bile duct ligated mice with a FXR agonist failed to rescue from 
liver injury and profoundly downregulated the expression of MRP4. Present 
results demonstrate that FXR antagonism effectively r gulates expression of 
MRP-4 in the liver and is a feasible strategy to target obstructive cholestasis. 
As already reported by Soissonet al.,485 the flexible nature of FXR side 
chains suggests that its ligand binding domain (LBD) may have considerable 
ability to accommodate differently shaped ligands changing in response to the 
binding with them. For these reason, in order to raion lize the binding mode 
of theonellasterol on FXR receptor, molecular docking calculations (by 
Autodock 4.2 software)56 were performed on several FXR structures co-
crystallized with different compounds462,486,487,488 with the aim to predict the 
position of the LBD in complex with marine sterol 198. As reported, the 
activation of the FXR by the sterols molecules is, among the others, regulated 
by the interaction between the OH at C-3 of steroid skeleton and the amino 
acids of the catalytic triad (namely Tyr in Helix 7, His in Helix 10/11, Trp 
Helix12).462 In all the three dimensional models (Figure 6.34A) the 
theonellasterol is able to interact with the catalytic triad, and in particular it 
forms a hydrogen bond with Tyr358 and 365 in Helix 7 for the pdbs 1OSV462 
and 1OSH486 respectively, and with His447 for the pdbs 3DCT,487 3BEJ,485 
3RUU,488 and His444 for 1OSV462 (Helix 10/11).  






Figure 6. 34 (A) Superimposition of the different docking poses of theonellasterol (198) in the 
rat FXR (198 and 1OSV462 yellow), and human FXRs (198 and 3BEJ485 orange; 198 and 
1OSH486 pink; 198 and 3DCT487 purple; 198 and 3RUU488 light blue). (B) Superimposition of 
theonellasterol (yellow) with 6-ECDCA (sky blue), and Z (pink)/ E (light pink) gugglusterone 
in the binding pocket of FXR (1OSV). Amino acids interacting with theonellasterol (yellow) 
are depicted in green, amino acids interacting with6-ECDCA and theonellasterol are depicted 
in sky blue, amino acids interacting with Z/E gugglusterone and theonellasterol are depicted 
light pink, amino acids interacting with 6-ECDCA and Z/E gugglusterone in red, and amino 
acids interacting with all molecules are depicted in blue. 
 
On the other hand, only in the three dimensional models with 3DCT,487 
3RUU,488 and 1OSV462 the marine sterol establishes hydrophobic interactions 
with Helix 12 and in particular with the Trp469 (3DCT,487 3RUU,488) or 
Trp466 (1OSV462). Considering also the others interactions with the LBD, the 
complex with the 1OSV462 was chosen for the molecular docking analysis 
because 198 and 6-ECDCA (192, Figure 6.4) show similar chemical features 
with respect to the other molecules co-crystallized with the FXR considered 
structures.  
On this basis, in addition to the two hydrogen bonds (Figure 6.34B) 
between theonellasterol with Tyr358 (Helix 7) and His444 (Helix 10/11) 




reported above, the trans junction between A/B rings and its peculiar 
unsaturation between C-8 and C-14 cause a different spa ial arrangement 
(Figure 6.34B) with respect to the semi-synthetic agonist 6-ECDCA462 (192, 
Figure 6.4) and the natural antagonist guggulsterone445c,d (196, Figure 6.4) 
isomers not allowing the hydrophobic contact with Met362, Phe326, Phe333 
and Tyr366. On the other hand, the 198 steroid skeleton interacts with Leu345 
and Trp466 in the same manner of guggulsterone and 6-ECDCA respectively, 
and with Ala288, Leu284, and Met447; while its alkylic chains is in close 
contacts with Arg328 and His291, and with Ile332 (See Figure 6.34B) as 
reported for 6-ECDCA and guggulsterone respectively.  
Furthermore, 198 maintains the same hydrophobic interactions of 6-
ECDCA and guggulsterone with His444, Ile349, Met287, Met325, Ser329, 
Tyr358 in the ligand binding site. In conclusion, even if the sterol 1 shows a 
more simple skeleton with respect to the 4-methylene steroids previously 
reported in the paragraoh 6.2,294 these docking results suggest that the different 
pattern of hydrophobic interactions established with FXR may be efficient and 
critical for the competition of theonellasterol with 6-ECDCA in occupying the 
FXR binding site.370,294,462,445c,d,489 
 
6.5.2. Computational Details 
The molecular docking calculations were performed by Autodock 4.2 
software56 on 4 x AMD Opteron SixCore 2.4Ghz, using a grid box size of 94 x 
96 x 68, with spacing of 0.375 Å between the grid points, and centered at 
20.689 (x), 39.478 (y), 10.921 (z), covering the active site of the 
FXRs.462,485,486,487,488 To achieve a representative conformational space during 
the docking studies and for taking into account the variable number of active 
torsions, 10 calculations consisting of 256 runs were performed, obtaining 




2560 structures for the sterol 198. The Lamarckian genetic algorithm (LGA) 
was employed for docking calculations, choosing an initial population of 600 
randomly placed individuals. The maximum number of energy evaluations and 
of generations was set up to 5 x 106 and to 6 x 106 respectively. Results 
differing by less than 3.5 Å in positional root-mean-square deviation (RMSD) 
were clustered together and represented by the most favorable free energy of 




















The Bile Acid Receptor GPBAR-1 (TGR5) 
Agonists 




7.1 The Bile Acid Receptor GPBAR-1 (TGR5) Modulates 
Integrity of Intestinal Barrier and Immune Response to 
Experimental Colitis 
In this chapert, it will be described the rationaliz t on of the binding mode 
of two known anti-inflammatory drugs taurolithocholic (224, Scheme 7.1) acid 
and ciprofloxacin (225, Scheme 7.1) with the Bile Acid Receptor GPBAR-1 
(TGR5), acting as agonist of this nuclear receptor.296  
Bile acids play an essential role in integrating multiple homeostatic 
functions in the liver and gastrointestinal tract. In recent years these end-
product of cholesterol metabolism have been shown to signal through 
activation of variety of nuclear and cell surface receptors.490 Activation of 
Farnesoid-x-receptor (FXR), pregnane-x-receptor (PXR), and constitutive 
androstane receptor (CAR), along with the vitamin D receptor (VDR), by 
primary bile acids chenodeoxycholic acid (CDCA, 191 in Figure 6.4) elicits a 
series of genomic effects that have been deemed essential for regulation of 
lipid, cholesterol and bile acid homeostasis, local immune response and insulin 
signaling in intestinal and liver tissues.490,491 Knocking down the expression of 
FXR, the main bile acid receptor, results in a multilevel dysregulation of 
glucose, lipid, cholesterol and protein metabolism, highlighting the essential 
role of this receptor in maintaining homeostasis in entero-hepatic tissues.490,491 
In addition, bile acids exert non-genomic effects.490,491 These non-genomic 
effects have been ascribed to the activation of a cell surface receptor named 
TGR5 or M-BAR, a member of the rhodopsin-like superfamily of G protein 
coupled receptor (GPCR), recently christened as a bile acid-activated GPCR 
(GP-BAR1).492,493 GP-BAR1 is restricted to a limited number of tissue , with 




the highest expression detected in brown adipose tissue, spleen, 
macrophages/monocytes, gallbladder and intestine.492,493,494  
In the small and large intestine, GP-BAR1 has been detected in the enteric 
ganglia of the myenteric and submucosal plexus, in the muscularis externa and 
in the mucosa, in enterocytes of the crypts and villi, while in the cecum and 
colon the receptor is expressed, thought at lower, in muscle layers and 
mucosa.495 In target cells, GP-BAR1 activation by secondary bile acids, 
lithocolic acid (LCA) and tauro-LCA (TLCA), increase  the intracellular 
concentrations of cyclic adenosine monophosphate (cAMP) and causes the 
receptor internalization.490,491,492,493 In intestinal endocrine L-cells that are 
higly enriched in receptor expression, GP-BAR1 activ tion by bile acids and 
dietary agents stimulates the secretion of glucagon-like peptide (GLP)-1, an 
insulinotropic hormone that regulates insulin and glucagon secretion along 
with gastrointestinal motility and appetite.490,491,492,493,496 In addition to its 
intestinal localization, GP-BAR1 has been detected in peripheral blood 
derived macrophages and liver macrophages where it exerts an immune-
modulatory activity.491,493 This activity is inhibitory in nature and manifests 
itself by attenuation of macrophage’s effector functions including reduction of 
phagocytic activity as well and generation of lipopolysaccharide (LPS)-
stimulated cytokines (TNF-a, IL-1a, IL-1b, IL-6, and IL-89).491,497  
Despite its role in integrating intestinal homeostasis and glucose 
metabolism is well defined, it is not known whether GP-BAR1 participates 
into local regulation of intestinal inflammation and whether its ablation would 
manifest by an exaggerated inflammatory response to intestinal antigens. 
Because the expression of GPBAR1 is highly restricted to the intestine and 
identification of a regulatory role would be of interest to ground intestine-
specific anti-inflammatory therapies, it was investiga ed whether GPBAR1 




plays a functional role in regulating intestinal homeostasis and inflammation-
driven immune response.  
As for the majority of G-protein-coupled receptors (GPCRs), the structure 
of TGR5 has not yet been determined experimentally, nd so a homology 
modeling study was performed in order to obtain theree dimensional 
structure of the receptor. In particular, basing on the good recent results 
obtained by Hov et al.498 the human adenosine A2a receptor was used as 
template for our modeling studies. After this preliminary step, the predicted 
TGR5 structure (Figure 7.1) was used to analyze, by means of molecular 
docking calculations, the interactions of the agonist taurolitholic acid (224, 
Scheme 7.1), and ciprofloxacin (225, Scheme 7.1) with the model of the G-
protein-coupled receptor in order to generate a structu e-activity relationship 














Scheme 7. 1 Chemical structure of  t-LCA (224),  and ciprofloxacin (225). 
 
As reported in the previous work the binding site of the agonist is located at 
the N-terminal-extracellular portion,499 and so the reported docking 
calculations (Autodock4.2 software)56 was focused around this protein portion.  





Figure 7. 1 Predicted three dimensional model of the TGR5 receptor. 
 
The TLCA derivative presents an EC50 of ~300 nM; as previously reported 
by other research groups, the hydroxyl group at C-3 is involved in hydrogen 
bond interactions with the receptor and removal of this group causes decrease 
in potency toward TGR5 activation.499,500,501 As shown in Figure 7.2, the BA 
accommodates on the TGR5 receptor surface, and it is involved in van der 
Waals interactions with Trp65, Asn66, Ser68, Arg69, Asn144, Cys145, 
Ser146, Leu231, Leu235. The OH at C-3 interacts with hydroxyl groups of 
Tyr209 and Ser147, the NH of the taurine interacts wi h CO of Gln67, also in 
agreement with the hydrogen bond model proposed by Tiwari et al.,499 and the 
sulfate group protrudes toward the solvent. 
Impossibile v isualizzare l'immagine. La memoria del computer potrebbe essere insufficiente per aprire l'immagine oppure l'immagine potrebbe essere danneggiata. Riavviare il computer e aprire di nuovo il file. Se v iene visualizzata di nuovo la x rossa, potrebbe essere necessario eliminare l'immagine e inserirla di nuovo.
 
Figure 7. 2 Three dimensional model between TLCA 
TGR5 receptor. 
 
For what concerns the
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and also its piperazine gr
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Figure 7. 3 Three dimensional model between ciprofloxacin 
of TGR5 receptor. 
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All these findings, regarding the binding pose of ciprofloxacin in the same 




Figure 7. 4 Superimposition of TLCA (purple) and ciprofloxacin (yellow) on and calculated 
structure of TGR5 receptor.the TGR5 surface. 
 
Results of docking studies were confirmed by in vitro studies in GLUTag 
cells, a cell line highly enriched in GP-BAR1.502 Exposure to ciprofloxacin 
(Figure 7.5A) resulted in a concentrationdependent increase of ([cAMP]i) with 
an EC50 of <8 mM (n =3). Ciprofloxacin, 10 mM, was as effective as 10 mM 
TLCA (n =3).  
In the search for ligand that could be exploited therapeutically as GP-BAR1 
ligand, we have identified ciprofloxacin as a GP BAR1 agonist. Ciprofloxacin, 
is widely used in the treatment of infections due to Gram negative bacteria in 
Crohn’s disease. In addition, ciprofloxacin has been shown to increase 
([cAMP] i) in monocytes and macrophages, and by this mean to exert a 
Impossibile v isualizzare l'immagine. La memoria del computer potrebbe essere insufficiente per aprire l'immagine oppure l'immagine potrebbe essere danneggiata. Riavviare il computer e aprire di nuovo il file. Se v iene visualizzata di nuovo la x rossa, potrebbe essere necessario eliminare l'immagine e inserirla di nuovo.




counterregulatory effect on cytokine production triggered by LPS.503 So far the 
molecular mechanisms mediating these effects were left unknown. 
 
 
Figure 7. 5 Panel A. Ciprofloxacin and TLCA increases ([cAMP]i) in GLUTag cells. N= 4; 
P,0.05. Panel B. Ciprofloxacin and taurolithocholic acid , 10 mM, caused a 2–3 fold increase 
in ([cAMP]i) in spleen-derived monocytes isolated from GP-BAR1 wild type mice (n = 4–5; 
P,0.05), but not in cells isolated from GP-BAR12/2 mice. Panel C. Ciprofloxacin, 10 mM, 
inhibits LPS-induced TNFa release in GP-BAR1+/+ monocytes but not in cells isolated from 
GPBAR1 2/2 mice (n = 6; P,0.05 versus naive). 
 
 




By in silico screening, docking calculation and in vitro experiments have 
shown that ciprofloxacin functions as GPBAR1 agonist. Indeed, not only 
ciprofloxacin entertains meaningful interaction with key aminoacids in the 
binding site of GPBAR1, as demonstrated by docking experiments, but it 
triggers changes in [cAMP]i in GLUTag cells, an L-like cell line generated 
from an entero-endocrine tumor and highly enriched in GPBAR1, and in 
spleen-derived monocytes.490,491,492,493,502 In summary, GP-BAR1 is involved 
in regulating intestinal homeostasis and that its ab ence manifests by an 
increased intestinal permeability and enhanced susceptibility to develop colitis 
in response to barrier braking agents. Expression of GP-BAR1, in fact, 
increases in response to inflammation in rodent models of colitis and in 
inflamed tissues obtained from Crohn’ disease patients. Moreover, here it was 
discovered that ciprofloxacin, a widely used antibiotic, is a GP-BAR1 agonist 
and that activation of GP-BAR1 with this agent or oleanolic acid, a natural 
GP-BAR1 ligand, attenuates colon inflammation in rodent models of colitis. 
 
7.1.1 Computational Details 
The results recently published by Hov et al498 was used as reference for 
homology modeling studies. In their work, the human adenosine A2a receptor 
(pdb code:3EML) was used as template for the structu e studies. In order to 
obtain the three dimensional model of the TGR5 receptor we used the 
alignment reported by Hov et al., see Figure 7.6.  
The alignment was used as input for the automated homology modeling 
program MODELER.216 The number of generated loops was set to 5 along 
with high optimization level for models and loops. The generated models of 
TGR5 showing the lowest energy, lowest restraint violat ons were selected for 
further refinement of the main and side chains. 




hTGR5           SPIPKGALGLSLALASLIITANLLLALGIAWDRRLRSPPAGCFFLSLLLAGLLTGLALPT 
Template 3EML   IMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQ-NVTNYFVVSLAAADIAVGVLAIP 
hTGR5           LPGLWNQS-RRGYWSCLLVYLAPNFSFLSLLANLLLVHGERYMAVLRPLQ-----PPGSI 
Template 3EML   FAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLVTGTRA 
hTGR5           RLALLLTWAGPLLFASLPALGWNHWT-------PGANCSSQAIF-PAPYLYLEVYGLLLP 
Template 3EML   KGIIAICWVLSFAIGLTPMLGWNNCGQSQGCGEGQVACLFEDVVPMNYMVYFNFFACVLV 
hTGR5           AVGAAAFLSVRVLATAHRQL---------------------------------------- 
Template 3EML   PLLLMLGVYLRIFLAARRQLNIFEMLRIDEGLRLKIYKDTEGYYTIGIGHLLTKSPSLNA 
hTGR5           ------------------------------------------------------------ 
Template 3EML   AKSELDKAIGRNTNGVITKDEAEKLFNQDVDAAVRGILRNAKLKPVYDSLDAVRRAALIN 
hTGR5           ------------------------------------------------------------ 
Template 3EML   MVFQMGETGVAGFTNSLRMLQQKRWDEAAVNLAKSRWYNQTPNRAKRVITTFRTGTWDAY 
hTGR5           -----LTWRQARAQAGAMLLFGLCWGPYVATLLLSVLAYEQRPPLGPGTLLSLLSLGSAS 
Template 3EML   RSTLQKEVHAAKSLAIIVGLFALCWLPLHIINCFTFFCPD-CSHAPLWLMYLAIVLSHTN 
hTGR5           AAAVPVAMGLGDQRYTAPWRAAAQRCLQGL 
Template 3EML   SVVNPFIYAYRIREFRQTFRKIIRSHVLRQ 
Figure 7. 6 The sequence alignment of 3EML and human TGR5. 
 
7.1.1.1  Model refinement 
Hydrogen atoms were added to the selected models using Maestro 8.5 
software package.159 In details the charges of side chains were assigned 
considering their pKa at physiological pH. The geometry of the model for the 
target was optimized in three steps: 
1) optimization of model with the added hydrogen atoms by Amber force 
field504 (steepest descent method, 500 steps and convergenc threshold of 0.05 
kJ mol-1 Å-1). 
2) optimization of the side chains using the same crit ria of step 1. 
3) optimization of the whole structure by Polak-Ribiere Conjugate Gradient 
(PRCG, 9 x 107 steps, convergence threshold 0.001 kJ mol-1 Å-1). 
The quality of the obtained model for TGR5 was valid ted using the 
software PROCHECK218 (Figure 7.7). 





Figure 7. 7 Ramachandran plot of TGR5 calculated by PROCHECK using a hypothetical 
resolution of 2 Ǻ. 
 
The homology model for TGR5 was used in molecular docking calculations 
using AutoDock 4.2.56 
To achieve a representative conformational space during the docking 
studies and for taking into account the variable number of active torsions, 10 
calculations consisting of 256 runs were performed, obtaining 2560 structures 




for each ligand. The Lamarckian genetic algorithm was employed for docking 
calculations, choosing an initial population of 450 randomly placed 
individuals. The maximum number of energy evaluations and of generations 
was set up to 5 x 106 and the maximum number of generations to 6 x 106. A 
mutation rate of 0.02 and a crossover rate of 0.8 were used, and the local 
search frequency was set up at 0.26. Results differing by less than 2 Å in 
positional root-mean-square deviation (rmsd) were clustered together and 
represented by the result with the most favourable fre  energy of binding. For 
all the docked structures, all bonds were treated as active torsional bonds 
except the amide bonds. Illustrations of the 3D models were generated using 























Structural Studies of Natural Products 
 
 





8.1 DFT/NMR integrated approach: a valid support to the 
total synthesis of chiral molecules 
The entire stereochemical knowledge of a natural product is of 
fundamental importance in many different fields, spanning from chemical 
physics to biochemistry. The correct assignment of the configurational pattern 
in chiral organic compounds, containing more than one stereocenter, is 
undoubtedly a key step of the structure elucidation process. This process, in 
fact, is essential in several fields that not only i clude the total synthesis of 
the molecules under investigation but also the understanding, at the molecular 
level, of the biological mechanism of active natural compounds; 
stereochemical knowledge is also fundamental for structure-activity studies of 
drug–receptor systems.505 Basically, there are different approaches to identify 
the exact structure and/or stereochemistry of organic products. The classic 
chemical approach, represented by the total synthesis, has played a major role 
in the structural assignments and revision for a long time, but the additional 
costs in terms of time and money represent some of its most important 
weaknesses. The classical chemical approach is in fact often replaced by a 
series of more rapid methods, such as NMR, circular dichroism (CD), X-ray 
crystallography, and mass spectrometry (MS). Nevertheless, the correct 
structural assignment of unknown or known natural products is often very 
difficult to obtain, especially when a small quantity of the natural compound 
is available, limiting the full possibility of the currently available 
spectroscopic methods. For this reason, many examples of structural 
revision75 have appeared in literature, where total synthesis is able to show 
that previous assignments were wrong. This situation s particularly 
unfortunate in all cases where the total synthesis of a (wrong) proposed 





structure does not afford the natural products, andespecially for complicated 
molecules, this translates in an enormous waste of ime and money. The use 
of quantum mechanical (QM) methods, in fact, was suggested as a rapid, 
efficient, and economical method for the resolution f stereochemical 
problems, such as in the example of the structural determination and/or 
revision of active natural compounds.81,82,506 Moreover, the enormous 
enhancement in the performance of computers nowadays along with the user-
friendliness of the commercial quantum chemistry software packages should 
also encourage the synthetic chemists to perform such kind of analysis prior 
to proceeding to the chemical synthesis, excluding in this way candidate 
molecules that are not in accordance with the experimental data.  
In this paragraph, it was demonstrate that a fast quantum chemical analysis 
of the stereoisomers of the two natural compounds kedarcidin chromophore 
(226–228) (from the oldest to the revised structure) and palau’amine (229) 
would have avoided the synthesis of the wrong proposed structures by means 
of density functional theory (DFT) calculation of the coupling constant and 
GIAO (gauge including atomic orbitals) calculation f 13C chemical shifts 
(cs).507 The DFT/NMR integrated approach was applied to these two 
compounds to show that the reported results could have been sufficient to 
exclude the proposed structures and could have directly suggested the 
structure of the correct compounds.  
Kedarcidin chromophore is a compound that belongs to the enediyne 
family of antitumor antibiotics. These compounds are characterized by a 
unique molecular architecture, an intriguing mode of action, and high potent 
biological and pharmacological activities. They include, along with 
kedarcidin chromophore, calicheamicins, esperamicins, dynemicin A, 
neocarzinostatin chromophore, and C1027 chromophore. All these 





compounds possess a common enediyne reactive center along with a 
chemical functionality that can trigger a cascade of vents to form a highly 
reactive aryl-diradical. These molecules also possess a recognition unit 
responsible for delivering and establishing their position to the biological 
target, i.e. DNA. Under diverse conditions, these molecules may undergo a 
Bergman cyclization,508 which transforms the enediyne moiety into a very 
reactive aryl-diradical.509 The diradical abstract hydrogen atoms from each 
DNA strand lead to scission of the duplex, such damage cannot be repaired 
by any of the intracellular DNA repair paths. A first-structure elucidation of 
kedarcidin chromophore was proposed in 1992 by Leetand coworkers. It is 
here displayed as 226510 (Scheme 8.1).  
Subsequently, in 1997, Hirama et al. in the course of their synthetic study 
toward the synthesis of kedarcidin demonstrated that the fragment degraded 
from the chromophore was not an α-amino acid derivative, but a β-amino 
ester.511 They also disputed the absolute configuration of all the stereogenic 
centers of the molecule and proposed that the structure of kedarcidin 
chromophore had to be revised as 227.511 Very recently, Myers et al. 
synthesized 227 through an unambiguous enantioselective approach and,
comparing its spectroscopical data with the data of the natural compounds, 
discovered some significant inconsistencies that led them to suggest 228 as 
the structure of kedarcidin chromophore (Scheme 8.2).512  
In particular, they observed for 228 a ca zero coupling constant between 
H-10 and H-11 whereas such coupling results were 5.4 Hz in CDCl3 for 
authentic kedarcidin chromophore. Moreover, they noticed the lack of a 
nuclear overhauser effect (NOE) between the pyridyl H-4' and H-10 and the 
presence of an NOE between H-10 and H-12b in the product of 
borohydrideinduced cycloaromatization of kedarcidin chromophore. 






Scheme 8. 1 Structure of kedarcidin chromophore as α-amino acid derivative (226) proposed 
by Leet in 1993. 
 
Finally, they showed that synthesized 227 is a mixture of atropisomers in 
both DMSO-d6 and C6D6, probably due to a slow flipping of the pyridyl ring 
around two preferential arrangements, one with the c lorine atom pointing 
toward the central core and the other one resulting from a 180° rotation of the 
pyridyl ring and with the chlorine atom pointing in the opposite direction with 
respect to the enedyine moiety. On the other hand, they argued that structure 
228, derived by epimerization of the mycarose-bearing carbon 10, could not 
exist in the atropisomeric form in which the chlorine atom is oriented toward 
C-10, in accordance with the single atropisomer spectra displayed by the 
natural product.512 
 






Scheme 8. 2 Previous structure proposed by Hirama in 1997 (227) and revised structure (228) 
proposed by Myers in 2007 of kedarcidin chromophore. 
 
Palau’amine is a marine natural product originally isolated in 1993 by 
Scheuer and coworkers from the sponge Stylotella aurantium.513 The natural 
product is an oroidin dimer, belonging to the class of pyrrole-imidazole 
alkoloid family together with the styloguanidines, the konbu’acidins, 
brominated palau’amines, and the stylissadines A and B. 
Palau’amine is a potent immunosuppressive agent thapossesses an 
interesting biological activity; in fact, its anticancer, antifungal, and 
antibacterial properties are undergoing preclinical studies.514 More precisely, 
this marine natural product is a contiguous hexacyclic alkaloid that contains 
two guanidine units, a pyrrole carboxylic acid and an unbroken chain of eight 
chiral centers. However, owing to the presence of these chiral centers, the 
exact stereochemistry of palau’amine has been subject to controversies. The 
initial structure proposed by Scheuer t al. 229a513 (Scheme 8.3) had the 
relative configuration assigned as 6R∗, 10S∗, 11 R∗, 12 S∗, 16 S∗, 17 S∗, 18 
R∗,20 R∗, and this resulted in a cis-fusion between D and E rings, and the 





chlorine atom on the α-face of the molecule. Very recently, the isolation and 
structural elucidation of two additional palau’amine congeners, the 
tetrabromostyloguanidine515 (also carteramine A516) and the konbu’acidin 
B,517 prompted the revision of the initial assignment of the relative 
configuration of palau’amine. These three different research groups with 
others, in fact, proposed the revision of its stereoch mistry using NMR 
spectroscopy, computational methods,515,518,519 correlation with related 
compounds,516,517,520 and reisolation and characterization of palau’amine 
itself.521 The proposed revised structure 229b (Scheme 8.3) has the relative 
configuration assigned as 6 R∗, 10 S∗, 11 R∗, 12 R∗, 16 S∗, 17 R∗, 18 R∗, 20 R∗ 
and thus there is a trans junction between D and E rings and a chlorine atom 
on the β-face of the molecule. 
 
 
Scheme 8. 3 Original 229a and revised 229b structure of palau’amine. 
 
The main difference between the two possible models of the palau’amine 
is the junction from E–D rings and the relative configuration of carbon 17. In 
the first assignment of Scheuer and coworkers, the fusion was assigned as cis, 
based on the J-coupling constant (14.1 Hz) between H-11 and H-12 so that 





‘even relatively large for a cis-fusion, was considered comparable to other 
values of J constant observed in similar rigid, spiroannulated five-members 
rings.513 Together with the reassignment of the junction as tr ns, the relative 
configuration of carbon 17 was corrected by NMR spectroscopy517 and 
molecular modeling of other congeners.518 Nevertheless, despitemany 
creative and insightful attempts in the absence of X-ray crystallographic data, 
the confirmation of the correct structure would eventually rely on the total 
synthesis of the natural product; however, unfortuna ely, the total synthesis of 
palau’amine has not yet been achieved.  
In light of the above considerations, here, the use of QM methods was 
highlighted, in particular, the DFT calculation of the J values and the GIAO 
calculation of 13C cs in the structure revision.  
In the case of kedarcidin chromophore, in fact, to give further support to 
the configurational arrangement proposed by Myers et al.512 and to investigate 
the overall conformational features and the atropisomerism associated with 
the natural and the synthetic compounds, a conformational analysis of 227 
and 228 at the QM level was underteken, followed by a DFT calculation of 
significant J values for the two main atropisomers of 227 and 228, whereas, 
in the case of palau’amine, in order to obtain its exact relative configuration, 
the calculation of significant J values was followed by a GIAO calculation of 
13C cs. 
In order to obtain support on the configurational assignment of C-10 of 
kedarcidin, the 3JH–H-coupling value for H-10 and H-11 was primarily 
considered. First, a conformational search on both the possible atropisomers 
for 227 and 228, depicted as 227a and 227b and as 228a and 228b in Figure 
8.1, was performed by means of molecular dynamics at different temperatures 
(400, 600, and 800 K) and with a Monte Carlo conformational search using 





the MM3522 force field included in the MacroModel software pack ge.159 
Even though 227 and 228 are extremely flexible molecules, the chromophore 
core is rather rigid; therefore, only the lowest energy atropisomers were 
considered for the two diastereomers (227a and 227b and 228a and 228b in 
Figure 8.1). On the geometries thus obtained, QM optimization of the 
energies and the geometries were performed in vacuo at the DFT level using 
the mPW1PW91 functional and the 6-31G(d) basis set,84 and single-point 
calculations using a polar continuum model(PCM) were performed with the 
6-31G(d,p)84 basis for the simulation of the DMSO solvent. 
The calculations for 227 are in accordance with the presence of two 
atropisomers that are very close in energy; in fact, the predicted differences 
are 1.8 and 1.3 kJ/mol accounting for a 1.8 : 1 and 1.3 : 1 ratio in vacuo and 
DMSO respectively. These results are in good qualitative accordance with the 
reported 2 : 1 ratio in DMSO-d6. Interestingly, it is structure 227a (Figure 
8.1), which presents the chlorine atom directed away from the central core, to 
be the lowest in energy based on the results of the calculations, in accordance 
with what was proposed by Myers and coworkers.512 
Also, the evidence of the presence of a single atropisomers for 3 is well 
reproduced by the results of the DFT calculation in vacuo and DMSO, which 
indicate differences of 5.4 and 2.5 kJ/mol respectiv ly. As expected, it is 
atropisomer 228a, presenting the chlorine atom away from C-10, which was 
predicted to have the lowest energy, in accordance with what was proposed 
by Myers et al.512 






Figure 8. 1 Three-dimensionalmodels of possible kedarcidin chromophore atropisomers for 
227 and 228. 
 
Apart from the above observations regarding the conformational behavior of 
kedarcidin chromophore, which is in accordance with hat was observed in 
the NMR spectra of the natural product and of 227, the results of the DFT 
calculation of the kedarcidin core fragment was examined (Computation 
Details) J values between H-10 and H-11 for 227a, 227b, 228a, and 228b 





using the mPW1PW91 functional and the 6-311++G(2df, p) basis set.84 In 
accordance with the experimental data collected by Myers, such values are 
predicted to be 0.1 Hz for 227a and 0.1 Hz for 227b. The values predicted for 
228a and 228b are of 6.1 and 4.7 Hz respectively, and, compared to the 
experimental value of 5.4 Hz reported in CDCl3, they strongly support that 
the kedarcidin chromophore structure be revised as 228, confirming the 
hypothesis proposed by Myers et al.,512 in particular, suggesting a 1 : 1 ratio 
between 228a and 228b. On the other hand, the theoretical energy difference 
of 2.5 kJ/mol in DMSO (5.4 kJ/mol in vacuo) between 228a and 228b would 
indicate a preponderance of conformation 3a. Such results, even if not in 
perfect accordance with the results of the J analysis, are in good agreement 
with what was observed by Myers et al.,512 suggesting that kedarcidin 
chromophore could have in its most stable conformation only one 
predominant atropisomer (228a) characterized by the chlorine atom of the 
pyridyl ring oriented away from the core portion of the molecule (Figure 8.1). 
Such structural attributes, together with other features of this conformation 
may be useful in better understanding the mechanism of action of kedarcidin 
chromophore at the molecular level.  
The same approach was used for the palau’amine. In fact, the 3JH–H-
coupling value for H-11 and H-12 was primarily considered to obtain support 
or denial of the revised structure. Conformational search on both the possible 
diastereoisomers 229a and 229b depicted in Scheme 8.3 was performed by 
molecular dynamics at different temperatures (450, 700, and 800 K), and by 
the Monte Carlo conformational search using the MMFFs158 force field 
included in the MacroModel software package.159 Minimum energy 
conformer for each model were subjected to full geom try and energy 
optimization by QM methods at DFT level in vacuo using them 





PW1PW91functional and the 6-31G(d) basis set.84 On the basis of the 
obtained geometries (Figure 8.2), the calculation, in vacuo, of the J-coupling 
constants was executed always using the same functional and the 6-
311++G(2df, 2p) basis set.  
 
 
Figure 8. 2 Three-dimensionalmodels of the two diastereoisomers (229a and 229b) of 
palau’amine. 
 
In the reported calculations, the coupling constant 3JH–H of the D and E rings 
were only considered, which are diagnostic in the correct assignment of 
natural product configuration, and, in particular, the calculated values with 
the experimental Js recorded in DMSO (Table 8.1) were compared. As shown 
in Table 8.1, the value of 13.2 Hz, corresponding to the value of 3JH11–12 of 
compound 229b, displays the best agreement with the experimental dat  (14.4 
Hz) with respect to compound 229a that has a calculated J value of 8.8 Hz. 
This result is aligned and is consistent with the recently proposed revised 
structure, indicating that the junction between D and E rings is trans.  
Moreover, the value of 9.6 Hz, related to the value of the coupling constant of 
3JH18–17 of compound 229b, is in good agreement with experimental value of 
9.0 Hz, suggesting that the relative configuration of carbon 17 may be revised 
as R∗. 





Table 8. 1 Comparison between experimental (DMSO)518 and calculated (in vacuo) 
(stereoisomers 229a and 229b) 3JH-H values in Hz of rings D and E. 
 Calculated Exp DMSO 
 229a 229b  
3JH11-12 8.8 13.2 14.4 
3JH12-18 9.0 9.6 9.0 
3JH18-17 10.3 9.6 9.0 
3JH12-13α 8.5 9.0 10.2 
3JH12-13β 9.9 7.0 7.2 
aMAE 2.3 0.7  
aMean Average Error =∑[|Jexp-Jcalc|]/n 
 
In summary, analyzing all the other calculated J-coupling constants of the 
two possible diastereoisomers 229a and 229b, we noted, as also outlined by 
the mean average error (MAE = ∑[|Jexp−Jcalc|]/n summation through n of the 
absolute values of the differences of the corresponding experimental and 
calculated J-coupling constants) in Table 8.1, that model 229b fits better with 
the experimental NMR data reported in literature,513,514,517 and therefore with 
the proposed revised structure.  
Moreover, to give further support to the revised configurational 
arrangement of palau’amine, we performed single-point GIAO calculations 
using the mPW1PW91 functional and the 6-31G(d,p) basis set.84 The analysis 
of model compounds was carried out taking into consideration the calculated 
13C values in DMSO (Table 8.2). 
It is noteworthy that a high accuracy in reproducing the experimental 
chemical shifts is provided by this level of theory, which has proved 
successful in the configurational analysis of several natural 
compounds.523,524,525,526 





Table 8. 2 Comparison between experimental 13C chemical shifts in DMSO518 with calculated 
13C chemical shifts in DMSO of diastereoisomers 229a and 229b, and their a|∆δ| values.  
  229a   229b   
carbon δExp δcalc 
a|∆δ|, ppm δcalc 
a|∆δ|, ppm 
6 67.5 73.0 5.5 67.1 0.4 
10 79.4 84.7 5.3 84.0 4.6 
11 55.3 54.8 0.5 54.7 0.6 
12 40.6 42.9 2.3 39.1 1.5 
13 44.8 51.0 6.2 46.2 1.4 
16 70.3 77.5 7.2 73.1 2.8 
17 73.7 69.9 3.8 76.4 2.7 
18 47.0 41.1 5.9 51.5 4.5 
19 40.2 43.5 3.3 44.7 4.5 
20 82.2 85.6 3.4 83.7 1.5 
bMAE 13C 4.3  2.5 
a|∆δ|= |δExp - δcalc|, absolute differences for experimental versus calculated 
13C NMR chemical 
shifts. 
bMean Average Error =∑[|δexp - δcalc|]/n. 
 
Because such accuracy is seldom observed on sp2 carbon atoms, they have 
not been reported and considered in the configuration l assignment in the 
present paper and in preceding contributions reportd in the literature.525 In 
particular, for what concerns 13C calculated results, we have considered the 
∆δ parameter (differences in experimental vs calculated 13C NMR chemical 
shifts) and the MAE parameter (MAE = ∑[|δexp − δcalc|]/n, summation through 
n of the absolute values of the differences in the correspondingexperimental 
and calculated 13C chemical shifts); such parameters have been succesfully 
used in the characterization of unknown stereostructu es by us and by other 
research groups.76 The analysis of Table 8.2 suggests that the structure of 
palau’amine is 229b. In fact, taking into consideration the calculated 





chemical shifts, there is a very large difference, as shown in Table 8.2, 
between the |∆δ| 13C cs values of the two diastereoisomers. It was observeed, 
in fact, that the larger differences in |∆δ  13C of 229a and 229b not only 
regard C-12 of the junction (2.3 vs 1.5 respectively) but, as shown in Figure 
8.3, also C-6, C-13, C-16, C-20 (5.5 vs 0.4, 6.2 vs 1.4, 7.2 vs 2.8, and 3.4 vs 
1.5 respectively), while the values of absolute differences for experimental 




Figure 8. 3 |∆δ| values (parts per million) of the experimental (DMSO) versus theoretical 
carbon chemical shifts (DMSO) for sp3 Cs of diastereoisomers 229a and 229b. 
 
Finally, through the evaluation of the MAEs for 229a and 229b models (4.3 
vs 2.5 respectively), the GIAO calculated 13C chemical shifts indicated that 
compound 229b fits better with the experimental data, confirming the revised 
structure of palau’amine recently proposed with a trans junction between the 
rings D and E, and the chlorine atom on the β-face of the molecule. 
 
8.1.1 Computational details 
Molecular mechanics/dynamics calculations on each of the compounds 
under examination, compounds 227 and 228 for kedarcidin chromophore and 





compounds 229a and 229b for palau’amine, were performed at different 
temperatures (between 400 and 800 K/10 ns) on on quad-core Intel® Xeon® 
3.4 GHz using the MM3522 force field in the first case and the MMFFs158 in 
the second case within the MacroModel software package.159 All the 
structures so obtained (numbering 100) for each structu e were minimized 
using the Polak-Ribier conjugate gradient algorithm (PRCG, 1000 steps, 
maximum derivative less than 0.05 kcal/mol). This led to the selection of the 
lowest energy minimum atropisomers of 227 and 228, namely 227a and 227b 
and 228a and 228b (Figure 8.1) for kedarcidin chromophore, and of the
lowest energy minimum conformers for palau’amine. Such geometries were 
in accordance, in both cases, with the results of aparallel conformational 
search performed with the Monte Carlo multiple minium (MCMM) method 
of the MacroModel software package (MM3 force field for kedarcidin and 
MMFFs for palau’amine, 50 000 steps). The empirical geometries either of 
the minimum energy conformers 227a, 227b, 228a, and 228b (kedarcidin 
chromophore) or of the minimum energy stereoisomers 229a and 229b 
(palau’amine) were optimized at the DFT mPW1PW91 levelusing the 6-
31G(d) basis set84 (Gaussian 03 software package).160 J-coupling calculations 
were performed using the mPW1PW91 functional and the 6-311++G(2df, 2p) 
basis set for a significant fragment of kedarcidin core (C-1, C-8, C-9, C-10, 
C-11, C-12, O-9, O-10, O-11) and for palau’amine; in all the cases, the 
previously optimized geometry at the mPW1PW91/6-31G(d) level84 was 
considered as input. For kedarcidin chromophore, single-point calculations 
using the IEF-PCM solvent continuum model, as impleented in Gaussian 
(DMSO),527 were performed for estimating the relative energy differences 
between 227a and 227b, and 228a and 228b.  





For palau’amine, moreover, single-point 13C cs calculations, carried out 
using inputs of the mPW1PW91/6-31G(d)84 optimized structures, were 
performed employing the same functional combined with the 6-31G(d,p)84 
either in vacuo or using the IEF-PCM solvent continuum model, as 
implemented in Gaussian (DMSO and D2O solvent).
527 The calculated values 
of chemical shifts of palau’amine were referred to he theoretical 
tetramethylsilane 13C cs value (previously optimized at DFT level), computed 
at the same level of theory, except for carbon 17, which was referred to the 
chlorocyclohexane. 
 





8.2 Quantitative NMR-derived interproton distances 
combined with quantum mechanical calculations of 13C 
chemical shifts in the stereochemical determination of 
conicasterol F, a nuclear receptor ligand from Theonella 
swinhoei. 
Historically, natural products have represented a principal source of 
therapeutic agents, and so complete knowledge of their constitution and three 
dimensional structure is necessary to design and chara terize new molecular 
platforms with potential utility in therapy. In this context, NMR spectroscopy 
together with modern computational techniques represents an efficient and 
effective approach to stereochemical determination in solution. It is absolutely 
critical that the structural information obtained from NMR spectroscopy is as 
accurate and reliable as possible, because when it fails to provide an 
unequivocal answer, the traditional fallback positin s the time-intensive and 
expensive solution of total synthesis. In NMR spectroscopy, the Nuclear 
Overhauser Effect (NOE) is undoubtedly a powerful tool for establishing 
stereochemical and conformational details of chemical structures. However, 
because many factors may perturb NOE intensities, including spin diffusion, 
additional cross-relaxation pathways, selective polarisation transfer, variation 
in τc between spins, accuracy of signal integration and conformational 
flexibility, 96 the analysis of NOE data are generally qualitative (NOE/no NOE) 
or semi-quantitative (strong/medium/weak) when applied to stereochemical 
determination of small molecules such as natural products.96 On the other 
hand, recent improvements in NMR hardware (non-quadrature detection, 
improved RF generation and digital receivers etc), NOE experimental 
methods, (e.g. 1D-DPFGSE99,100,101 sequences, zero-quantum suppression)102 





and data analysis, such as the PANIC method of Macura108,109 have made 
quantitative measurements of NOEs more reliable. On this basis, it was 
recently reported103,104,105 that many of the ‘perturbing’ factors outlined above 
do not contribute substantially to NOE experiments conducted on small 
molecules, and indeed the NOE can be applied quantitatively with surprisingly 
high levels of accuracy of interproton distances in both rigid and flexible 
organic test molecules. Specifically, the accurate NOE-distance methodology 
compares the relative NOE intensities (and hence relativ  build-up rates) for 
pairs of spins in transient NOESY (or ROESY) experim nts when the 
molecule of interest is in the fast tumbling regime and the measurements are 
made within the Initial Rate Approximation limits.103 The relative intensity 
values are obtained from the standardization of each NOE peak intensity 
versus the irradiated peak in the same selective inversion experiment, because 
in this way any perturbation, which proportionately affects all spins in a given 
experiment, is minimized. In fact, Macura109 et al. and others110 have 
highlighted that employing relative, rather than absolute, intensities of NOEs 
(the so-called ‘PANIC’ method) from within a single experiment corrects for 
other forms of relaxation in 1D- or 2D-NOESY experiments and effectively 
extends the period during which the Initial Rate Approximation holds for the 
relative values of NOE enhancements.528  
Also recently, the QM/NMR81,82 has demonstrated success76,529 as a tool for 
differentiating diastereoisomers, to understand the mechanism of action of a 
determinate molecule,505 as support to the total synthesis,507 or to determine 
the structure of unusual natural substances,530 being able to identify the correct 
configuration in an efficient and accurate fashion. In the QM/NMR approach, 
DFT values of NMR parameters, i.e. chemical shifts (13C and 1H) and scalar 
coupling constants (3JH-H and 
2,3JC-H), are compared with experimental values 
 
 
to assign constitution and configuration. In fact, in many cases if the system is 
treated at a sufficient level of theory, the correct molecular arrangement will 
predictably be the isomer charact
and measured spectroscopic properties, where the best fit is identified using 
statistic parameters such as mean absolute error (MAE), Total Absolute 
Deviation (TAD), or others.
especially diagnostic in cases where there are multiple quaternary centres 
which strongly limit stereochemical analysis by traditional coupling constant 
and/or NOE analysis.
On this basis, the
approaches (accurate NOE
a new efficient and robust method for the stereostructu al determination of the 
organic compounds (Figure 
 
Figure 8. 4 General protocol for combin
with quantum chemical calculations of NMR parameters in stereochemical determination.
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erized by the best match between calculated 
531 In particular, the chemical shift 
 
 aim was to combine these two different validated 
-distance analysis and QM/NMR analysis) to obtain 
8.4).  












The combination of the two methods allows the stereoch mistry to be 
determined by two experimentally independent methods, providing greater 
confidence in the final structural assignment. This is especially important in 
cases where one technique or the other is not completely unequivocal in 
distinguishing all structural candidates. Here, it was described the results of 
the first application of the combined method to unknown structures, and in 
particular the stereostructure assignments of conicasterol F (230) and 
theonellasterol I (231) (Figure 8.5), two new 4-methylene polyhydroxylated 
steroids isolated from the marine sponge Theonella swinhoei.532 These 
compounds are especially challenging for stereochemical determination (vide 




Figure 8. 5 Conicasterol F (1) and theonellasterol I (2) from the marine sponge Theonella 
swinhoei. 
 
Marine sponges of the genus Theonella have attracted gr at interest from 
the scientific community for the impressive variety of bioactive secondary 
metabolites with unusual structures and powerful biological activity. In 
particular, the recent exploration of a specimen of Theonella swinhoei 
collected at the Solomon islands led to the isolatin of new cyclic peptides 





perthamides C-F,458,459 and solomonamides,460 endowed with anti-
inflammatory activity. From the same sponge two sulfated sterols, 
solomonsterols A and B and new theonellasterols294,533 and conicasterols,533 
have shown to be potent ligands of human nuclear receptors with 
pharmacological potential in the treatment of immune-driven inflammatory 
bowel diseases.473  
The molecular formula of conicasterol F (230) was established as C29H46O4 
from HR ESIMS (m/z 465.3532, calcd. 465.3556 [M+Li]+), and 13C NMR data 
(Table 8.8). The seven degrees of unsaturation implied by the formula were 
ascribed to six rings and one C=C bond (δC 151.6 and 104.5). The 1H NMR 
spectrum showed signals for six Me groups [(δH 0.66 (s), 0.73 (s), 0.78 (d), 
0.86 (d), 0.91 (d) and 0.84 (d)], two olefinic H-atoms (δH 4.64 and 5.30) and 
one O-bearing CH group (δH 3.67), consistent with a 3-hydroxy-4-methylene-
24-methyl steroidal system. The HMBC correlations from CH2-29 to C3, C4 
and C5 and the allylic 1H-1H COSY correlations of CH2-29 with H-3 and H-5 
confirmed the presence of exocyclic CH2 group at C4. In addition to the 
signals arising from the 4-methylen-3β-hydroxy ring A, the 13C NMR 
spectrum of 1 (Table 8.8) showed the presence of one oxygen-bearing methine 
carbon (δC 65.0) and three oxygen-bearing quaternary carbons (δC 79.8, 61.5, 
60.8). The HMBC correlation between the angular methyl Me-18 protons and 
the carbon at δC 79.8 indicated that C-14 was an oxygen-bearing carbon, 
whereas the position of the secondary alcoholic functio  at C15 (δC 65.0, δH 
4.18) was deduced by 1H-1H COSY spin system from H17 (δH 1.61) to H15 
(δH 4.18). The HMBC correlations of H-7 at δH 1.86 with C-14, C-8 (δC 60.8) 
and C-9 (δC 61.5) suggests an epoxide ring between C14 and C-8 and the 
presence of an oxygen bearing carbon at C9 position which is further 
substantiated by an HMBC crosspeak Me-19/C-9 (δC 61.5).  





Table 8. 3 1H and 13C NMR data (500 and 700 MHz, C6D6) for conicasterol F (230).  
Conicasterol F (1)a 
Position δH δC 
1α 1.34 ovl 
30.3 
1β 0.88 m 
2α 1.74 ovl 
32.2 
2β 1.27 m 
3 3.67 dd (4.6, 11.4) 72.6 
4 - 151.6 
5α 1.99 br d (11.6) 45.3 
6α 1.38 m 
22.6 
6β 1.45 m 
7α 1.86 ovl 
27.3 
7β 
2.26 ddd (1.9, 4.3, 
14.3) 
8 - 60.8 
9 - 61.5 
10 - 39.5 
11β 2.51 dd (2.1, 7.3) 50.1 
12α 1.92 d (14.0) 
35.7 
12β 1.67 dd (7.3, 14.0) 
13 - 44.9 
14 - 79.8 
15β 4.18 dd (1.4, 8.8) 65.0 
16α 2.07 m 
40.9 
16β 1.77 ovl 
17 1.61 m 50.6 
18 0.66 s 14.8 
19 0.73 s 18.5 
20 1.21 m 35.0 














24 1.25 ovl 39.3 
25 1.54 m 32.7 
26 0.86 d (6.7) 18.6 
27 0.91 d (6.7) 20.6 
28 0.84 d (6.5) 15.8 
29a 4.64 br s 
104.5 
29b 5.30 br s 
aCoupling constants are in parentheses and given in Hertz. 
1H and 13C assignments were made based on COSY, 
HSQC, HMBC and ROESY experiments as described in 
the main text. 
 
The additional epoxy functionality at C9/C11 of ring C is suggested in the 
1H NMR spectrum by a resonance at δH 2.51 (dd, J= 7.3, 2.1 Hz) that is 
correlated in the HSQC spectrum with C-11 at δC 50.1 and which showed 
COSY crosspeaks exclusively with the protons at δH 1.67 and 1.92 assigned to 
H2-12. These data thus also account for the additional degree of unsaturation 
established on the basis of mass data. 
The stereochemical assignment of the majority of the steroid skeleton is 
straightforward. The absolute steroidal configuration as depicted in Figure 
8.14 was assumed on biogenetic grounds. The coupling co stants between H-3 
[δH 3.67 (dd, J=4.6, 11.4 Hz)] and H2-2, and the ROESY correlations H-3/H-
5α, indicated that H-3 was axial and therefore the OH-3 was β-oriented. The 
axial disposition of H-11 [δH 2.51 (dd J =2.1, 7.3 Hz)] and, consequently, the 





α-orientation of the C9/C11 epoxide ring, was evident from the 3JHH vicinal 
coupling to H2-12 and ROESY correlations to axial protons Me-19, H-8 and 
Me-18. The α-orientation of 15-OH was similarly assigned on thebasis of a 
ROESY correlation between H-15 and Me-18. The configuration at C-24 on 
the flexible side chain was determined was determined to be the same of 
conicasterol by comparison of 1H and 13C chemical shifts.533  
Theonellasterol I (231) was isolated as an optically active pale yellow oil 
and a molecular formula of C30H48O4, was established by high resolution mass 
spectrometry. The 1H and 13C NMR spectra of 231 were very similar to those 
of conicasterol F (Table 8.4), with the data for the steroidal core being 
essentially identical (∆δ <0.5 ppm).  
 
Table 8. 4 1H and 13C NMR data (500 and 700 MHz, C6D6) for theonellasterol I (231). 
Position δH δC HMBC 
1α 1.33 ovl 
30.1 - 
1β 0.89 m 
2α 1.74 ovl 
32.0 - 
2β 1.28 m 
3 3.65 dd (4.7, 11.3) 72.5 C4 
4 - 151.1 - 










7α 1.87 ovl 
27.3 C6, C8, C14 
7β 2.26 ddd (1.8, 4.3, 14.5) 
8 - 60.8 - 
9 - 61.6 - 
10 - 39.7 - 
11β 2.50 dd (2.1, 7.3) 49.8 C12 
12α 1.93 d (14.1) 
35.5 C9, C13, C14, C17, C18 
12β 1.66 dd (7.3, 14.1) 
13 - 45.0 - 
14 - 79.9 - 
15β 4.18 d (8.7) 65.0 - 
16α 2.08 m 
40.7 C13, C14, C15, C17 
16β 1.78 ov 
17 1.61 m 50.4 - 
18 0.66 s 14.5 C12, C13, C14, C17 
19 0.72 s 18.4 C1, C5, C9, C10 
20 1.20 m 35.0 - 
21 0.80 d (6.5) 18.5 C17, C20, C22 













24 0.99 m 46.2 - 
25 1.72 ovl 29.1 - 
26 0.89 d (7.1) 19.1 C24, C25, C27 





29 0.93 t (7.4) 12.4 C24, C28 
30 
4.64 br s 
5.31 br s 
104.5 C3, C4, C5 
aCoupling costants are in parentheses and given in hertz. 1H and 13C assignments aided by 
COSY, TOCSY, ROESY, HSQC and HMBC experiments. 
 
The only difference between these two molecules lies in the steroidal side 
chain, with an ethyl group replacing the C24 methyl in 230. On the basis of 
chemical shift similarities, both the constitution a d stereochemistry of the 
tetracyclic nucleus of theonellasterol I (231) was assumed to be the same as 
conicasterol F (230). On the other hand, the configuration at C24 were 
determined by comparison of 13C-NMR data with the epimeric steroidal side 
chain.534,535 





8.2.1 Assignment of the relative configuration of 8-14 epoxy 
ring in conicasterol F  
The presence of four contiguous quaternary centres in ring C of 230 
severely hampers the stereochemical assignment of the relative configuration 
of the 8-14 epoxy ring, with the lack of protons at C8 and C14 making 
conventional 3JHH and NOE analysis impossible. Therefore this molecule was 
selected as a suitable case study to test the proposed combination of 
quantitative ROE-derived interproton distances with QM calculation of NMR 
parameters (Figure 8.4). The relative rigidity, the molecular size, and the 
solubility in non-viscous benzene, should ensure appropriate conditions for 
accurate interproton measurements by ROE.103 On the other hand, because the 
only difference between the two possible diasteroisomers of the compound 
230 is the stereochemistry of C8 and 14 (Figure 8.15), substantial chemical 
shift differences are expected for the carbon atoms clo e to the junction 
between C-D rings, suggesting the potential for steeostructure validation by 
GIAO calculation of 13C NMR chemical shifts.  
 
 
Figure 8. 6 Molecular structure of the two possible diasteroisomers (230a and 230b) of 
conicasterol F. 
 





Following our protocol (Figure 8.4), molecular dynamics and Monte Carlo 
conformational search calculations (see Computationl Details) were 
performed on both possible stereoisomers 230a and 230b (Figure 8.6), using 
the MMFF158 force field (MacroModel software package).159 In each case, 
only a single conformer of the steroid ring system was found. The resulting 
geometries for 230a and 230b were optimized (Figure 8.7) at the DFT level 
using the MPW1PW91 functional and 6-31G (d)84 basis set (Gaussian 09 
Software Package).536 Calculated interproton distances were obtained directly 
from the DFT-optimised geometries without further co rections. 
 
 
Figure 8. 7 Optimized geometries of diastereoisomers 1a and 1b of conicasterol F. 
 
Quantitative experimental interproton distances for 230 were obtained from 
1D-ROESY spectra.103 Figure 8.8 shows an example of the data obtained, with 
the selective 1D-ROESY spectrum of H29a, with clear ROE enhancements for 
H29b, H6α, H6β and Me19 of 230. 
Selective 1D-ROESY experiments were performed only on the key 
protons537 around the junction C-D (See Figure 8.5), namely proton H7β, 


















Figure 8. 9 Selective 1D
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-ROESY spectrum (600 MHz, C6D6) of H29a of conicasterol F




















Figure 8. 11 Selective 1D
 
Figure 8. 10 Selective
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-ROESY spectrum (600 MHz, C6D6) of Me18 of conicasterol F.








Figure 8. 12 Selective 1D
 
The 1D-ROESY spectra were calibrated in the PANIC fashion
setting the integral value for the irradiated peak in each case arbitrarily to 
1000103 and thus standardizing the absolute values of the ROE intensities to 
this in every 1D-ROESY spectrum. Interproton dista
using Equation 1.22
 
Equation 1. 22 
 
where ηIS is the intensity of the NOE for a given proton pair I and S, r
corresponding interproton distance, 
single chosen NOE for which the interproton distance is assumed based on 
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-ROESY spectrum (600 MHz, C6D6) of H15β of conicasterol F.











IS is the 
a





geometric constraint. The methylene protons H29a-H29b was chosen as the 
reference ROE (ηref = 81.54) for the 1D-ROESY dataset with the 
corresponding intermethylene distance of 1.85 Å as the reference distance 
(rref).  
Applying equation 1.22 in turn to each ROE resonance (ηIS) observed in the 
1D-ROESY spectra, allows the calculation of the corresponding interproton 
distance (rIS). Methyl groups were treated by using r
-3 averaging as described 
in reference 96, as this gives slightly improved fits over r-6 averaging on 
molecules of the size of conicasterol. A subset of these values are shown in 
Table 8.5 which were identified as useful for stereochemical structure 
elucidation i.e. those where DFT-calculated interproton distances in 230a and 
230b differed by >0.03Å (~1%) from each other.  
On the basis of the data in Table 8.5, it is clear th t diastereomer 230b 
shows the best fit with the estimated experimental data (MAE 3.0%, standard 
deviation (STD) 2.6%), while diastereomer 230a is clearly less satisfactory 
(MAE 7.8%, STD 5.9%). Critically, the MAE and STD values for 230b fall 
within the expected range of errors previously repoted103 for this accurate 
NOE/ROE-distance method (MAE and STD both <4%), while those for 230a 
fall well outside this range.  
As might be expected, the largest contributions to the MAE for 1a 
(underlined in the Table 8.10) relate to the protons close to the C-D junction 
(Figure 8.14), e.g. H7β-H15β, and Me18-H15β, where the conformation of 
ring C is influenced by the relative stereochemistry of the epoxide rings. 
However, it must be emphasised that in both of these ca es (H7β-H15β, and 
Me18-H15β), a qualitative ROE/NOE analysis would not have differentiated 
between the diastereomers, as the ROE peaks would have been present, but 
with very weak intensities for either diastereomer.  





Table 8. 5 Interproton distances determined by ROE for H7β, H11β, H15β, Me18 and H29a-b 
of conicasterol F (230) in d6-benzene and comparison with DFT calculated value for 1a and 
1b. Value in bold was used to calibrate the ROEs.  
  Exp. 230a 230b 






H29a H29b 1.85 1.85 - 1.85 - 
H7β H15β 2.73 2.45 11.4% 2.71 0.5% 
H11β H12α 3.07 2.87 6.9% 2.92 5.1% 
H11β Me19 3.43 3.83 10.4% 3.20 7.4% 
H11β H1β 2.09 2.26 7.4% 2.12 1.7% 
H15β H16α 2.94 2.69 9.3% 2.87 2.5% 
H15β H16β 2.38 2.48 4.0% 2.32 2.9% 
Me18 H15β 3.42 4.37 21.7% 3.18 7.5% 
Me18 H11β 3.67 3.71 1.2% 3.54 3.7% 
Me18 H12β 3.12 2.89 8.1% 2.93 6.3% 
Me18 H16β 3.02 3.09 2.2% 3.01 0.4% 
Me18 H20 2.70 2.61 3.1% 2.74 1.6% 
Me18 Me19 3.31 4.00 17.2% 3.28 1.0% 
H29a H6α 2.34 2.44  4.2% 2.35  0.5% 
H29a H6β  2.39 2.33 2.7% 2.38 0.5% 
bMAE    7.8%  3.0% 
STD    5.9%  2.6% 




2D-ROESY spectra were also obtained for 230 (See Figures 8.13-18) and 
confirmed the trend of the 1D-ROESY data.  
 




















Figure 8. 14 2D-ROESY F2-slice at F1 chemical shift (600 MHz, C6D6) of H7β of 
conicasterol F. 



















Figure 8. 16 2D-ROESY F2-slice at F1 chemical shift (600 MHz, C6D6) of H15β of 
conicasterol F. 
Figure 8. 15 2D-ROESY F2-slice at F1 chemical shift (600 MHz, C6D6) of H11β of 
conicasterol F. 






























Figure 8. 17 2D-ROESY F2-slice at F1 chemical shift (600 MHz, C6D6) of Me18 of 
conicasterol F.  
Figure 8. 18 2D-ROESY F2-slice at F1 chemical shift (600 MHz, C6D6) of H29a of 
conicasterol E (1). 
 
 
Informative plots of computed 
each diastereomer (Figure 
for both 1D- and 2D
 
Figure 8. 19 DFT calculated interproton distances 
experiments (top view) and from 2D
 
However there is in fact a very slight deterioration in the quality of the 
overall fit from the 2D
3.9%, STD 3.5%) (Table 
These encouraging results are confirmed by 
In particular, we performed single
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vs ROE-determined interproton distances for 
8.19) clearly show that 1b provides a far superior fit 
- data.  
vs experimental from 1D
-ROESY experiments (bottom view). 
-ROESY data, for the ‘correct’ stereoisomers 
8.6) which is in line with our previous observations.
QM-NMR structural analysis. 












230a and 230b geometries (see above and Figure 8.7) using the MPW1PW91 
functional and the 6-31G (d,p) basis set84 (Gaussian 09 Software Package).536 
 
Table 8. 6 Interproton distances determined by 2D-ROESY for H7β, H11β, H15β, Me18 and 
H29a of Conicasterol F (230) in C6D6 and comparison with DFT calculated value for both the 
diastereoisomers. Value in bold were used to calibrate the ROEs. 
  Exp. 230a 230b 






H29a H29b 1.85 1.85 - 1.85 - 
H7β H15β 2.70 2.45 10.4% 2.71 0.4% 
H11β H12α 3.05 2.87 6.3% 2.92 4.5% 
H11β Me19 3.38 3.83 11.9% 3.20 5.6% 
H11β H1β 2.08 2.26 7.8% 2.12 2.1% 
H15β H16α 2.95 2.69 9.6% 2.87 2.8% 
H15β H16β 2.34 2.48 5.9% 2.32 0.8% 
Me18 H15β 3.41 4.37 22.0% 3.18 7.1% 
Me18 H11β 3.73 3.71 0.5% 3.54 5.5% 
Me18 H12β 3.32 2.89 15.2% 2.93 13.3% 
Me18 H16β 3.12 3.09 1.0% 3.01 3.6% 
Me18 H20 2.67 2.61 2.0% 2.74 2.7% 
H29a H6α 2.39 2.44  5.6% 2.35  0.7% 
H29a H6β  2.30 2.33 2.9% 2.38 1.9% 
bMAE    7.7%  3.9% 
STD    6.2%  3.5% 









For the 13C chemical shift analysis, the attention was docused on the key 
carbon atoms near the C ring because this is the region likely to be influenced 
by the stereochemistry of the epoxy ring.  
Moreover, the data evaluation was performed considering the ∆δ parameter 
(differences in experimental vs calculated 13C NMR chemical shifts) and the 
MAE parameter (MAE =∑[|δexp−δcalc|]/n, summation through n absolute values 
of the differences in the corresponding experimental and calculated 13C 
chemical shifts); which have been successfully used in the characterization of 
unknown stereostructures by us and by other research groups.76,529,531 Table 
8.7 lists selected experimental and calculated chemical shifts for carbons near 
the C ring in 230a and 230b.  
Once again, the chemical shift data strongly suggests that diastereomer 
230b is the correct structure for 230, with a very large difference between the 
average |∆δ| values of the MAE values for 230a and 230b (3.7 vs 0.8 
respectively).  
Critically, the |∆δ| MAE for 230b in Table 8.7 falls within the MAE 
calculated for the whole molecule (1.4 ppm, Table 8.8) and is comparable to 
the and is comparable to the expected error range (≤2.0 ppm) for QM/NMR 













Table 8. 7 Comparison between experimental 13C chemical shifts in benzene with calculated 
13C chemical shifts in vacuo of diastereoisomers 1a and 1b and their a|∆δ| values. 
  230a 230b 
Carbon δexp δcalc 
a|∆δ|,ppm δcalc 
a|∆δ|,ppm 
7 27.3 31.4 4.1 28.1 0.8 
8 60.8 62.8 2.0 61.3 0.5 
9 61.5 62.9 1.4 61.6 0.1 
14 79.8 72.8 7.0 79.1 0.7 
13 44.9 42.6 2.3 46.1 1.2 
12 35.7 41.5 5.8 36.4 0.7 
11 50.1 54.1 4.0 49.6 0.5 
18 14.8 19.1 4.3 15.9 1.1 
15 65.0 75.3 10.3 64.3 0.7 
16 40.9 40.2 0.7 41.4 0.5 
17 50.6 50.5 0.1 48.1 2.5 
20 35.0 33.2 1.8 35.0 0.0 
bMAE 13C   3.7  0.8 




Table 8. 8 Comparison between experimental 13C chemical shifts in C6D6 and calculated 
13C 
chemical shifts in vacuo of diastereoisomers 230a and 230b and their a|∆δ| values. 
  1a 1b 
Carbon δexp δcalc 
a|∆δ|,ppm δcalc 
a|∆δ|,ppm 
1 30.3 29.5 0.8 30.8 0.5 
2 32.2 30.9 1.2 30.8 1.3 
3 72.6 72.6 0.0 72.5 0.1 
4 151.6 150.8 0.8 150.8 0.8 
5 45.3 46.6 1.3 46.0 0.7 





6 22.6 24.5 1.9 23.7 1.1 
7 27.3 31.4 4.1 28.1 0.8 
8 60.8 62.8 2.0 61.3 0.5 
9 61.5 62.9 1.4 61.6 0.1 
10 39.5 43.4 3.9 41.8 2.3 
11 50.1 54.1 4.0 49.6 0.5 
12 35.7 41.5 5.8 36.4 0.7 
13 44.9 42.6 2.3 46.1 1.2 
14 79.8 72.8 7.0 79.1 0.7 
15 65.0 75.3 10.3 64.3 0.7 
16 40.9 40.2 0.7 41.4 0.5 
17 50.6 50.5 0.1 48.1 2.5 
18 14.8 19.1 4.3 15.9 1.1 
19 18.5 16.7 1.8 20.1 1.6 
20 35.0 33.2 1.8 35.0 0.0 
21 18.7 20.4 1.7 20.2 1.5 
22 33.4 33.5 0.1 35.2 1.8 
23 30.9 27.6 3.3 29.9 1.0 
24 39.3 39.7 0.4 40.2 0.9 
25 32.7 28.2 4.5 35.7 3.0 
26 18.6 14.1 4.5 22.9 4.3 
27 20.6 22.7 2.1 15.9 4.7 
28 15.8 15.8 0.0 12.4 3.4 
29 104.5 102.1 2.4 103.0 1.5 
bMAE 13C   2.6  1.4 
a|∆δ|= |δexp−δcalc|, absolute differences for experimental versus calculated 




The graphical representation of the errors in calcul ted chemical shifts 
(Figure 8.20) clearly shows that 230b is the best match with the experimental 





data for every carbon with the one exception of C-17 where both 
diastereomers give calculated values which are within reasonable error limits. 
 
 
Figure 8. 20 |∆δ| values (parts per million) of the experimental (benzene) versus theoretical 
carbon chemical shifts (vacuo) for Csp3 of diastereoisomers 1a and 1b. 
 
In summary, the evaluation of the GIAO calculated 13C chemical shifts 
MAEs for 230a and 230b geometries (3.7 vs 0.8 ppm respectively) confirm 
the stereochemical assignment made on the basis of the accurate ROE-distance 
analysis. Both methods independently identify a tr ns C/D ring junction, 
allowing the assignment of conicasterol F as 230b depicted in Figure 8.6. 
Moreover, here it was demonstrated the proposed method as a powerful tool in 
stereochemical structure determination, and its application is strongly 
recommend prior to, or indeed as a complete alternative to, total synthesis 
when traditional NMR data analysis is not sufficient to distinguish 
stereochemical alternative, such as in the case of conicasterol F (230).  
Further, conicasterol F (230) and theonellasterol I (231) are ligands of two 
well-known nuclear receptors, PXR and FXR, Farnesoid-X-receptor (FXR) 
and the pregnane-X-receptor (PXR), two nuclear receptors both functioning as 
bile acid activated receptors, have emerged as the main receptors involved in 





regulating bile acid synthesis, detoxification and excretion in the liver and 
gastro-intestinal tract.366,367,538,539  
From the pharmacology stand point, a dual ligand, such as conicasterol F 
(230), holds potential in the treatment of liver disorders characterized by 
cholestasis and/or impaired metabolism of xenobiotics and, because both FXR 
and PXR exert anti-inflammatory effects in the intestine, in the treatment of 
inflammatory bowel diseases. In conclusion this discovery reaffirms the utility 
of examining natural product libraries for identifying novel receptor ligands 
potentially useful in the treatment of liver-related immune disorders. 
 
8.2.1 Computational details 
Molecular dynamics and Monte Carlo calculations were both performed on 
conicasterol F (230) on 4 x AMD Opteron SixCore 2.4Ghz. The dynamics 
calculations of 230 were performed at two different temperatures (600 and 750 
K for 8 ns using 1.5 fs as time-step) using the MMFF158 force field 
(MacroModel software package).159 During both calculations, a standard 
constant temperature velocity-Verlet algorithm was used to integrate the 
equations of motions.540 All the obtained structures (numbering =150, select d 
at regular intervals throughout the simulation) from Molecular Dynamics 
calculations for each isomer were minimized using the Polak-Ribier conjugate 
gradient algorithm (PRCG, 100000 steps, convergence threshold 0.005 kJ mol-
1 Å-1), leading to the selection of the lowest energy mini um conformer for 
both the diastereoisomers. The distribution of resulting geometries were in 
accordance with the results of a parallel conformation l search performed with 
the Monte Carlo multiple minimum (MCMM) method (MMFFs,158 10000 
steps, numbering 150, stored on a similarity and an energy criterion), where 
the variables used for the calculations included all the possible rotable 





torsions. The empirical geometries from the conformer search for 
diastereoisomers 230a and 230b were optimized in vacuo at the DFT 
MPW1PW91 level using the 6-31G(d)84 basis set (Gaussian 09 software 
package),536 and then the optimized structures are used as inputs for the single-
point 13C chemical shift calculations performed in vacuo employing the same 
functional combined with the 6-31G(d,p)84 basis set. The calculated values of 
chemical shifts of conicasterol F (230) were referred to the theoretical 
tetramethylsilane 13C chemical shift value (previously optimized at DFT 
































A critical issue that determines the specificity of pharmacological response 
is related to the ability of a cellular receptor to recognize certain molecules. 
Relatively weak interactions with the active molecul  are critical for the 
interaction with a receptor, and these are all dependent on its chemical 
structure and configuration. Another fundamental issue is the chirality of the 
ligand; thus, in most cases the receptor can bind, more or less specifically, 
only one of the two enantiomers according to the thr e-point model. As a 
consequence, in order to design and characterize new molecular platforms 
useful for any therapy it is necessary to know exactly the conformation and 
the configuration of the ligand.  
In this context, the combination between NMR spectroscopy78b,541 and 
modern computational techniques542 (molecular docking, molecular dynamics 
and conformational search) certainly represents one of the most effective 
approaches, which were applied in order to design, rationalize, and perform 
structural studies on new potential antitumor and/or antiinflammatory 
molecules.  
The results obtained described above can be outlined in three main areas of 
activity: 
 
a) Support in the design of original scaffolds for the generation of 
libraries potentially utilizable in therapy.  A molecular docking technique 
was exclusively used to conduct this rational design taking into account the 
analysis of ligand-target interactions and the synthetic possibilities. This kind 
of approach was successfully applied leading to the identification of new 
potential inhibitors for HDAC enzymes -both ciclic (mono and bis amides,156 
paragraph 2.2; conformationally locked calixarenes, paragraph 2.4), and linear 





2.6)- and for microsomal prostaglandin E2 synthase (mPGES)-1 enzyme (two 
series of triazole-based compounds; paragraphs 4.2 and 4.3).269,297  
In the paragraph 2.2, it was described the design collection of mono and bis 
amides (18-24) that have showed a satisfying level of antiproliferative 
activity, and from whose a new series of hydroxamic tertiary amines were 
designed (paragraph 2.3). In particular, a good accordance between molecular 
modeling predictions and biological results was found, and in fact, all the 
synthesized compounds (25-34) displayed a considerable HDAC inhibition 
activity. Especially, as predicted by docking calculations, compound 30 
showed the highest inhibitory activity in the nanomolar range (IC50 0,07 µM 
30 vs 0,022 µM TSA),while 28 has showed a calculated and experimental 
inactivity.  
Moreover, in the paragraph 2.4, alkyl- and arylamidocalix[4]arene 
derivatives 35-45 have been designed and theoretically evaluated by ocking 
studies as potential histone deacetylase inhibitors (HDACi). On the basis of 
the trimodal distribution of the calculated inhibiton constants (Kd), five alkyl- 
or arylamido derivatives (37, 41, 42, 43, and 45) were synthesized and tested. 
A qualitative accordance between the experimental results and the theoretical 
predictions was obtained, confirming that appropriately substituted 
arylamidocalix[4]arenes are active HDACi.  
On the other hand in the paragraph 2.6 the structural elements responsible 
of the selective binding towards a specific isoform of HDAC have been 
investigated. It should be highlighted that class I and II proteins present a 
considerable sequence similarity in the catalytic site. In order to verify the 
theoretical findings, selective inhibitors able to discriminate between HDAC1 
and 2 are designed, and then synthesized and testedby biological assays on all 





whereas the 111 inhibits HDAC8, suggesting that the structural modification 
of the appendage of the metal binder can lead to isoform selectivity in 
agreement with theoretical analysis. The 112 has showed similar inhibitory 
activity on HDAC3 and 8, confirming the theoretical prediction that structural 
modification of the linker alters the interaction of the cap group with HDAC2. 
Even though the small molecules showed a modest potency, the experimental 
data confirm theoretical observations, opening a new avenue for a targeted 
rational design of selective inhibitors towards the different HDAC isoforms.  
Alongside the results reported above, in this thesis the design of two series 
of mPGES-1 inhibitors was described. In the pagraph 4.2, in silico screening 
to rapidly direct the synthesis, based on the copper-catalyzed 3 + 2 Huisgen's 
reaction (click chemistry) of potential mPGES-1 inhibitors was described.  
26 (140-165) new triazole-based compounds were designed in accordance 
with the pocket binding requirements of human mPGES-1. Docking results, in 
agreement with ligand efficiency values, suggested the synthesis of 15 
compounds that at least in theory were shown to be more efficient in 
inhibiting mPGES-1. Biological evaluation of these lected compounds has 
disclosed three new potential anti-inflammatory drugs: (I) compound 143 
displaying selectivity for mPGES-1 with an IC50 value of 3.2 µM, (II) 
compound 159 that dually inhibits 5-lipoxygenase and mPGES-1, and (III) 
compound 146 apparently acting as 5-lipoxygenase-activating protein 
inhibitor (IC50 = 0.4 µM).  
Moreover, in the paragraph 4.3 the design and synthesis, and biological 
evaluation of a second series (167-181) of mPGES-1 inhibitors based on a 
triazole scaffold are described. The reported studies allowed us to draw a SAR 
profile and to optimize this series with the identification of compounds 175, 





assay. In addition, compounds 170, 175, 177 and 179-181 also blocked 5-LO 
activity in cell-free and cell-based test systems, emerging as very promising 
candidates for the development of safer and more effective anti-inflammatory 
drugs. In particular taken together, compound 179 turned out to be the most 
potent dual mPGES-1/5-LO inhibitor out of these series with 4- and 7-fold 
lower IC50 values versus the parental lead compound 143 (IC50 = 0.68 µM). 
 
b) Rationalization of the biological activity of compounds by the study 
of the drug-receptor interactions. In this thesis, the molecular docking was 
used to rationalize the binding modes of several compounds with known 
biological activities. In particular, the reported results are related to Ugi 
products derivatives of CHAP 1161a (HDAC inhibitors, paragraph 2.5), new 
and potent inhibitor of NMPRTAse analogs of FK866 and CHS 828221 
(chapter 3), marine natural products as inhibitors f hsPLA2 (BLQ
291 and 
CLDA,292 chapter 5), 4-methylen sterols extracted from Theonella swinhoei as 
ligands of FXR and PXR (chapter 6),294,357,358,359 and moreover of known 
compounds as taurolitholic acid and ciprofloxacin (chapter 7),296 agonists of 
TGR5. 
In the paragraph 2.5 a full rationalization of binding mode of novel Ugi 
products (36-77) containing a zinc-chelating moiety is presented. 74 shows 
improved inhibitory potencies compared to SAHA, demonstrating that 
hindered lipophilic residues grafted on R-aminoacylmides scaffold with 
NHR1COCHR2NR3 as cap group can favour in the interaction with the 
enzyme. These findings are also confirmed by calculted and experimental 73 
inactivity. 
In the chapter 3, from a biological screening of a small library of triazole-





representative compounds were analyzed and a full rationalization of their 
binding mode was reported. Moreover, via molecular docking, the excellent 
potential of click chemistry for rapidly generating structure-activity 
relationships and for drug screening was reinforced. 
In the paragraph 5.2 and 5.3 the molecular basis of the human group IIA 
secretory phospholipase A2 inactivation by bolinaquinone (BLQ, 182), and 
cladocoran A (CLD A, 183) has been investigated for the comprehension of 
their relevant antiinflammatory properties, through t e combination of 
spectroscopic techniques, biosensors analysis, massspectrometry (MS) and 
molecular docking. The reported results suggest a mechanism of competitive 
inhibition guided by a non-covalent molecular recognition event, disclosing 
the key role of the BLQ hydroxyl-quinone moiety and of CLD A γ-
hydroxybutenolide ring in the chelation of the catalytic Ca2+ ion inside the 
enzyme active site.  
Moreover, CLD A is able to react selectively with Ser82, although this 
covalent event seems to play a secondary role in terms of enzyme inhibition. 
The understanding of the sPLA2-IIA inactivation mechanism by BLQ and 
CLDA could be useful for the development of a new chemical class of PLA2 
inhibitors, able to specifically target the enzyme active site. 
In the paragraph 6.2 the putative binding modes to nuclear receptors (NRs) 
of 10 polyhydroxylated steroids, theonellasterols B-H (200-206) and 
conicasterols B-D (207-209) extracted from marine sponge Theonella 
swinhoei, were described. Pharmacological and structure-activity relationship 
analysis have demonstrated that these natural polyhydroxylated steroids are 
potent ligands of human nuclear pregnane receptor (PXR) and modulator of 
farnesoid-X-receptor (FXR). In addition, the molecular characterization of 





PXR ligand so far identified, highlighting its pharmacological potential in the 
treatment of liver disorders. 
In the pargraph 6.3 the isolation and pharmacological characterization of 
conicasterol E (213) (Theonella swinhoei) in comparison to CDCA, a natural 
FXR ligand, 6-ECDCA, a synthetic FXR agonist, and rifaximin, a potent PXR 
agonist, were decribed, demostrating its FXR modulator endowed ith PXR 
agonistic activity. The relative positioning in the ligand binding domain of 
FXR, explored through docking calculations, demonstrated a different spatial 
arrangement for conicasterol E and pointed to the presence of simultaneous 
and efficient interactions with the receptor that might support its biological 
activity.  
In the paragraph 6.4 the isolation and the structural elucidation of a family 
of polyhydroxylated steroids (241-223) from the marine sponge Theonella 
swinhoei were reported. Decodification of interactions of this family with 
nuclear receptors has showed that these steroids are potent agonists of human 
pregnane-X-receptor (PXR) and antagonists of human farnesoid-X-receptor 
(FXR) with the putative binding mode to nuclear receptors (NRs) obtained 
through docking experiments.  
Moreover in the paragraph 6.5, the discovery of theonellasterol (198) 
(Theonella swinhoei) as a highly selective FXR antagonist that protects against 
liver injury in cholestasis was reported. In particular, detailed description of 
the putative binding mode in several FXR crystal structures was reported in 
order to have a more precise description of the flexib  Helix 12 in the ligand 
binding site.  
Finally, in the chapter 7, ongoing the lack of the crystal structure of TGR5, 
the human adenosine A2a receptor was used as templa for homology 





structure. The so obtained structure was used as receptor model for the 
docking calculations to rationalize the binding modes of TGR5 agonist: the 
taurolitholic acid (TLCA, 224) and ciprofloxacin (225). 
 
c) Determination of relative configuration of natural products This 
kind of approach was successfully used in order to esolve stereostructural 
assignments of four natural products.507, 532  
In the paragraph 8.1, the analysis of kedarcidin chromophore (228) and 
palau’amine (229) configuration through quantum chemical calculation of Js 
and chemical shifts was suggested as a fast and convenie t approach utilizable 
prior to proceeding to the total synthesis of complex natural compounds in 
order to avoid loss of time and resources employed in the total synthesis of 
wrong diastereoisomers.  
On the other hand, in the paragraph 8.2 the first application of combined 
accurate ROE-distance analysis with DFT calculations f NMR chemical 
shifts was reported to achieve the relative configuration assignment of a 
marine natural products, conicasterol F (230) and its and its 24-ethyl 
derivative, theonellasterol I (231), new polyhydroxylated steroids isolated 
from the marine sponge Theonella swinhoei. In this paragraph, it was 
demonstrated the substantial advantages of this combined approach as a tool 
for structural studies of natural products, providing a powerful alternative to, 
or information to underpin, total synthesis when more classical NMR data 
analysis fails to provide unequivocal results. Moreover, their pharmacological 
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